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Summary 
 
While there is consensus on what biological parameters are consistent 
with diagnosis of diabetes, there is a scarcity of biomarkers which 
might identify different biochemical phenotypes of disease, 
underlying β cell mass  or propensity to complications in diabetes. The 
studies presented in this thesis were undertaken based on observations 
from our research group’s previous study, which identifed differentially 
expressed mRNAs in extracellular medium of glucose-responsive vs. 
glucose-non-responsive cell lines. As level of expression of mRNAs was 
dependent on glucose responsiveness and cell mass, we aimed to 
investigate whether similar mRNA expression pattern changes would 
be observed in human serum in patients with known diabetes.  
We collected samples from patients with impaired fasting glucose, 
impaired glucose tolerance, newly diagnosed type 2 diabetes, newly 
diagnosed type 1 diabetes, poorly controlled type 2 diabetes and 
long-standing type 1 diabetes as well as healthy controls. In this work, I 
present findings from studies on patients newly diagnosed with type 2 
diabetes, newly diagnosed type 1 diabetes and long-standing 
diabetes, compared to their healthy controls.  
We have not found differential expression of mRNA identified in the 
cell lines study in our newly diagnosed type 2 diabetes patients and 
the research group’s decision was not to extend mRNA studies to 
other groups of subjects, which may be attempted with resolution of 
current financial constraints.  
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We also examined sera of patients with type 1 diabetes with 
proteomic and novel metabolomic methods. Proteomic analysis 
identified down-regulation of anticoagulant protein S in patients with 
newly diagnosed type 1 diabetes, but no reported thrombotic events. 
While proteomics also identified reduced levels of vitronectin in 
patients with established type 1 diabetes, this is of unknown 
signficance.  
In metabolomic analysis, the most consistently altered metabolic 
pathway was the caffeine metabolism, with five caffeine metabolites 
being significantly down-regulated in patients with newly diagnosed 
type 1 diabetes, possibly indicating increased caffeine consumption 
by controls. Other pathways significantly altered were those of 
carbohydrate and lipid metabolism. 1,5-anhydroglucitol, a known 
marker of glycemic control, was unsurprisingly significantly down-
regulated in patients with newly diagnosed type 1 diabetes, in 
conjunction with significantly raised glucose levels in these patients. 
Lipid metabolites were were lower in patients with type 1 diabetes 
than in controls; this was coupled with higher total and LDL cholesterol 
in controls than in patients with type 1 diabetes. Therefore it is 
unknown if changes in lipid metabolites are reflective of type 1 
diabetes, or due to the high cholesterol in control samples 
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1 Introduction 
 
1.1 Diabetes 
Diabetes is a disease affecting a growing proportion of the world’s 
population. According to the World Health Organisation, 346 million 
people in the world have diabetes (1). At least 90% of these are 
affected by type 2 diabetes (1). It is expected that the number of 
people with diabetes will rise to 552 million by 2030, according to the 
International Diabetes Federation (2) . Albeit there are many causes 
and types of diabetes, this research focused on the two predominant 
types: type 1 and type 2 diabetes mellitus.  
 
1.1.1 Type 1 Diabetes 
 
Type 1 diabetes (T1DM) is an autoimmune disease precipitated in 
genetically susceptible individuals by environmental factors resulting in 
destruction of pancreatic β cells (3). In 2010, 479 000 children younger 
than 14 in the world suffered from type 1 diabetes. Its incidence is 
growing by 3% yearly and the reasons behind this increase are not 
known (2).  
Type 1 diabetes can occur at any age, but the peak incidence is just 
before school and in puberty (2).  
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Type 1 diabetes is associated with the appearance of humoral and 
cellular islet autoimmunity and defective immunoregulation (4). The 
original trigger for the autoimmune destruction cascade is elusive. 
According to current genetic research, the following genes are the 
likeliest susceptibility genes for diabetes: human leukocyte antigen 
(HLA), insulin, protein tyrosine phosphatase, non-receptor type 22 
(lymphoid)(PTPN22), interleukin-2 receptor alpha (IL2Ra), and 
cytotoxic T lymphocyte-associated protein 4 (CTLA4) (5).  
The products of HLA class II genes on chromosome 6p21 are 
associated with presentations of antigen to the cellular immune 
system (6). Several HLA class II genes are implicated: from those 
making the individual highly prone to development of T1DM (DR3/4-
DQ8 heterozygous haplotype to those conferring protection 
(DRB1*1501-DQA1*0102-DQB1*0602 haplotype, found in ~20% of the 
population but only 1% of patients) (7). HLA-B*39 allele, a class I gene, 
was found to be a significant risk factor for development of T1DM, 
associated with a lower age at diagnosis (8). Insulin gene variability, 
caused by polymorphisms of the IDDM2 locus on chromosome 11, 
accounts for lesser genetic predisposition. One form of polymorphism 
(variable number of tandem repeats, VNTR, type I) results in lower 
transcription rates of insulin and its precursors in the thymus, leading to 
reduced tolerance and T1DM development. A protective 
polymorphism also exists, VNTR type III. Individuals with this 
polymorphism have higher thymic clearance of insulin-reactive T-cells 
and hence less chance of developing autoimmunity to the β cells (5).  
The PTPN22 gene encodes the lymphoid protein tyrosine phosphatase 
(LYP). LYP is an important negative regulator of T-cell receptor 
signalling (5).  
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An allelic variation of the interleukin (IL)-2 receptor-α gene (IL2RA) 
region has been described as a risk factor for T1DM. This receptor is an 
essential molecule expressed on T cells upon activation. The 
mechanism by which it confers autoimmunity is unclear at present (5).  
The CLTA-4 gene, another gene implicated in development of T1DM, 
encodes cytotoxic T lymphocyte-associated protein 4 (CTLA-4. It is 
necessary for negative regulation of immune responses, as evidenced 
by the severe lymphoproliferative disorders seen in knock-out mice. It 
is also associated with other autoimmune conditions (multiple sclerosis, 
rheumatoid arthritis, systemic lupus erythematosus) (5). 
At least 40 new loci, possibly implicated in T1DM pathogenesis, were 
found in recent genome-wide studies, some of them encoding 
interleukin-10 (9). Almost all of the identified loci appear to alter risk of 
diabetes by effects on the immune system (6).  
Most patients with type 1 diabetes at diagnosis have circulating 
antibodies although the presence of autoantibodies is not a 
diagnostic criterion: islet cell antibody (ICA), insulin autoantibody 
(IAA); antibody to glutamic acid decarboxylase (GAD) 65; antibody 
to tyrosine phosphatases (IA-2 and IA2-β); zinc transporter 8 antibodies 
(ZnT8) (10). The prevalence of diabetes-associated autoantibodies in 
the general population is unknown. In the Finnish Type 1 Diabetes 
Prediction and Prevention study, 7410 children positive at birth for 
presence of type 1-associated HLA-haplotypes were followed up and 
tested for the presence of diabetes-associated autoantibodies. Over 
10 years, 15.8% (1173) of them became ICA-positive and, of those, 155 
developed type 1 diabetes. The combination of persistent ICA and 
IAA positivity resulted in the highest positive predictive value (91.7%), 
positive likelihood ratio (441.8), cumulative disease risk (100%), and 
specificity (100%) (11).  
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Once islet autoantibodies have developed, the progression to 
diabetes in antibody-positive individuals is determined by the age of 
antibody appearance and by the magnitude of the autoimmunity, in 
turn related to the age of the subject (4).  In a study by Verge, 
individuals with two or more positive autoantibodies had a 68% 5-year 
risk for developing type 1 diabetes, and those with all three (ICA, IAA 
and GAD) antibodies had an estimated 100% 5-year risk (12). 
Approximately 4% of normal individuals will be positive for one 
diabetes-related autoantibody (13). Family members of patients with 
T1DM may be antibody positive even without progression to diabetes 
(14).  
Various environmental factors have been implicated as triggers of 
autoimmune β cell destruction. Enteroviruses, in particular Coxsackie 
viruses, have been extensively investigated as a possible precipitant, 
but definitive confirmation of their role as triggers is lacking. In a Finnish 
prospective study, enteroviral infections were detected in 57% of the 
children in a 6-month period preceding the first appearance of 
autoantibodies compared with 31% of the matched control children 
in the same age-group (odds ratio 3.7, 95% CI 1.2-11.4) (15). Other 
viruses (rotaviruses, rubella) have been found to be connected to the 
onset of T1DM in small studies, but these results were not consistently 
replicated (5). An argument against rubella being a significant cause 
of T1DM is in the fact that widespread immunisation programmes in 
wealthier countries since 1969 have effectively eradicated the 
infection. Concerns that, on the contrary, immunisation against rubella 
and mumps, might be contributing to the rise in T1DM incidence, 
although postulated, have not been confirmed (5). Other 
environmental factors have been investigated: Mycobacterium avium 
in cow’s milk, cow’s milk protein per se and vitamin D deficiency. 
Vitamin D levels were found to be low in young adults at the onset of 
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T1DM in Sweden (16). Further support for the vitamin D hypothesis was 
provided by a recent Indian study which found an interaction 
between the vitamin D receptor and HLA alleles, postulating that 
vitamin D deficiency in early childhood might prompt autoimmunity 
via poor expression of HLA DRB1 0301 in thymus (17).  
Interesting data came from a recent prospective study of Finnish 
children which showed that changes in metabolic profiling preceded 
the onset of autoimmunity in children who had been followed from 
birth and proceeded to develop T1DM. Children who developed 
diabetes had reduced serum levels of succinic acid and 
phosphatidylcholine (PC) at birth, reduced levels of triglycerides and 
antioxidant ether-phospholipids throughout the follow up, and 
increased levels of proinflammatory lysophosphatidylcholines 
(lysoPCs) months before seroconversion to autoantibody positivity. 
Diminished levels of ketoleucine and elevated glutamic acid also 
preceded appearance of insulin and glutamic acid decarboxylase 
autoantibodies (18). Lysophosphatidylcholine appears to be a 
proinflammatory mediator and may be intricately involved in 
disrupting endothelial barrier function resulting in inflammatory 
responses in the vessel wall (19).  It is, therefore, for the first time 
possible to speculate that changes in the metabolic milieu might 
trigger the autoimmune reaction.  
 
1.1.2 Type 2 Diabetes 
 
Type 2 diabetes mellitus (T2DM) is increasing in prevalence at an even 
more alarming rate than T1DM, and this is often referred to as an 
epidemic. It is a disease of relative insulin deficiency, gradually 
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progressing to absolute insulin deficiency in some, caused primarily by 
reduced insulin sensitivity (insulin resistance).  
In the healthy human, insulin decreases lipolysis in the adipose tissue 
and promotes lipogenesis. In the skeletal muscle, insulin promotes 
glucose entry and glycogen synthesis. In the liver, insulin promotes 
glycogen synthesis and de novo lipogenesis, while also inhibiting 
gluconeogenesis (20). Insulin resistance is the inability of peripheral 
target tissues (muscle, adipose tissue and liver, primarily) to respond 
appropriately to normal circulating concentrations of insulin produced 
in the pancreas. To maintain euglycaemia, the pancreas 
compensates by secreting greater amounts of insulin, which is 
effective in overcoming insulin resistance in some patients but in 
others this compensatory mechanism fails and type 2 diabetes ensues. 
In patients with type 2 diabetes, insulin resistance precedes the onset 
of the disease by several years and gradually increases over time due 
to a combination of environmental and genetic factors (21).  
There is a strong relationship between insulin sensitivity and body 
weight. Worldwide obesity is the driving force behind globally 
increased insulin resistance and thus type 2 diabetes, but it is not the 
only factor; there is a strong genetic predisposition such that family 
members of subjects with T2DM can be shown to be insulin resistant 
even when they have normal body weight (22).  Aging and 
decreased physical activity further increase insulin resistance which, 
combined with an impaired insulin secretory response of pancreatic β 
cells to glucose, results in type 2 diabetes mellitus. To date, 44 different 
loci increasing the susceptibility to diabetes have been identified as 
part of genome-wide studies and large scale meta-analyses; these, 
however, account for only 10% of observed familial clustering in 
patients of European descent (23). The mechanism by which the 
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genetic susceptibility leads to insulin resistance is still poorly 
understood. 
Insulin resistance in obesity is associated with overabundance of free 
fatty acids (FFAs), released from the adipose tissue by lipase and from 
other tissues by lipoprotein lipase (LPL). FFAs reduce insulin sensitivity in 
muscle partly by inhibiting insulin-mediated glucose uptake (24).  
Another mechanism for muscle insulin resistance is intramyocellular 
lipid (IMCL) accumulation, i.e. increased fat content within the 
muscle. It causes an imbalance in skeletal muscle lipid influx, lipid 
metabolism, and oxidative capacity. (25). A number of compounds 
are accumulated: diacylglycerols (DAGs), long chain fatty acyl-CoAs 
(LCFA-CoAs), acylcarnitines, and ceramides (25). The mechanisms by 
which accumulation of IMCL causes insulin resistance are not 
completely elucidated. It is clear, however, that total levels of DAG, 
ceramides and LC-FA-CoA are not adequate predictors of obesity-
induced insulin resistance. It appears that specific characteristics of 
these molecules (degree of saturation, chain length, stereo specificity 
and intracellular localisation) might be factors influencing the level of 
insulin resistance in the muscle (25).   
As insulin-mediated glucose uptake in the muscle is impaired, glucose 
is diverted to the liver. In the liver, increased liver lipid also impairs the 
ability of insulin to regulate gluconeogenesis and activate glycogen 
synthesis. In contrast, lipogenesis remains unaffected and, together 
with the increased delivery of dietary glucose, leads to worsening non-
alcoholic fatty liver disease (NAFLD) (20). Impaired insulin action in the 
adipose tissue allows for increased lipolysis, which will promote re-
esterification of lipids in other tissues (such as liver) and further 
exacerbates insulin resistance. In addition, in obesity, adipose tissue 
macrophages are activated and secrete inflammatory cytokines, 
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interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α). In 
adipocytes, these cytokines promote lipolysis. In muscle cells, 
cytokines can promote increase lipid oxidation and, in extreme 
situations, may promote muscle atrophy via increased proteolysis. In 
the liver, cytokine signalling may serve to increase lipogenesis and 
impair lipid oxidation (20). 
In the preclinical period, pancreatic β-cells respond to insulin 
resistance by increasing their cell mass and insulin secretion. When this 
fails to compensate for insulin resistance, overt type 2 diabetes ensues.  
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1.2 Clinical features of diabetes 
 
The onset of autoimmune type 1diabetes is usually fast, with a history 
ranging in days to weeks, whereas progress from insulin resistance to 
frank diabetes is a lot slower in type 2 diabetes. It is estimated that 
type 2 diabetes may be present for 9-12 years before diagnosis (26). 
Regardless of whether diabetes onset is fast, as in T1DM, or slower, as 
in T2DM, the resulting hyperglycaemia will, once it regularly exceeds 
the renal threshold, cause osmotic symptoms. These are polyuria and 
nocturia, due to osmotic effects of glucose excreted in the urine; 
polydipsia, due to haemoconcentration and activation of thirst 
mechanisms. Fatigue, chronic skin and genitourinary tract infections 
are common.  
In patients with type 1 diabetes, the clinical presentation is usually 
dramatic with an abrupt onset of symptoms when the level of insulin 
reaches a point at which euglycaemia can no longer be maintained.  
When the lack of insulin is severe enough, the inability to stimulate 
glucose uptake, coupled with increased fat breakdown, causes 
diversion to energy production from lipolysis, yielding ketones as a by-
product, and may result in diabetic ketoacidosis and coma.  
In patients with T2DM, the presentation is usually more insidious and 
diagnosis may be accidental. Because of the association with obesity, 
particularly abdominal obesity, there may be other metabolic 
abnormalities associated and this has led to the use of the term 
metabolic syndrome which also incorporates dyslipidaemia and 
hypertension with some level of dysglycaemia (27, 28).
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1.3 Complications of diabetes 
 
Four molecular mechanisms have been  proposed as pathways 
through which hyperglycaemia causes micro- and macrovascular 
complications: increased polyol pathway flux; increased intracellular 
advanced glycation end product (AGE) formation; activation of 
protein kinase C; increased hexosamine pathway flux (10). 
Increased flux through the polyol pathway consumes the reduced 
form of nicotinamide adenine dinucleotide phosphate (NADPH). 
NADPH depletion is thought  to exacerbate intracellular oxidative 
stress and cause cellular injury (10). Intracellular auto-oxidation of 
glucose results in production of intracellular dicarbonyls (glyoxal, 3-
deoxyglucosone, methylglyoxal), also known as AGE precursors(10). 
They damage intracellular and extracellular proteins and matrix 
components. Intracellular protein modifications may alter cellular 
functions. Modifications of extracellular matrix proteins result in 
abnormal interactions with other matrix proteins and integrins 
(receptors mediating attachment of the cell to the surrounding tissue) 
(29) . The modified proteins bind to receptors on endothelial cells, 
mesangial cells, and macrophages causing expression of cytokines 
and growth factors including interleukin 1, IGF-1, TNF-α, transforming 
growth factor-β (TGF-β), macrophage colony stimulating factor, 
granulocyte-macrophage stimulating factor, platelet-derived growth 
factor, thrombomodulin, tissue factor, vascular cell adhesion molecule 
1 (VCAM 1) and vascular endothelial growth factor (VEGF). Induction 
of VEGF has been implicated in the vascular hyperpermeability 
associated with diabetes (30).  
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Increased intracellular glucose causes rise in diacylglycerol; this in turn 
activates protein kinase C (PKC) isoforms β and delta (10). The 
activation of PKC initiates a complex network of intracellular signalling 
that alters transcription factor binding to the promoter regions of 
responsive genes, which in turn alters gene expression.  Activation of 
these isoforms also leads to a change in expression of endothelial 
nitric oxide synthase, endothelin 1, VEGF, TGF-β, plasminogen 
activator inhibitor (PAI-1), which  modulates vascular endothelial 
permeability and neovascularisation and activation of nuclear factor 
κB and nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases, which in turn increases superoxide production (31)(Figure 
1.3.1).   
Superoxide presence causes impairment of endothelium-dependent 
relaxations, increase in smooth muscle contractions, and release of 
constrictor prostanoids, leading to impairment of endothelial cell 
function (31, 32).  
 Increases in vascular permeability, angiogenesis, cell growth and 
apoptosis, vessel dilation, cytokine activation, basement membrane 
thickening and extracellular matrix expansion have all been observed 
with increased PKC activity (31, 33). Support for the hypothesis that 
PKC is involved in complication development comes from the 
observation that inhibitors of protein kinase b isoform improve 
retinopathy and nephropathy in experimental models (30).  
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Figure 1.3.1  Mechanisms of protein kinase C activation of transcriptional factors involved in 
development of diabetes complications; SHP-1 protein tyrosine phosphatase, Akt, serine-
threonine kinase, ERK extracellular signal-regulated kinase; p38 MAPK mitogen-activated protein 
kinase; GSK-3β  glycogen synthase kinase β; VEGF-A vascular endothelial factor A; PDGF-B, 
platelet-derived growth factor β; ET-1 endothelin 1; CTGF, connective tissue growth factor; TGF-β, 
transforming growth factor β; VCAM, vascular cell adhesion molecule, ICAM, intercellular 
adhesion molecule; Egr-1, early growth response 1, NF-κB, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1, SP1, specificity protein 1; NADPH oxidase, nicotinamide 
adenine dinucleotide phosphate oxidase; PLA2, phospholipase 2; eNOS, endothelial nitric oxid 
synthase; Na-K-ATPase, sodium-potassium-adenosine-triphosphatase; DAG, diacylglycerol; PKC, 
protein kinase C, AGE, advanced glycation products. Adapted from Geraldes (31). 
 
Hyperglycaemia increases hexosamine pathway flux by providing 
more fructose-6-phosphate for the rate-limiting enzyme of the 
pathway glutamine: fructose-6-phosphate amidotransferase. Activity 
of this pathway leads to increased donation of N-acetylglucosamine 
moieties to serine and threonine moieties of complication-promoting 
factors such as PAI-1 or TGF-β. It has been proposed that all four of 
these pathways are associated with overproduction of superoxide by 
mitochondria. (30).  
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Regardless of the mechanism leading to hyperglycaemia, its long-
term effect is micro- and macrovascular damage. Damage to the 
capillaries and precapillary arterioles causes thickening of the 
capillary basement membrane. This in turn causes damage to the 
retina (causing retinopathy), kidneys (causing nephropathy) and 
autonomic and peripheral nerves (causing neuropathy). 
Atherosclerosis is significantly accelerated in diabetes, particularly in 
type 2 diabetes, resulting in higher incidence of macrovascular 
complications (ischaemic heart disease, stroke) with higher 
haemoglobin A1C (HbA1C) (34).  
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1.4 Laboratory findings and treatment 
targets in diabetes 
 
1.4.1 Criteria for diagnosing diabetes 
 
According to the American Diabetes Association and World Health 
Organisation, diabetes is diagnosed either in a symptomatic individual 
with a random glucose of ≥11.1 mmol/L or, in an asymptomatic 
subject, with two separate measurements of fasting plasma glucose ≥ 
7.0 mmol/L or 2h-post glucose load reading of ≥11.1 mmol/L or, 
alternatively, a HbA1C of ≥6.5% (1, 35).  
Fasting plasma glucose is defined as a morning blood sample taken 
after a fast lasting at least 8 hours. Two-hour plasma glucose is 
understood to be a sample taken two hours after a standard load of 
75g of glucose has been taken orally.  
Haemoglobin A1c (HbA1c) is the product of glycation of 
haemoglobin. When blood glucose enters the erythrocytes, it glycates 
the amino group of lysyl residues as well as the amino terminals of 
haemoglobin. The fraction of glycated haemoglobin, normally about 
5%, is proportionate to blood glucose concentration. Since the half-life 
of an erythrocyte is typically 60 days, the level of glycated 
haemoglobin (HbA1c) reflects the mean blood glucose concentration 
over the preceding 6–8 weeks (36).  
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The definition of normal fasting plasma glucose varies depending on 
whether one takes ADA or WHO criteria into consideration: by ADA 
standards, fasting glucose of 5.6-6.9 mmol/L is in the impaired fasting 
glucose range, while for European Association for Study of Diabetes 
and WHO, the cut-off begins at 6 mmol/L (1, 37). Postprandial glucose 
values at 2-hours after ingestion of glucose above 7.8 mmol/L and 
below 11.1 mmol/L are considered as impaired glucose tolerance by 
ADA, EASD and WHO (1, 38).  
 
1.4.2 Treatment targets for prevention of complications 
of diabetes 
 
In order to prevent complications of diabetes, laboratory and clinical 
targets are set for all cardiovascular and other risk factors. HbA1C is to 
be kept at < 53 mmol/mol (<7%) or even <48 mmol/mol (<6.5%) if 
possible, taking individual characteristics of the patient in the account 
and allowing for more lenient target in older patients with 
comorbidities (39). Blood pressure is to be controlled at <130/80 mmHg 
(38). Dyslipidaemia needs to be treated particularly vigorously in 
patients with existing cardiovascular disease or in patients over 40 
years of age with at least one cardiovascular risk factor. Low density 
lipoprotein (LDL) target in patients without overt cardiovascular 
disease should be < 2.6 mmol/L, while in those with known 
cardiovascular disease, a target of <1.8 mmol/L should be considered. 
High density lipoprotein level of > 1.0 mmol/L and triglyceride level 
<1.7 mmol/L are desirable (38).  
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Spot urine testing for microalbuminuria, reported as ratio between 
urinary albumin and urinary creatinine, is currently the  preferred 
method for monitoring for development of nephropathy, as it 
compares adequately with 24-hour proteinuria measurements (40). 
Prevention of microalbuminuria and subsequent nephropathy is best 
achieved with treatment of hyperglycaemia as well as hypertension 
control, using angiotensin-converting enzyme inhibitors (ACEI) or 
angiotensin receptor blockers (ARB) (38). 
While we have a reasonable understanding of the pathophysiology of 
diabetes, the processes that lead to its complications and good 
evidence for the benefit of interventions in preventing complications, 
we still have a poor understanding of why some individuals with 
diabetes are relatively more or less prone to developing 
complications.  While glycaemic parameters are good biomarkers of 
complication risk, some patients appear not to develop severe 
complications despite poor control.  A greater understanding of why 
this is the case and which might allow a more personalised approach 
to diabetes management could be provided by novel biomarkers if 
they could be shown to reflect the severity of β cell mass loss at 
diagnosis or be predictive of future complication development. 
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1.5 Biomarkers of interest in this study 
1.5.1  Definition 
The term “biomarker” was defined by the National Institutes of Health 
(U.S. Department of Health and Human Services) as a “characteristic 
that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” (41). There are currently no 
known biomarkers for β cell mass. As type 1 diabetes has been 
suggested to occur when 90-95% of β cells have been destroyed, and 
at diagnosis of type 2 in obese people there is about 60% of β cell 
mass remaining, finding either cell components or cell products 
associated with β cell mass would be helpful in quantifying the severity 
of the pancreatic lesion at diagnosis and might inform treatment (42, 
43) 
The biomarkers currently used (fasting and postprandial glucose, 
HbA1c) reflect the degree of serum and tissue hyperglycaemia, the 
final consequence of β cell exhaustion and destruction, rather than 
the β cell mass or pathophysiological processes that led to the 
occurrence of the disease.  
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1.5.2 Whole genome microarray studies of insulin-
producing cell lines previously undertaken by our 
group 
In order to investigate the mechanism behind the loss of glucose-
stimulated insulin secretion, which may be part of the answer to the 
oetiology of β-cell insensitivity to high glucose in diabetes, our 
collaborators performed whole genome microarray studies on insulin-
producing cell lines (44).  
The cell cultures used in these experiments were MIN6(L) (glucose-
responsive), MIN6(H) (glucose non-responsive) and MIN6 B1 cells as 
well as monkey kidney fibroblast cells engineered to produce human 
preproinsulin (PPI) (Vero-PPI) (44, 45).  
MIN6 cells come from a transformed mouse β-cell line and exhibit 
glucose-stimulated insulin secretion comparable with cultured normal 
mouse islet cells (46). Glucose-stimulated insulin secretion (GSIS) is lost 
in long-term cultured MIN 6 heterogeneous cells. MIN6(L) cells 
(passage 18) and MIN6(H) (passage 40) cells were established from 
MIN6 to be glucose responsive (L) and nonresponsive (H), respectively 
(44).  
Whole genome microarray and conditioned medium mRNA studies 
were performed on these cell lines (44).  
MIN6 B1 cell line, a subclone of MIN6 cell line, is a highly glucose-
responsive cell line that responds to glucose in a concentration-
dependent manner (47). MIN6 B1 cell line maintains glucose 
responsiveness in short-term cultures. However, when passaged 
repeatedly, Dr Rani observed that MIN6 B1 cells start losing the 
glucose responsiveness and determined the passage at which the 
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GSIS was lost by performing GSIS assays as the cells were grown from 
lower  to higher passage (44). Whole genome microarray analysis on 
biological triplicate samples of glucose-responsive low passage (p19) 
(MIN6 B1(GSIS)) and glucose-non-responsive higher passage (p23) 
(MIN6 B1(Non-GSIS)) was performed (44).  
Vero cells are derived from epithelial cells of kidney from African 
green monkey (Cercopithecus aethiops) and engineered by one of 
our collabolators, Dr. Lorraine O’Driscoll, to produce and process 
human preproinsulin by transfection of the human preproinsulin cDNA 
(48). Vero-PPI cells secreted mature human insulin but did not show 
glucose-stimulated insulin secretion. 
Whole genome microarray studies were performed on both MIN 6 and 
MIN6 B1 cell lines.  
Whole genome microarray analysis on biological triplicate samples of 
glucose-responsive low passage (p19) (MIN6 B1(GSIS)) and glucose-
non-responsive high passage (p23) (MIN6 B1(Non-GSIS)) has identified 
111 differentially-regulated genes (44). Of these, 16 gene transcripts 
were selected based on p-value <0.05, fold change ≥1.2, for 
validation using qRT-PCR, including thyoredoxin interacting protein 
(Txnip), endothelial growth factor 1 (Egr1), glucagon (Gcg) and 
proprotein convertase subtilisin/kexin type 9 (Pcsk)(44). qRT-PCR was 
performed in triplicate for each gene transcript, and the fold change 
was determined after normalisation to the expression of a 
housekeeping gene, β-actin. Comparison of qRT-PCR data with 
microarray data demonstrated matching trends in expression 
changes for both methods. 
Txnip and Egr1 were up-regulated, whereas Gcg and Pcsk9 were 
down-regulated in MIN6 B1(Non-GSIS) compared to MIN6 B1(GSIS).  
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When MIN 6 and MIN 6 B1 microarray studies were compared, a set of 
33 common differentially regulated gene transcripts were found.  
There were 7 common upregulated (among them, Txnip) and 18 
down-regulated genes in MIN6 and MIN6 B1 cells (among them, Gcg). 
Eight gene transcripts which were down-regulated in MIN6 were up-
regulated in MIN6 B1 cells (among them, Egr1) and 1 gene transcript 
that was down-regulated in MIN6 B1 was up-regulated in MIN6 cells 
(44).  
To investigate the relevance of Txnip in glucose- stimulated insulin 
secretion, silencing of Txnip was performed using small interfering RNA 
(siRNA) transfection in high passage (glucose non-responsive) MIN6 
cells (44). Silencing of Txnip increased glucose-stimulated insulin 
secretion (44). 
  
1.5.3 Extracellular ribonucleic acids (RNAs) analysis 
performed by our grup 
Further experiments were performed by members of our group to 
evaluate the ocurrence of mRNAs in the extracellular medium of the 
above named cell cultures (45).  
Over the last 25 years, contrary to previous beliefs that RNA is to be 
found only within cells, significant amounts of RNA have been found 
extracellularly, particularly in cancer patients. In patients with cancer, 
extracellular mRNAs were found to correlate to the tumour mass 
and/or activity in various cancers, including melanoma and cancers 
of the lung, thyroid, breast, bladder and prostate (49-51). Extracellular 
RNAs have been detected in majority of body fluids (serum, plasma, 
saliva, milk, urine, bronchial lavage), as well as cell culture 
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supernatants (52-57). In particular, messenger RNAs (mRNAs) were 
proven to be extractable from fresh and frozen serum samples (58). 
It is unclear how the RNAs are released from cells: whether by active 
secretion, as a result of apoptosis and necrosis or some combination 
of the above (59). In serum of cancer patients, increased levels of 
serum ribonucleases are found; mRNA may be protected from these 
by apoptotic bodies (50, 60). Mammalian cells might be 
communicating between each other by secreting mRNA and short 
mRNAs  (micro RNAs) into exosomes, small membrane vesicles of 
endocytic origin released into the extracellular environment on fusion 
of multivesicular bodies with the plasma membrane (61). Exosomes 
secreted into urine by all kidney cells have been found to contain 
mRNA, micro-RNA and proteins and their utility as biomarkers for 
kidney disease is currently being investigated. (62).  Exosome-
transferred mRNA was described as capable of coding for exosome-
specific proteins in the recipient cells (61). 
Over the last decade, a number of circulating mRNAs were detected 
to be significantly differently expressed in sera of patients with 
diabetes. Differential expression of serum mRNAs has been found in 
diabetic retinopathy and neuropathy, in particular serum neuron-
specific enolase mRNA, which is higher in patients with diabetes 
compared to healthy controls, but decreases in patients with diabetic 
neuropathy (63). In patients with diabetic retinopathy, serum 
rhodopsin (biological pigment in retinal photoreceptor cells) mRNA 
level is higher than in normal controls, while retinal amine oxidase (a 
candidate for the role of retinal signal transmission modulator) levels 
are lower (64, 65). Nephrin (a cell adhesion molecule from the kidney 
glomerular filtration barrier) mRNA levels were found to be higher in 
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normoalbuminuric patients with diabetes when compared to healthy 
subjects (66). 
While enolase, rhodopsin and nephrin show promise in identifiying 
patients with complications, it would be very exciting if a serum 
biomarker could be identified able to foretell the loss of β cells before 
the disease or indeed the complications had time to develop.  
Our group further investigated whether any of the mRNAs identified in 
whole genome microarray studies would be found in the extracellular 
matrix of the cell lines. Several mRNAs were isolated from the 
conditioned medium of the three types of cell lines mentioned above: 
MIN 6 low and high passage (L, 18 and H, 40, respectively), MIN6 B1 
and Vero-PPI. The isolated mRNAs were encoded by Pdx1 (murine 
pancreatic and duodenal homeobox gene 1), Pld1 ( murine 
phospholipase D gene), Npy (murine neuropeptide y gene), Egr1 
(murine early growth response gene 1), Chgb (murine chromogranin 
B), Ins1 (murine insulin 1 gene), Ins2 (murine insulin 2 gene), Pax4 
(murine paired box transcription factor 4 gene) and Actb (murine β-
actin gene). Degrees of gene expression of Pdx1, Egr1 and Chgb 
reflected the numbers of MIN6 B1 cells conditioning the medium (45). 
This made us wonder whether mRNAs released from β-cells of the 
human pancreas into the serum of patients with diabetes might reflect 
the amount of remaining β-cells.  
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1.5.3.1 Thyoredoxin interacting protein (Txnip) 
 
Txnip, thioredoxin-interacting protein is part of a ubiquitous mammal 
antioxidative cell mechanism for regulating cellular redox balance 
(67, 68). It was also called or thioredoxin-binding protein-2 (TBP-2)  and 
vitamin D up-regulated protein 1 (VDUP), because of its relationship to 
1,25(OH)2-cholecalciferol (69)  . It was first discovered in 1994 in 
leukaemia HL60 cells treated with vitamin D (70).   
Intracellular redox balance is maintained by reactive oxygen species 
(ROS) scavenging systems. Two major intracellular thiol-reducing 
mechanisms are the interacting glutathione and thioredoxin systems. 
Thioredoxin reduces ROS through reversible oxidation of thioredoxin at 
two cysteine residues (Cys-32 and Cys-35); thioredoxin is then reduced 
by thioredoxin reductase and NAPDH (71)  . Thioredoxin-interacting 
protein (Txnip), the endogenous inhibitor of thioredoxin inhibits 
thioredoxin antioxidative function by binding to its redox-active 
cysteine residues (67) (Figure 1.5.1.)  
Txnip was recently found to be part of the family of arrestin signalling 
proteins (72). Arrestins were originally identified as intracellular proteins 
that bind to phosphorylated G protein-coupled receptors (GPCRs) 
and cause their desensitization, thus ‘arresting’ their activation (72). In 
diabetic mouse models, deficiency of another arrestin, β-arrestin-2, 
was recently described to affect insulin receptor signalling and 
contribute to insulin resistance (73) and yet another, α-arrestin, arrestin 
domain-containing protein 4, is an equally potent inhibitor of glucose 
uptake in vitro despite its inability to bind thioredoxin (74). 
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It is known from cell culture studies that hyperglycaemia inhibits 
thioredoxin ROS-scavenging function through induction of Txnip (75). 
However, Txnip does not act on glucose metabolism through inhibition 
of thioredoxin; glucose-uptake function is intrinsic to the arrestin 
domains of Txnip (72). The molecular mechanisms for how arrestin 
domains regulate glucose uptake remain unknown (72). 
 
Figure 1.5.1  Role of TXNIP in the thioredoxin system. Thioredoxin (TXN) reduces oxidised cysteine 
residues (protein-S2) on cellular proteins. Reduced TXN (TXN-(SH)2) is regenerated via the action 
of thioredoxin reductase (TXR) at the expenditure of NADPH. When TXN reduces the oxidised form 
of thioredoxin peroxidise (TXP), the reduced enzyme (TXP-(SH)2) is available to scavenge reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2) and the superoxide anion (O2ꜙ ). TXNIP 
binds and inhibits the reduced form of TXN, thereby functioning as a rheostat that modulates both 
redox status and ROS-mediated signalling to regulate metabolism and other cellular processes. 
(Dashed lines indicate unknown processes) From Muoio, Cell Metabolism, 2007 (68) 
 
The metabolic functions of Txnip were revealed when a nonsense 
mutation in the Txnip gene was identified as being responsible for the 
phenotype of the ‘hyplip’ mouse, which has high triglyceride levels 
along with elevated ketone and lactate levels, consistent with 
decreased fatty acid flux through the tricarboxylic acid cycle in the 
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mitochondria (76). Hui described a similar phenotype in his Txnip-
knockout mice: insulin levels were three times higher than normal, with 
animals suffering from hypoglycaemia, hypertriglyceridaemia and 
hepatic steatosis with a block in gluconeogenesis (77).  
Txnip acts on the liver, most likely by inducing  gluconeogenesis (74). 
Txnip-null mice in Chutkow’s experiment were hypoglycaemic, 
hypoinsulinaemic, and had blunted glucose production following a 
glucagon challenge, consistent with a central liver glucose-handling 
defect (74). Glucose release from isolated Txnip-null hepatocytes was 
2-fold lower than wild-type hepatocytes, whereas β-hydroxybutyrate 
release was increased 2-fold, supporting an intrinsic defect in 
hepatocyte glucose metabolism(74). While hepatocyte-specific gene 
deletion of Txnip did not alter glucose clearance compared with 
littermate controls, Txnip expression in the liver was required for 
maintaining normal fasting glycaemia and glucose production. In 
addition, hepatic over-expression of a Txnip transgene in wild type 
mice resulted in elevated serum glucose levels and decreased ketone 
levels (78).  
 In a clinical human study which combined euglycaemic-
hyperinsulinaemic clamps with genome-wide expression profiling, in 
healthy subjects insulin suppressed expression of Txnip in the muscle, 
while glucose stimulated its expression (79). In healthy people and 
those with pre-diabetes, as glucose uptake rates increased, Txnip 
expression decreased but this inverse correlation was missing in 
people with diabetes (79). Forced expression of Txnip in cultured 
adipocytes significantly reduced glucose uptake, while silencing with 
RNA interference in adipocytes and in skeletal muscle enhanced 
glucose uptake (79). Txnip is consistently elevated in muscle of people 
with diabetes and pre-diabetes (79). Txnip thus seems to act as a 
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negative feedback regulator for glucose uptake: when glucose is 
plentiful, Txnip is induced and then inhibits further glucose uptake, 
most likely through enhanced flux through the mitochondrial citric 
acid cycle (72, 74, 79) (Figure 1.5.2.).  
 
 
Figure 1.5.2  Model of TXNIP regulation and action and its potential role in the pathogenesis of 
type 2 diabetes . A. Glucose induces the expression of TXNIP in a variety of cells and tissues. 
Insulin suppresses the expression of TXNIP. Forced expression of TXNIP results in reduced glucose 
uptake, while inhibition of TXNIP enhances glucose uptake. This suggests that TXNIP serves as a 
glucose- and insulin-sensitive homeostatic switch that regulates glucose uptake in the periphery. 
(B) Role of TXNIP in glucose toxicity in the β-cell and in impaired glucose uptake in the periphery. 
Insulin deficiency or hyperglycaemia can increase TXNIP levels in muscle, resulting in impaired 
peripheral glucose uptake. The pancreatic β-cell is initially able to compensate by secreting more 
insulin, but eventually the β-cell compensation fails. The resulting hyperglycaemia may then 
elevate pancreatic β-cell TXNIP expression, which can induce apoptosis (80). The loss of β-cells, in 
turn, results in decreased insulin production that further exacerbates peripheral IGT. The vicious 
cycle would eventually spiral to T2DM. Adapted from Parikh et al (79).  
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In human muscle from healthy subjects, microarray genome profiling 
before and after euglycaemic-hyperinsulinaemic clamp, glucose 
stimulated and insulin suppressed Txnip expression (79). As glucose 
uptake rates increased, Txnip expression decreased in healthy 
subjects, but also those with pre-diabetes; however, this was not 
observed in subjects with diabetes (79).  
It has long been known that hyperglycaemia exacerbates β-cell 
failure and impaired skeletal muscle glucose uptake, the process 
referred to as ‘glucose toxicity’ (81-83) Currently it is thought that this 
happens through ROS, but Parikh et al. propose that Txnip might be 
the missing link through its role in control of peripheral glucose uptake 
and β-cell toxicity (79-81, 84).This seems like a plausible hypothesis, 
considering that Txnip is essential for maintenance of fasting 
normoglycaemia through its effects on the hepatocytes and that 
hepatic over-expression of Txnip results in hyperglycaemia (74).  
In Parikh’s study, in biopsies of vastus lateralis muscles after the 2-h 
euglycemic hyperinsulinemic clamp, Txnip was more expressed in the 
muscles patients with diabetes than in subjects with normal glucose 
tolerance (Figure 1.5.3) (79, 85). The same held when vastus lateralis 
muscle biopsies of fasting subjects who subsequently underwent  2h-
hyperinsulinemic euglycemic clamp to assess glucose disposal were 
analysed: Txnip was more expressed in patients with type 2 diabetes 
than in normoglycaemic subjects (79, 86) . 
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Figure 1.5.3. TXNIP expression in individuals with diabetes or at risk of developing diabetes.  
A) TXNIP expression levels from males from Northern Europe with NGT, IGT, or T2DM. * p < 0.02; 
** p < 0.01, Mann-Whitney U-test. B) TXNIP expression levels from NGT individuals of Mexican-
American descent with (FH+) or without (FH−) family history of T2DM, as well as individuals with 
T2DM; * p < 0.03, Mann-Whitney U-test. (Adapted from Parikh et al (79) 
 
In Parikh’s clamp studies, Txnip expression was inversely correlated with 
the total body rate of insulin-stimulated glucose metabolism in males 
with normal glucose tolerance and  impaired glucose tolerance but 
not in  type 2 diabetes(Figure 1.5.4).  
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Figure 1.5.4.  Insulin-mediated glucose uptake vs Txnip expression in a microarray in 43 males 
from Northern Europe with normal glucose tolerance (NGT, n=17), impaired glucose tolerance 
(IGT, n=8) and type 2 diabetes (T2DM, n=18) who underwent euglycaemic-hyperinsulinaemic 
pump studies;  a.u.-arbitrary units, i.e. relative numbers of Txnip expression normalised to 
cyclophilin A reference. Adapted from Parikh et al (79)  
 
Apart from mediating insulin sensitivity, Txnip causes pancreatic β cell 
apoptosis and death, as described by Minn in 2005 and by Chen in 
2008 (80, 87). Recently it was shown that Txnip mediates 
endoplasmatic reticulum stress-mediated β cell death by increasing 
interleukin-1β mRNA transcription and activating interleukin-1β 
production (88). It is proposed that Txnip might be the ‘switch’ that 
integrates glucose sensing and insulin signalling in controlling the cell 
energy status (68)(Figure 1.5.1). Txnip gene transcription is supressed by 
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metformin, raising a possibility that Txnip regulation might be part of 
metformin’s elusive mode of action (89).  
Txnip also has a role in human cancer in growth suppression, inhibition 
of metastasis and proapoptosis through inhibition of thioredoxin (TRX) 
(90).  
As Txnip was differentially more expressed in the conditioned media of 
the glucose-unresponsive (MIN-6) vs glucose-responsive cells in our 
group’s recent cell study (91) and similar trend has been observed in 
studies of human biopsies, we set out to investigate if human serum,  
would replicate the differential expressions seen in the extracellular 
medium. 
 
1.5.3.2 Early growth response 1 (Egr1) 
 
Egr 1 is a zinc-finger protein, functioning as a transcriptional regulator. 
In cell cultures, Egr1 is inducible by insulin (92) and glucose induces 
Egr1 mRNA transcription in various β-cell models. In diabetic Zucker 
rats, Egr1 was up-regulated, but this did not have any effect on 
glucose-stimulated insulin secretion; however, in the same study, Egr1 
gene silencing inhibited proliferation of INS-1 cells (an insulinoma β-cell 
line), in a glucose-independent manner, suggesting reduced Egr1 
expression may contribute to decreased β-cell proliferation and 
consequent β cell failure (82). 
Egr1 belongs to the EGR family of C2H2-type zinc-finger proteins. It is a 
nuclear protein and functions as a transcriptional regulator. The 
products of target genes it activates are required for differentiation 
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and mitogenesis (93). The gene coding for it is based on the short arm 
of 5th chromosome (93).  
Upon stimulation by a variety of extracellular signalling molecules, 
including insulin, the biosynthesis of Egr1 is increased and its 
transcription is regulated by Ca2+ (92, 94). Many biological roles have 
been attributed to Egr1, ranging from controlling synaptic plasticity, 
wound repair, female reproductive capacity, inflammation, 
coagulation and vascular hyperpermeability of the lung, growth 
control, and apoptosis (94). In unstimulated cells, only low levels of 
Egr1 are detectable, while upon stimulation by a variety of 
extracellular signalling molecules, the biosynthesis of Egr-1 is increased 
(92, 94). Alterations of Egr1 by mitogenic stimuli have been reported in 
vivo, especially in normal and pathophysiological states associated 
with rapid cellular proliferation (92). It has been reported that infusion 
of growth factors (vascular endothelial growth factor, VEGF, and 
epidermal growth factor, EGF) induced Egr1 in the heart, brain, liver 
spleen, lung, brain and skeletal muscle of investigated animals. 
Glucose increases Egr1 mRNA transcription in various cell models of β 
cells, and this induction is particularly associated with insulin secretion 
(95). As a transcription factor, Egr1 can regulate expression of tumour 
necrosis factor alpha, a known promoter of insulin resistance (96). Egr1 
was also found to be implicated in development of adipocyte insulin 
resistance (97). In pancreatic β cells, Egr1 regulates expression of 
pancreas duodenum homeobox-1 (PDX-1), a key regulator of 
pancreatic β cell development, function and survival (98). Deficit in 
PDX-1 expression result in insulin deficiency and hyperglycaemia and 
Egr1 up-regulates this expression by activation of the pdx-1 promoter 
(98).  These data suggest that Egr1 may be a potential marker of β-cell 
mass and/or function.  
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1.5.4 Serum proteomics 
 
While measuring mRNA levels in serum and tissues will partly determine 
the transcriptome, made of messenger RNA and micro RNA (miRNA), 
it is impossible to predict the amount of protein produced by any 
given mRNA (99). Proteomics simultaneously measures large numbers 
of proteins in a complex tissue, making it a snapshot of cell’s, tissue’s or 
organism’s protein production. The difficulty with assessing serum 
proteins is in the abundance of albumin and globulins. Various 
techniques have been used to extract and map low abundance 
proteins by depleting high-abundance proteins (100). The most 
common technologies in proteomics are based on two-dimensional 
gel electrophoresis and chromatographic separation methods 
combined with mass spectroscopy (101). Protein concentrations in 
biological fluids are determined by genetic variation, but 
environmental factors play a dominant role (102).  
Considering that diabetes type 2 is a disease of many organs, serum is 
a potentially interesting sample for proteomics studies as blood is in 
contact with all tissues in the body. So far, a number of studies have 
looked at proteome in serum of patients with type 1 and type 2 
diabetes (103, 104).  
Within the last 10 years, several studies have reported differentially 
expressed proteins in skeletal muscle from patients with diabetes (105, 
106). In Giebelstein’s muscle study of patients with type 2 diabetes, 
there was a switch towards increased abundance of proteins from the 
glycolytic pathway and decreased abundance of mitochondrial 
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proteins; this was inversely correlated to glucose disposal during 
euglycaemic-hyperinsulinaemic clamp (107). 
A number of differentially expressed proteins was described in animal 
and human pancreata, involved in protein biosynthesis, endoplasmic 
reticulum stress, microvascular endothelial dysfunction, impaired 
glucose sensitivity, mitochondrial dysfunction and impaired hormone 
secretion (108).  
Serum proteomics studies have been done previously in patients with 
type 1 diabetes. Metz reported 2-fold up-regulation of alpha-2-
glycoprotein 1 (zinc), corticosteroid-binding globulin, and lumican in 
type 1 diabetic samples relative to control samples, whereas clusterin 
and serotransferrin were 2-fold down-regulated in patients with type 1 
diabetes These proteins have been linked to mobilisation of lipids, 
cytoprotection and kidney adaptation to hyperglycaemia (103). 
Another study identified 50 differentially expressed proteins between 
patients with type 1 diabetes and their controls; this protein list is 
prepared for publication (109). 
 
A serum proteome study found extracellular glutathione peroxidase 
and apolipoprotein E  to be progressively reduced in diabetic patients 
with microalbuminuria and chronic renal failure (110). Transthyretin, 
apolipoprotein A1, apolipoprotein C1 and cystatin C were also 
identified as markers for diabetic nephropathy in patients with type 1 
diabetes (111).  
Anti-aldolase antibody was identified in serum proteomic analysis as a 
marker for diabetic retinopathy and clusterin levels were found to be 
reduced in the vitreous fluid of patients with proliferative diabetic 
retinopathy (112, 113) .  
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Area of urinary proteomic markers in diabetes is thriving: a recent 
study four urinary proteins were found to be predictive for 
development of microalbuminuria in the cohort of 465 patients with 
type 1 diabetes who were prospectively followed and monitored for 
occurrence of microalbuminuria for 6 years (114). Four urinary proteins 
were found to be predictive of development of microalbuminuria: 
Tamm-Horsfall glycoprotein, α-1 acid glycoprotein, clusterin, and 
progranulin (114). 
  
Further studies of protein expression in diabetes patients with better 
techniques for extraction of low-abundance proteins and label-free 
approach are necessary in order to create a map of proteomic 
biomarkers which might be used in early assessment of the disease 
and its complications.   
 
1.5.5 Serum metabolomics 
 
Metabolomic profiling is a relatively new method of identifying huge 
volumes of metabolites present at any given time in a substrate—a 
serum sample, a cell culture or an organism. It has been made 
possible by the development of methods capable of rapid, high 
throughput characterization of the small molecule metabolites. It 
provides an insight into genotype-phenotype-environment 
interactions as it will be dependent as much on the genetic make-up 
of an organism and its expression in phenotype as it will be on what an 
organism eats or breaths.  
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The metabolome makes up the smallest set of biomarkers (102). The 
Human Metabolome Project began in January 2005 with a grant from 
Genome Canada, a non-profit organisation engaged in genome 
research. Human Metabolome Project established freely-availably 
Human Metabolome Database, maintained by the University of 
Alberta, Canada (www.hmdb.ca ), in which there are currently 41,519 
metabolite entries, including lipids, sugars, nucleotides, amino acids, 
organic acids and other low-molecular-weight compounds. 
Additionally, there are about 7200 protein and DNA sequences linked 
to these metabolite entries (115, 116). Considering the diversity of 
metabolites and the span of their concentration levels, a combination 
of techniques is used for their identification. The most commonly used 
techniques are nuclear magnetic resonance and various types of 
mass spectrometry (MS), most often combined with a 
chromatographic separation process, such as gas or liquid 
chromatography (102).  
Several metabolomic profiles have been described in diabetes. Orešič 
described increased levels of succinic acid and phosphatidylcholine 
at birth in patients who would later develop type 1 diabetes(18). He 
also shows reduced levels of triglycerides and antioxidant ether 
phospholipids through childhood and increased levels of 
proinflammatory lysophosphatidilcolines before seroconversion and 
occurrence of anti-GAD antibodies (18). Li & Xu found increased levels 
of 2-hydroxyisobutyric acid, linoleic acid, palmitic acid and phosphate 
in patients with diabetes when compared to healthy controls, 
reflecting induction of insulin resistance (117). A German study 
analysing the metabolome on multiple platforms unsurprisingly found 
increased levels of sugar metabolites and a reduced level of 1,5-
anhidroglucitol, increased level of branched chain amino acids (used 
in gluconeogenesis), lower phosphatidylcholine and higher 
51 
 
phosphatidylethanolamine (subtler markers of dyslipidaemia), β-
hydroxibutyrate (reflecting a shift to fatty acid metabolism as source 
of energy), but also higher levels of 3-indoxyl sulphate, a known 
nephrotoxin and stimulant of progression of renal failure. Further 
metabolomic studies are required, particularly in type 1 diabetes and 
they may enhance our understanding of the pathophysiology of the 
condition.
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1.6 Aims of this thesis 
 
The aims of this work were:  
To establish whether extracellular mRNAs previously found to be 
significantly differentially expressed in glucose-non-responsive cells 
from insulin-producing cell lines were found in human serum,  
To establish whether the extracellular mRNAs identified in the cell line 
work were differentially expressed in humans with newly diagnosed 
type 2 diabetes when compared to healthy controls,  
To investigate the proteomic profile of the patients with newly 
diagnosed type 1 diabetes, as well as changes occurring later in the 
course of type 1 diabetes, and 
To determine the metabolomics profile of patients with new onset 
type 1 diabetes when compared to healthy controls.  
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2 Materials & methods 
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2.1 Subjects 
 
The local ethics committee approved the study and all subjects gave 
written informed consent before entering it. 
We recruited patients with newly diagnosed type 2 diabetes, patients 
with newly diagnosed type 1 diabetes, patients with long-term type 1 
diabetes and healthy controls. 
Samples from patients with newly diagnosed type 2 diabetes were 
labelled T2Nx. Samples from patients with newly diagnosed type 1 
diabetes were labelled T1Nx, while samples from patients with 
established diabetes were labelled T1Ox. Samples from controls were 
labelled Ux, when their BMI was <30 kg/m2, and Mx, where their BMI 
was over 30 kg/m2..  
 
2.1.1 Patients with newly diagnosed type 2 diabetes 
 
We recruited 19 patients (10 male, 9 female) in whom type 2 diabetes 
(T2DM) has been diagnosed up to 6 months previously and 19 
age/sex/BMI-matched controls. The patients with new type 2 diabetes 
were all referred by their general practitioners (GPs) to the 
Department of Endocrinology and Diabetes in Connolly Hospital, 
Blanchardstown between January 2008 and January 2009. Their 
diabetes was either diet-controlled (N=8) or they were treated with 
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metformin only (N=11). Characteristics of these patients and their 
controls are presented in table 3.2.1. 
We analysed samples from these patients and their controls for 
extracellular mRNAs, previously found to be differentially expressed in 
conditioned medium of glucose-unresponsive vs. glucose-responsive 
cell lines (45, 91).  
 
2.1.2 Patients with newly diagnosed type 1 diabetes 
 
Eight patients with type 1 diabetes diagnosed within six months prior to 
entering the study were invited to take part (labelled as ‘T1DM new’ or 
T1Nx). They presented to the Department of Endocrinology in Connolly 
Hospital Blanchardstown following referral by their GPs between April 
2008 and April 2010.  
The patients were instructed to come in fasting (defined as no food 
from midnight). They were instructed not to take any insulin on the 
morning of testing. The last ‘allowed’ insulin dose was long-acting 
insulin the night before.  
The samples of patients with newly diagnosed type 1 diabetes were 
analysed by proteomic and metabolomic methods. These patients 
and their controls are presented in table 4.2.1. 
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2.1.3 Patients with established type 1 diabetes 
 
From the cohort of patients with established diabetes type 1, we 
recruited 8 patients with long-term type 1 diabetes, defined as 18 
months and more, with average duration of disease of 14±9 years 
(range 5-26 years).  
The patients were instructed to come in fasting (defined as no food 
from midnight). They were instructed not to take any insulin on the 
morning of testing. The last ‘allowed’ insulin dose was long-acting 
insulin the night before.  
Proteomic and metabolomic analyses were performed on these 
samples, labelled ‘T1DM old’ or T1Ox.  
These patients and their controls are presented in table 4.2.2. 
The results of proteomic analysis were validated by extending ELISA 
validation on the sample of 30 patients with established type 1 
diabetes, recruited with same inclusion/exclusion criteria. 
Characteristics of the cohort of 30 patients with established type 1 
diabetes are presented in table 4.2.3.  
2.1.4 Healthy controls  
The healthy controls were recruited from the employees of the 
Connolly Hospital through written advertisements on department 
boards, as approved by the Ethics Committee.  They were age-, BMI- 
and sex-matched to patients. Their samples were labelled at 
recruitment as Ux, if their BMI was ≤30kg/m2. and Mx, if their BMI was 
>30kg/m2.  
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All healthy controls had oral glucose tolerance tests done to exclude 
diabetes, using a standard oral glucose load of 75g. The accepted 
normal values used were: for fasting glucose, 5.6 mmol/L and for 2-
hour postprandial glucose, 7.8 mmol/L, as per American Diabetes 
Association guidelines (38).  
Samples from healthy controls were used for mRNA extraction, 
proteomic and metabolomic profiling. The characteristics of healthy 
controls are presented in tables 3.2.1, 4.2.1, 4.2.2 and 4.2.3.  
 
 
2.2 Study protocol and laboratory 
methods 
In this section, laboratory methods common to all analyses are 
described. 
At screening, a full history was taken, including diabetes history, 
symptoms of diabetes complications, past medical history, family 
history, history of gestational diabetes (in females), smoking history, 
steroid use in the six months preceding the diagnosis,  and current 
prescribed and over-the-counter medications.  on exercise was 
collected by patients’ self-reporting; no grading of intensity of physical 
activity was attempted. Full physical examination was performed, 
including retinal exam in patients with diabetes. Biometric data 
(height, weight, waist circumference, hip circumference, blood 
pressure, heart rate) were collected. Blood pressure was measured 
once, sitting, after completion of the questionnaire. Heart rate was 
measured at the same time, sitting, counting the beats in 30 s and 
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multiplying by 2; this was confirmed by ECG . Waist circumference was 
measured on bare skin, half-way between lower ribs and iliac crest. 
Hip circumference was measured at the maximum buttock 
circumference level.  
 Blood was drawn for measurement of fasting plasma glucose, insulin, 
HbA1c, total cholesterol, HDL, LDL (calculated), triglycerides, bilirubin, 
aspartate aminotransferase (AST), alanine transaminase (ALT), gama-
glutamyl transferase (GGT), urea, creatinine, sodium (Na), potassium 
(K),  C-reactive proteine (CRP), calcium (Ca), phosphate (PO4), 
erythrocyte sedimentation rate (ESR) and full blood count (FBC). All 
samples were coded at collection (T2N for patients with newly 
diagnosed type 2 diabetes, T1N for patients with newly diagnosed 
type 1 diabetes, T1O for patients with established, ‘old’, type 1 
diabetes, U for controls with BMI<30, M for controls with BMI > 30).  
Homeostatic model assessment (HOMA) of insulin resistance (IR) was 
calculated in type 2 diabetes patients and their controls, from fasting 
glucose and fasting insulin values using the online calculator supplied 
by the Diabetes Trials Unit at The Oxford Centre for Diabetes, 
Endocrinology and Metabolism (118, 119) 
Most routine blood tests were performed in the local laboratory. 
Biochemistry tests were analysed using Vitros 5600 and the Vitros 5.1 
Fusion analysers from Ortho-Diagnostics (Johnson & Johnson, UK): 
glucose by glucose oxidation colorimetry, cholesterol and triglyceride 
by enzymatic reactions colorimetry, HDL by colorimetric selective 
hydrolisation, bilirubin by end-point dual wavelentgth absorbance 
colorimetry, AST by  multi-point enzymatic spectrophotometry, ALT by 
multi-point enzymatic reflectance spectrophotometry, GGT by multi-
point rate enzymatic spectrophotometry, urea by urease enzymatic 
colorimetry, creatinine by enzymatic two-point rate colorimetry, 
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sodium and potassium by direct potentiometry, calcium by Arsenazo 
III dye colorimetry, phosphate by ammonium molibdate colorimetry.  
Haemoglobin A1C was analysed using reversed phase cation 
exchange chromatography on Adams™ HA-8160 (Arkray Inc, Kyoto, 
Japan/ Menarini, UK).  Spot urine was collected and checked for 
microalbuminuria using Olympus microalbumin kit on Olympus 5400 
analyser (Olympus, UK). Full blood count was analysed on Coulter 
LH780 (Beckman Coulter Inc, Brea, CA, USA) and ESR on Alifax Test 1 
(HAEM-008) (Alifax S.p.A, Padova, Italy). Insulin was analysed in St. 
James’s Hospital, Dublin, using the ST AIA-PACK IRI two-site 
immunoenzymometric assay (TOSOH Bioscience, Inc, San Francisco, 
USA).  
Samples, identified by code only, were transported to Dublin City 
University, National Centre for Cellular Biotechnology for RNA and 
proteomics analyses. Metabolomic analyses were performed by 
Metabolon Inc. USA 
The blood for RNA, proteomic and metabolomic analyses was sent to 
Dublin City University (DCU) within 1-2 hours of venepuncture. Two 
blood specimens of approximately 10mL were taken and the red 
blood cells were allowed to clot naturally. These specimens were 
processed in DCU within 3-4 hours of blood draw. Serum specimens 
from control volunteers (no history or symptoms of diabetes) were also 
collected and processed the same way. Upon arrival to Dublin City 
University, samples were re-coded (DS-1, DS-2…).  
Blood specimens were processed by removing the serum from the 
clotted blood and placing into a 10mL centrifuge tube. The tubes 
were then centrifuged at room temperature for 15 minutes at 400 rcf 
(relative centrifugal force). After centrifugation the cleared serum was 
carefully removed and passed through a 0.45μm filter to further ensure 
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no particles / platelets were retained. The serum was then aliquoted 
into 1mL aliquots and stored at -80°C until analysed. 
For metabolomic studies, blood specimens were re-coded by 
Metabolon Inc, as described in section 5.1.  
Details of mRNA extraction, proteomics and metabolomic methods 
are presented in sections 3.1, 4.1 and 5.1.  
Data were analysed using Microsoft Office Excel 2007 (Microsoft, , 
Redmond, WA 98052-6399, USA) and IBM SPSS 20 (IBM Corporation, 
New York, NY10504-1722, USA). Differences between groups were 
assessed using T-tests and Chi-squares, as appropriate. Relationships 
were assessed by correlation calculation, using Spearman’s 
coefficients because of small group size.  
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3 Serum mRNA analysis in newly-
diagnosed type 2 diabetes patients
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3.1 Materials and methods 
3.1.1 Identification of mRNA targets 
 
Several differentially expressed mRNAs were recently investigated in 
glucose-responsive vs. glucose-unresponsive mouse insulinoma (MIN-6) 
cell lines. Our colleagues in Dublin City University recently reported a 
direct association between thioredoxin-interacting protein (Txnip) and 
glucose-stimulated insulin secretion in MIN-6 cell lines; specifically, 
increasing Txnip levels correlated with increased intracellular reactive 
oxygen species levels and with significant glucose-sensitive insulin 
secretion loss (91). Conversely, both transient and stable knock-down 
of Txnip expression was associated with glucose-stimulated insulin 
secretion recovery (91). In addition, mRNA encoded by following 
genes was detected in extracellular conditioned medium of MIN-6 
and monkey kidney fibroblast cells engineered to produce human 
preproinsulin (PPI) (Vero-PPI): pancreatic and duodenal homeobox 1 
(Pdx1), neuropeptide Y (Npy), early growth response 1 (Egr1), 
phospholipase D1 (Pld1), chromogranin B (Chgb), insulin 1 (Ins1), insulin 
2 (Ins2), and actin β (Actb). (45). Serum from patients with type 2 
diabetes and healthy controls was analysed for all of these. 
 
3.1.2 RNA isolation from serum using TriReagent 
 
Frozen serum samples were allowed to thaw on ice. Upon thawing, 
serum samples were aliquoted into 250 L in labelled Eppendorf tubes. 
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To each 250 L serum aliquot 750 L TriReagent was added. 
TriReagent/serum samples were allowed to sit for 5 minutes to ensure 
complete dissociation of nucleoprotein complexes. 0.2mL of 
chloroform was added to each tube and shaken vigorously for 15 
seconds, then allowed to stand for 15 minutes at room temperature. 
The resulting mixture was then centrifuged at 13,000 rpm in a 
microcentrifuge for 15 minutes at 4oC. The colourless upper aqueous 
phase (containing RNA) was removed into a fresh RNase-free 
Eppendorf tube. Glycogen (Sigma, G1767) 1.25 µl (final concentration 
120 µg/ml) and 0.5 ml of ice-cold isopropanol (Sigma, I9516) were 
added. The samples were mixed by inverting, incubated at room 
temperature for 10 minutes and stored at -20˚C overnight, to ensure 
maximum RNA precipitation.  
Tubes were then centrifuged at 12,000 rpm for 30 minutes at 4˚C to 
pellet the precipitated RNA. Taking care not to disturb RNA pellet, the 
supernatant was removed and the pellet was subsequently washed 
by the addition of 750µL of 75% of ethanol and vortexed. 
Centrifugation was followed at 7,500 rpm for 5 minutes at 4oC. The 
supernatant was removed and the wash step was repeated. Each 
RNA pellet was allowed to air-dry for 10 minutes and subsequently re-
suspended in 5µL of RNase free water. To facilitate dissolution, 
repeated pipetting was done (Figure 3.1.1). 
 
3.1.3 RNA quantification using NanoDrop 
 
RNA was quantified spectrophotometrically at 260nm and 280nm 
using the NanoDrop® (ND-1000 spectrophotometer). A 1 L aliquot of 
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RNA was placed on the nanodrop pedestal, which is the receiving 
optic fibre. A second fibre optic cable, the source fibre, is brought into 
contact with the liquid sample, causing the liquid to bridge the gap 
between the fibre optic ends. The ND-1000 software automatically 
calculated the quantity of RNA in the sample based on an OD260 
being equivalent to 40mg/mL RNA. The software simultaneously 
measured the OD280 of the samples, allowing the purity of the sample 
to be estimated from the ratio of OD260/OD280. This was typically in 
the range of 1.8-2.0. A ratio of <1.6 indicated that the RNA may not be 
fully in solution. The RNA was diluted to 1 μg/μl stocks for the reverse 
transcription (RT). 
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Figure 3.1.1  RNA isolation using TriReagent from serum (Adapted with permission from Sweta 
Rani’s PhD Thesis, Investigation of molecular and cellular events associated with β cell function 
and elucidation of extracellular RNAs as potential biomarker for diabetes, Dublin City University, 
2008) 
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3.1.4 Quantitative real time reverse transcription-
polymerase chain reaction (qRT-PCR)  
 
TaqMan probes are oligonucleotides that have fluorescent reporter 
dyes attached to the 5' end and a quencher moiety (molecule 
capable of quenching the fluorescence of the reporter) coupled to 
the 3' end. Hence, under normal circumstances, the fluorescent 
emission from the probe is low. During the PCR, the probe binds to the 
gene of interest and becomes cleaved by the polymerase, hence the 
reporter and quencher are physically separated and the fluorescence 
increases (Fig. 3.1.2)  
 
Figure 3.1.2 TaqMan qRT-PCR principle (Adapted from product insert).  
Messenger RNA was copied to cDNA by reverse transcriptase using an 
oligo dT primer. First strand cDNA was synthesised by reverse 
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transcription (RT) by mixing 1 μL of oligodT with 4 μL of RNA  in a 0.5 ml 
Eppendorf tube (Eppendorf, 0030 121 023) and heated at 70°C for 10 
min followed by cooling on ice. 
In order to exclude any amplification product derived from genomic 
DNA or any other contaminant that could contaminate the RNA 
preparation, total RNA without reverse transcription was used as a 
negative control. Water on its own was amplified as a negative 
control to rule out presence of any contaminating RNA or DNA. 
The TaqMan® Real time PCR analysis was preformed using the 
Applied BioSystems Assays on Demand PCR Kits, using primer probe 
pairs as outlined in Table 3.1.1.  
Two μl of the cDNA was added to the MicoAmp fast optical 96-well 
reaction plate (Applied BioSystems, 4346906) followed by 18 μl of 
reaction master mix (as outlined in Table 3.1.2) 
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Table 3.1.1 qRT-PCR primer and their assay ID used for serum study 
Primer pair Supplier Supplier assay ID 
Thioredoxin interacting protein Applied BioSystems Hs00197750_m1 
Egr1 Applied BioSystems Hs00152928_m1 
Chromogranin B Applied BioSystems Hs00174956_m1 
Pancreatic and duodenal homeobox 1 Applied BioSystems Hs00426216_m1 
Phospholipase D1 Applied BioSystems Hs00160118_m1 
Neuropeptide Y Applied BioSystems Hs00173470_m1 
Insulin Applied BioSystems Hs00355773_m1 
Pax4 Applied BioSystems Mm01159036_m1 
Β-actin Applied BioSystems 4352933E 
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Table 3.1.2 Reagents for Taqman® qRT-PCR reaction. 
Reagents Volume 
Nuclease-Free water (Ambion, 9930) 6.8 μl 
TaqMan® Fast Universal PCR master mix (2 X) (Applied BioSystems, 
4352042) 
10 μl 
AmpErase® Uracil N-glycosylase (UNG) (Applied BioSystems, N8080096) 0.2 μl 
Assay-on-demand 1 μl 
Total 18 μl 
The PCR protocol followed in this study was: activation, at 50°C for 2 
min, followed by denaturation at 95°C for 20 s, followed by 40 cycles 
of denaturation at 95°C for 3 s and annealing/ extension at 60°C for 
30s 
Real-time PCR data was analysed using the comparative cycle 
threshold (Ct) method, which involves comparison of the Ct values of 
the samples of interest with a control or calibrator sample (such as an 
untreated sample). The Ct values of both the calibrator and the 
samples of interest are normalised to an appropriate endogenous 
control (in our case, β-actin), generating a ΔCt for both the sample of 
interest and the control/calibrator samples.  
ΔCt = Ct [target] – Ct [endogenous control] 
ΔΔCt is then calculated as the difference between ΔCt for the 
sample and calibrator. 
ΔΔCt = ΔCt [sample] - ΔCt [calibrator] 
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Relative quantification (RQ) of target expression is calculated from the 
equation below as a difference of one Ct is equal to 2 fold change in 
expression level.  
RQ = 2-ΔΔCt 
RQ values greater than one indicate an increase in expression 
(equivalent to fold values), while RQ values between zero and one 
indicate a reduction in expression levels. To obtain a fold value of RQ 
between 0 and 1, inversion of RQ is required (1/RQ).  
RNA extraction was performed with help and guidance of Drs Sweta 
Rani and Erica Hennessy.  
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3.2 Results of mRNA extraction studies 
3.2.1 Subjects 
 
We recruited 19 patients (10 male, 9 female) in whom type 2 diabetes 
(T2DM) has been diagnosed up to 6 months previously, treated either 
with diet (n=8) or metformin (n=11) and 19 age/sex/BMI-matched 
controls. Their characteristics are presented in table 3.2.1.  
Both patients and controls were instructed to attend having fasted 
from midnight the night before. Control subjects had oral glucose 
tolerance test to exclude diabetes.  
 
Table 3.2.1 Characteristics of newly diagnosed type 2 patients (T2DM) and their controls 
 T2DM Controls P 
Age [years  (±SD)] 51.2 (±8.2) 48.4(±7.3) 0.39 
Sex (F:M) 9:10 9:10 1.0 
BMI [kg/m (±SD)] 31.45 ± 3.42 29.64 ± 4.04 0.23 
BP systolic [mmHg (±SD)] 137.6 (±16.8) 132.8 (±11.5) 0.45 
BP diastolic [mmHg (±SD)] 83.8 (±6.7) 80.7 (±6.3) 0.27 
Heart rate (beats/min) 68.5 (±9.6) 71.7 (±10.4) 0.32 
Subjects taking beta-blockers 3/19 1/19 0.6 
Waist/ hip ratio (±SD) 0.97 (±0.06) 0.93 (0.05) 0.10 
Duration of diabetes [months (±SD)] 3 (± 2.4) -- N/A 
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 T2DM Controls P 
Cigarette smoking [pack-years (±SD) 13.2 (±18.9) 9.5 (±10.4) 0.45 
Alcohol [units/wk (±SD) 8.32 (±16.13) 11.89 (±10.78) 0.42 
Exercise [min/wk (±SD)] 148.68 
(±160.64) 
225.26 
(±166.71) 
0.15 
HbA1C [% (±SD)] 7.43 (±1.71) 5.44 (±0.27) <0.01 
Fasting glucose [mmol/L (±SD)] 7.93 (±2.68) 5.12 (±0.37) <0.01 
Fasting insulin [mU/L (±SD)] 10.3 (±5.3) 8.7 (±7) 0.43 
HOMA IR (±SD) 1.48 (±0.77) 1.13 (±0.89) 0.20 
Total cholesterol [mmol/L (±SD)] 5.13 (±1.05) 5.56 (±0.82) 0.05 
LDL [mmol/L (±SD)] 2.85 (±1.27) 3.36 (±1.57) 0.21 
HDL [mmol/L (±SD)] 1.18 (±0.31) 1.37 (±0.47) 0.14 
Triglyceride 1.80 (±1.44) 1.70 (±1.38) 0.82 
Statin use (n, %) 12 (63%) 1(5%) <0.01 
Aspirin use (n, %) 11 (58%) 3 (16%) 0.02 
Antihypertensive use (n,%) 5 (19%) 2 (10%) 0.40 
 
3.2.2 Extracellular mRNA 
 
Of the eight mRNA previously detected in the extracellular medium of 
the extracellular conditioned medium of MIN-6 and monkey kidney 
fibroblast cells engineered to produce human preproinsulin (Vero-PPI), 
we found two in the sera of patients with type 2 diabetes and controls: 
Txnip and Egr1 (45, 91). Expression of both these mRNAs was 
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compared to expression of endogenous control, β-actin, detected in 
both patients and healthy controls.  
 
3.2.2.1 Thioredoxin-interacting protein (Txnip) 
 
Expression of Txnip in sera of patients with newly diagnosed type 2 
diabetes and healthy controls was markedly heterogeneous. There 
was no significant difference in expression of Txnip, as calculated by 
independent T-test for ΔCtTxnip of patients with type 2 diabetes and 
ΔCtTxnip of controls (Figure 3.1.1, p=0.457). Data are presented in 
table 3.1.2.  Matched samples (patients and corresponding healthy 
controls) are presented in the same row. Expression of Txnip is 
calculated as explained in section 3.1.4.   
 
Figure 3.2.1  Expression of Txnip in patients with newly-diagnosed type 2 diabetes and their 
healthy controls. Error bars represent 95% confidence intervals. 
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Table 3.2.2 Txnip expression in patients with newly diagnosed type 2 diabetes (T2DM) and their healthy controls. 
T2DM Control 
ΔΔ Ct RQ Fold 
Sample Code Ct txnip Ct b-actin Δ Ct Sample Code Ct Txnip Ct b-actin Δ Ct 
DS-30 T2N9 37.394 30.997 6.397 DS-32 M6 27.603 29.533 -1.930 8.327 0.003 -321.130 
DS-28 T2N8 Undetected 38.432  DS-43 U16 32.596 34.506 -1.910    
DS-10 T2N4 32.716 34.321 -1.605 DS-3 M2 31.589 33.268 -1.679 0.074 0.950 -1.050 
DS-9 T2N2 31.419 33.559 -2.140 DS-52 M10 31.320 32.095 -0.775 -1.365 2.576 2.576 
DS-59 T2N12 36.253 38.339 -2.086 DS-55 M11 31.246 31.176 0.070 -2.156 4.457 4.457 
DS-23 T2N6 31.522 33.305 -1.783 DS-18 U6 32.428 34.116 -1.688 -0.095 1.068 1.068 
DS-41 T2N11 33.591 34.750 -1.159 DS-53 M9 35.159 34.835 0.324 -1.483 2.795 2.795 
DS-14 T2N3 30.188 34.521 -4.333 DS-2 M1 28.371 29.488 -1.117 -3.216 9.292 9.292 
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T2DM Control 
ΔΔ Ct RQ Fold 
Sample Code Ct txnip Ct b-actin Δ Ct Sample Code Ct Txnip Ct b-actin Δ Ct 
DS-31 T2N10 Undetected 37.946  DS-49 U24 Undetected 39.340     
DS-15 T2N5 28.837 30.788 -1.951 DS-54 U20 Undetected 38.612     
DS-21 T2N7 32.664 35.110 -2.446 DS-16 U5 33.735 35.665 -1.930 -0.516 1.430 1.430 
DS-103 T2N20 36.847 36.639 0.208 DS-19 M5 33.766 35.323 -1.557 1.765 0.294 -3.400 
DS-106 T2N22 undetected 36.698  DS-51 U19 35.093 39.031 -3.938    
DS-110 T2N23 35.583 38.129 -2.546 DS-37 U13 34.653 39.761 -5.108 2.562 0.169 -5.900 
DS-111 T2N24 undetected 38.685  DS-1 U4 36.524 37.104 -0.580    
DS-117 T2N25 34.432 37.268 -2.836 DS-36 U11 35.289 38.317 -3.028 0.193 0.875 -1.100 
DS-134 T2N28 36.474 37.247 -0.774 DS-33 U10 36.102 36.144 -0.042 -0.732 1.660 1.700 
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T2DM Control 
ΔΔ Ct RQ Fold 
Sample Code Ct txnip Ct b-actin Δ Ct Sample Code Ct Txnip Ct b-actin Δ Ct 
DS-135 T2N29 34.473 39.437 -4.964 DS-8 M3 35.843 38.260 -2.417 -2.547 5.844 5.800 
DS-96 T2N19 32.044 34.656 -2.613 DS-72 M12 34.633 39.294 -4.661 2.049 0.242 -4.100 
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In correlation analysis, data of the patient with newly-diagnosed type 
2 diabetes who was a significant outlier (T2N9) were disregarded as 
they were skewing the results significantly. It is unclear what is a cause 
of the significantly different result in T2N9—it is derived both from 
decreased expression of Txnip in subject T2N9, as well as increased 
expression of β-actin, when comparing it with other subjects with 
T2DM. As presence of β-actin demonstrates no issues with RNA 
extraction or PCR process, it is most likely this result is due to genuinely 
low Txnip level in this individual, the reason for which is unclear. The 
clinical characteristics of T2N9 were similar to the other patients with 
newly diagnosed type 2 diabetes. As inclusion of T2N9 produced 
statistically significant results, which could potentially be misleading, 
we decided to exclude this sample from further statistical analysis. 
In the remainder of the patients with newly-diagnosed diabetes, there 
was no correlation between ∆CtTxnip and age of patient, fasting 
glucose, fasting insulin, BMI, HbA1C, smoking (pack-years), exercise 
(self-reported in minutes per week), systolic or diastolic blood pressure, 
waist-hip ratio, HOMA%B, HOMA%S, HOMA-IR, total cholesterol or LDL.  
There was no difference in Txnip expression in patients with type 2 
diabetes who took metformin, medication postulated to act on 
hepatic insulin sensitivity through modification of Txnip, compared to 
patients who were only diet-controlled (Figure 3.2.2)(89, 120). 
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Figure 3.2.2 Expression of mean ∆CtTxnip in patients with newly-diagnosed type 2 diabetes 
depending on whether they were taking metformin (n=11) or were diet controlled (n=8). Error 
bars delineate 95% confidence intervals. 
ΔCtTxnip was inversely correlated to total cholesterol and HDL level in 
patients with diabetes who were not on statins (Spearman’s ς-0.812, 
p=0.05 and Spearman’s ς -0.841, p=0.036, respectively) (Figures 3.2.3 
and 3.2.4) 
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Figure 3.2.3 Correlation between ΔCtTxnip and total cholesterol in patients with newly-diagnosed 
type 2 diabetes who were not on statin treatment. 
 
Figure 3.2.4 Correlation between ΔCtTxnip and HDL in patients with newly diagnosed type 2 
diabetes who were not taking statins 
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3.2.2.2 Early growth response 1 (Egr1) 
 
Egr1 was detected in 18 out of 38 samples we analysed. More 
specifically, it was detected in 9 out of 19 patients with newly 
diagnosed type 2 diabetes and 9 of 19 healthy controls. The samples 
were analysed in two separate batches, 11 sample pairs (patients and 
controls) first and the remaining 8 sample pairs at a later date. No Egr1 
was found in the second batch of 8 sample pairs.   
It is unclear what caused the non-detection in the entire second 
batch as the methodology used was the same. In the first batch, in 
samples in which Egr1 was detected the levels were very low. When 
the Ct goes beyond 40,  it is designated as undetected, as at this 
point the instrument cannot distinguish between background noise in 
the system and actual signal from Egr1 detection. The only discernible 
difference between the batches was the prolonged storage time at -
80°C. As there are RNAses present in the serum, prolonged storage 
time might have led to RNA degradation. We wonder whether 
prolonged storage time might have pushed the previously low Egr1 
levels in both patients and controls into the undetectable range, 
beyond the level of sensitivity for the instrument. 
Here we present data from the first 11 patient/control sample pairs.  
The results are presented in table 3.2.3. 
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Table 3.2.3 Egr1 expression in patients with newly diagnosed type 2 diabetes and their healthy controls. 
T2DM Control 
 ΔΔ Ct 
  
RQ fold Sample Code Ct Egr 1 Ct β-actin Δ Ct Sample Code Ct Egr 1 Ct β-actin Δ Ct 
DS-30 T2N9 37.930 35.437 2.493 DS-32 M6  Undetected 38.678         
DS-28 T2N8 36.560 31.916 4.644 DS-43 U16 36.008 35.165 0.843 3.801 0.072 -13.940 
DS-10 T2N4 37.034 34.464 2.570 DS-3  M2 35.578 33.094 2.484 0.086 0.942 -1.060 
DS-9  T2N2 38.036 33.901 4.135 DS-52 M10 34.451 32.249 2.202 1.933 0.262 -3.820 
DS-59 T2N12 Undetected 38.779   DS-55 M11 33.059 31.542 1.517       
DS-23 T2N6 Undetected 33.545   DS-18 U6 36.115 33.127 2.988       
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T2DM Control 
 ΔΔ Ct 
  
RQ fold Sample Code Ct Egr 1 Ct β-actin Δ Ct Sample Code Ct Egr 1 Ct β-actin Δ Ct 
DS-41 T2N11 37.310 33.286 4.024 DS-53 M9 38.134 33.654 4.480 -0.456 1.372 1.370 
DS-14 T2N3 38.356 35.221 3.135 DS-2  M1  34.325 32.308 2.017 1.118 0.461 -2.170 
DS-31 T2N10 38.741 35.000 3.741 DS-49 U24 37.363 34.951 2.412 1.329 0.398 -2.510 
DS-15 T2N5 36.229 33.699 2.530 DS-54 U20 35.072 32.599 2.473 0.057 0.961 -1.040 
DS-21 T2N7 38.103 33.242 4.861 DS-16 U5 Undetected 35.030         
DS-103 T2N20 Undetected 36.639   DS-19 M5 Undetected 35.323         
DS-106 T2N22 Undetected 36.698   DS-51 U19 Undetected 39.031         
83 
 
T2DM Control 
 ΔΔ Ct 
  
RQ fold Sample Code Ct Egr 1 Ct β-actin Δ Ct Sample Code Ct Egr 1 Ct β-actin Δ Ct 
DS-110 T2N23 Undetected 38.129   DS-37 U13 Undetected 39.761         
DS-111 T2N24 Undetected 38.685   DS-1 U4  Undetected 37.104         
DS-117 T2N25 Undetected 37.268   DS-36 U11 Undetected 38.317         
DS-134 T2N28 Undetected 37.247   DS-33 U10 Undetected 36.144         
DS-135 T2N29 Undetected 39.437   DS-8 M3 Undetected 38.260         
DS-96 T2N19 Undetected 34.656   DS-72 M12 Undetected 39.294         
84 
 
Egr1 was significantly more expressed in patients with newly 
diagnosed type 2 diabetes with ΔCtEgr1 at 3.570 (± 0.922) vs. ΔCtEgr1 
of 2.380 (± 1.004) in healthy controls (p=0.019) (Figure 3.2.5). 
 
 
Figure 3.2.5 Mean Egr1 expression in patients with newly diagnosed type 2 diabetes vs. 
controls.Error bars delineate 95% confidence intervals. 
In patients with type 2 diabetes, ΔCtEgr1 was inversely correlated with 
waist-hip ratio (Spearman’s ρ -0.786, p=0.021) (Figure 3.2.6).  
 
Figure 3.2.6 Correlation between ΔCtEgr1 and waist/hip ratio in patients with newly diagnosed 
type 2 diabetes.  
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Apart from the clear relationship between the ∆CtEgr1 and waist/hip 
ratio, there was no significant correlation between ΔCtEgr1 and any 
marker of glycaemic/ lipaemic control or metabolic health in patients 
with newly diagnosed type 2 diabetes (BMI, blood pressure, heart rate, 
age, smoking in pack-years, exercise level in minutes/week, fasting 
glucose and fasting insulin level, HOMA%B, HOMA%S, HOMA-IR, total 
cholesterol, HDL, LDL, triglyceride level)  
In healthy controls, ∆CtEgr1 was inversely correlated with systolic 
blood pressure (Spearman’s ρ -0.667, p=0.05; figure 3.2.7) and heart 
rate (Spearman’s ρ -0.765, p=0.016; figure 3.2.8), but it bore no 
relationship to any other parameter of metabolic health tested.  
 
Figure 3.2.7 Correlation of ΔCtEgr1 and systolic blood pressure in healthy controls. 
 
Figure 3.2.8 Correlation between ΔCtEgr1 and heart rate in healthy controls.
86 
 
3.2.3 Summary of mRNA biomarker studies 
 
There was no significant difference of expression of thioredoxin-
interacting protein (Txnip) between patients with newly-diagnosed 
diabetes and their controls.  
In patients with newly-diagnosed diabetes not taking cholesterol-
lowering medications, Txnip expression was inversely correlated to 
total cholesterol, driven by inverse correlation to HDL.  
Egr1 was significantly more expressed in patients with newly 
diagnosed type 2 diabetes, when compared to healthy control 
subjects.  
In patients with newly-diagnosed type 2 diabetes, Egr1 expression was 
inversely correlated with waist-hip ratio; this was not observed in 
healthy controls. In healthy controls, Egr1 expression was inversely 
correlated with systolic blood pressure and heart rate, but there was 
no relationship with any other metabolic health parameter examined. 
Relationship between Egr1 and systolic blood pressure was not present 
in patients with newly diagnosed diabetes type 2.   
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3.3 Discussion on findings of serum 
mRNA analysis 
3.3.1 Txnip 
Thioredoxin-interacting protein, a part of one of the major redox 
systems in mammals, thioredoxin (TRX) system, binds to the active 
cysteine residue of thioredoxin and inhibits its antioxidative function 
(68). Additionaly, Txnip acts independently of its binding to TRX on cell 
growth inhibition through arrestin domain-mediated suppression of 
glucose uptake and metabolic reprogramming (72, 121). Txnip 
appears to regulate both insulin-dependent and insulin-independent 
pathways of glucose uptake in human skeletal muscle through a 
phosphorylated G protein-coupled receptor (72, 79). Txnip induces 
gluconeogenesis in the liver and blocks cellular glucose uptake (74, 
122).   
In our study, there was no difference between Txnip expression in sera 
of patients with newly-diagnosed type 2 diabetes and their matched 
controls (Figure 3.2.1) 
The first important question is: how much Txnip will wash off into the 
serum from tissues in which it is differentially expressed? In the only 
study known to us which simultaneously looked at Txnip expression in 
the tissue and Txnip serum levels, the over-expression in the tissue was 
not reflected in the increased serum level (123). It is therefore possible 
that the possible differential expression in tissues, observed in other 
human studies, did not translate into differentially expressed serum 
levels in our study (79). 
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We found no significant correlation between serum Txnip expression 
and fasting glucose or fasting insulin level, or indeed HbA1C.   
In various cell studies, glucose increased Txnip expression in tissues: in 
pancreatic islets, fibroblasts, mesangial kidney cells, rat 
cardiomyocytes and vascular endothelial and smooth muscle cells, 
human adipocytes (79, 124-128). In Parikh’s study, Txnip expression was 
increased in muscle biopsies of individuals with impaired glucose 
tolerance and diabetes, both in fasting samples and samples after 2h 
of hyperinsulinaemic-euglycaemic clamp, compared to healthy 
controls (79).  
In the same study, when serial muscle biopsies of healthy individuals 
were analysed before and after 2 hours of hyperinsulinaemic-
euglycaemic clamp, Txnip mRNA expression was suppressed in the 
second sample, i.e. was suppressed by insulin (79).  
Parikh points out that in insulin receptor-knockout mice treatment of 
streptozotocin-treated mice with insulin failed to suppress Txnip 
expression, indicating that intact insulin signalling was necessary for 
Txnip suppression by insulin (79).  
While we did not have the benefit of the hyperinsulinaemic-
euglycaemic clamp to assess paired samples in the same subject and 
hence could not measure glucose uptake or effect of insulin on Txnip, 
while keeping glucose level steady, we would have expected an 
increase of Txnip expression with raised fasting glucose, either as a 
spill-over from the liver or from the muscle. Txnip over-expression is 
associated with gluconeogenesis. Liver insulin resistance and, 
consequently, hyperglycaemia due to gluconeogenesis, is the 
pathophysiological basis for raised fasting glucose levels (74, 129), but, 
again, this pattern of relationship was not observed in our study as 
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reflected in Txnip mRNA. A possible explanation for this again might 
have arisen from different sample choice: as we studied serum, not 
tissue Txnip mRNA expression, a possible tissue expression increase, be 
it liver or muscle, may not have translated into an increased serum 
level.  
We found no difference in Txnip expreession in patients with diabetes 
who took metformin compared to those who were treatment-naïve 
(Figure 3.2.2). Metformin acts through improvement of hepatic insulin 
sensitivity via induction of cAMP kinase, causing enhancement of 
insulin-mediated suppression of gluconeogenesis and reduction of 
glucagon-stimulated gluconeogenesis (130-132). While two recent 
studies suggest that AMP kinase is a regulator of Txnip transcription via 
modulation of carbohydrate response element-binding protein 
(ChREBP) and that transcription of Txnip is repressed by metformin, no 
support for these findings could be found in the sera of our patients 
(89, 120). This, again, could be due to the increased tissue levels of 
mRNA not spilling into the sera in amount sufficient for detection.   
  
Another fact which might have affected our results was the absence 
of difference in insulin resistance between our patients and controls 
(Table 3.2.1). Our patients were significantly less insulin resistant than 
previously reported cohorts, with a HOMA-IR of 1.48±0.77. In a study of 
Mexican American subjects randomly selected from 2000 Census 
data, HOMA-IR was 3.8 in 39% of subjects; this threshold was taken as 
a mark of insulin resistance. In a study of subjects with normal glucose 
tolerance, randomly selected among staff in a Spanish hospital, 
HOMA-IR 75th percentile was at 2.6 (133, 134). Compared to these 
population data, our patients with newly diagnosed type 2 diabetes 
are surprisingly insulin sensitive.  
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It is difficult to compare our study to any of the above described. 
Firstly, we analysed Txnip mRNA in the serum, while all of the other 
data are either from non-human cell studies, cell studies or tissue 
samples. Our study also has a limitation of being a snapshot of fasting 
metabolism, rather than a reflection of a dynamic process of glucose 
handling.  
 
We wonder if it is possible that non-detection of differentially 
expressed levels of Txnip m RNA in our study could have been, at least 
in part, due to early stage of the disease in our patients, as evidenced 
by recent diagnosis, but, even more, by less insulin resistance than in 
some other studies. We intend to assess if serum expression of Txnip is 
different in patients with poorly controlled, longer-term diabetes.   
  
3.3.2 Egr1 
 
Egr 1 is a zinc-finger protein, functioning as a transcriptional regulator. 
In cell cultures, Egr1 expression is reported to be both inducible and 
repressed by insulin; glucose induces Egr1 mRNA transcription in 
various β-cell models (83, 92, 94, 135, 136).  
In diabetic Zucker rats, Egr1 is up-regulated and this has no effect on 
glucose-stimulated insulin secretion. Egr1 gene silencing inhibits 
proliferation of INS-1 cells in a glucose-independent manner, 
suggesting reduced Egr1 expression may contribute to decreased β-
cell proliferation and consequent β-cell failure (82). It has also been 
proposed that Egr1 overexpression is the mechanism by which 
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hyperinsulinism induces insulin resistance in adipocytes—by blocking 
phosphatidylinositide 3-kinases/ protein kinase B (PI3K/Akt) signalling 
through phosphatase and tensin homologue (PTEN) and augmenting 
extracellular signal-regulated kinase/ mitogen-activated protein 
kinase (Erk/MAPK) signalling through geranylgeranyl diphosphate 
synthase (GGPPS) (137).  
In our study, Egr1 was significantly more expressed in patients with 
newly-diagnosed type 2 diabetes than in their healthy controls. While 
this may appear expected, considering that insulin increases Egr1 
expression, there was no difference in fasting insulin level between 
patients and their healthy age-, gender- and BMI-matched controls. 
There was also no correlation between insulin level and Egr1 
expression.  
There was no correlation between Egr1 expression and any other 
marker of glycaemic control available to us (fasting glucose, HbA1C) 
either when the group was analysed as a whole or when only patients 
with type 2 diabetes were analysed separately.  
There is only one previous Egr1 human serum expression study known 
to us; this has shown Egr1 increase 1 and 2 hours after 75 g of oral 
glucose load as part of the oral glucose tolerance test (83). While 
fasting glucose was higher in the patients with newly diagnosed 
diabetes than in controls, there was no correlation observed between 
glucose level and Egr1 expression in our study, so it is possible that 
other postprandial factors, rather than glucose level per se, influence 
Egr1 expression.  
It is also known that Egr1 is a major transcription factor involved in 
atherosclerosis (138). Egr1 is five-fold more expressed in human 
atherosclerotic lesions compared to the adjacent tunica media (139) 
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and its pro-atherosclerotic action is insulin-induced; once stimulated 
by insulin, increased transcription of Egr1 entices endothelial cell 
proliferation and re-growth following mechanical injury (140).  
When only patients with newly-diagnosed type 2 were analysed, 
negative correlation was found between Egr1 expression and waist-
hip ratio. Waist-hip ratio is a known parameter of metabolic syndrome 
and Egr1 is an atherosclerosis marker; it is therefore somewhat 
surprising that Egr1 expression would be decreasing as the waist-hip 
ratio increases (141). We cannot find any reasonable hypothesis that 
would explain the observed phenomenon.  
In our study, there was no correlation between Egr1 and 
cardiovascular history (ischaemic heart disease, stroke disease) or 
blood pressure values, statin or antihypertensive medications use. 
In diabetic mice, Egr1 induces diabetic nephropathy by activating 
heparanase, an enzyme responsible for decomposition of glomerular 
basement membrane (142). We have found no relationship between 
Egr1 and creatinine levels or albumin-creatinine ratio in patients with 
newly-diagnosed diabetes.  
There is a paucity of human in vivo studies of Egr1 expression available 
for comparison. In vivo studies of patients with long-standing type 2 
diabetes and vascular complications are needed to assess if serum 
Egr1 can be used as a non-invasive marker of vascular atherosclerosis. 
Considering the problems with detection in our second batch, which 
was stored for a longer time, it may be wise to perform all the analyses 
as soon to draw time as possible.  
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4 Proteomics analysis in patients 
with established type 1 diabetes 
and newly-diagnosed type 1 
diabetes  
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4.1 Materials and methods 
 
Proteomic analysis was performed on serum samples from patients 
with newly-diagnosed type 1 diabetes, long-term type 1 diabetes, 
and two sets of controls: healthy controls (as defined in section 2.1, 
tables 4.2.1, 4.2.2 and 4.2.3) and a cohort of patients with various 
autoimmune conditions, whose sera were available from a previous 
experiment to our colleagues in DCU. The autoimmune group was 
included in this experiment to allow identification of markers directly 
related to type 1 diabetes, rather than markers of general 
autoimmune/inflammatory conditions. 
This additional group consisted of serum samples from patients with a 
range of autoimmune and inflammatory diseases such as rheumatoid 
arthritis, ulcerative colitis, asthma, eczema, systemic lupus 
erythematosus, Hashimoto’s thyroiditis, psoriatic arthritis and pernicious 
anaemia. The mean age of these patients was 31.4 ± 4.9 years. 
Unfortunately, we have no other biometric data or data related to 
glucose metabolism on them. 
4.1.1 Serum pre-treatment with ProteoMiner™ 
Serum samples were prepared using the ProteoMiner Protein 
Enrichment Kit (BioRad, 163-3007). ProteoMiner is a column-based 
technique, with the column containing a highly diverse bead-based 
library of peptide ligands. High-abundant proteins saturate their high 
affinity ligands and excess protein is washed away, while low 
abundant proteins are concentrated on their specific ligands.  (Figure 
4.1.1) 
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Figure 4.1.1. ProteoMiner™ technology. Each unique hexapeptide binds to a unique protein 
sequence. Because the bead capacity limits binding capacity, high-abundance proteins quickly 
saturate their ligands and excess protein is washed out. In contrast, low abundance proteins are 
concentrated on their specific ligands, thereby decreasing the dynamic range of proteins in the 
sample. When analysed in downstream applications, the number of proteins detected is 
dramatically increased. (Adapted from BIORAD ProteoMiner™ kit insert, available at 
http://wolfson.huji.ac.il/purification/PDF/AlbuminRemoval/BIORAD_ProteoMiner.pdf)  
 
ProteoMiner columns were prepared according to manufacturer’s 
instructions, 1mL of serum was then applied to column and rotated 
end-on-end for 2 hours to allow binding of protein to ligand. Column 
was then washed and proteins eluted in 300 L of elution buffer. 
50 L of elute was then processed using the ReadyPrep 2D Cleanup Kit 
(BioRad, 163-2130) according to manufacturer’s instructions. This kit 
allows for precipitation of protein leaving behind salts, detergents and 
nucleic acid contaminants. Precipitated protein was re-suspended in 
100 L of mass-spec grade water. Protein concentration was assessed 
96 
 
using Quick-Start Bradford Dye Reagent 1X (BioRad, 500-0205). Protein 
samples were diluted 1:4 with water, then 5 L diluted sample was 
added per well of a 96 well plate. Each sample was analysed in 
triplicate. 200 L of Bradford reagent was added to sample and 
incubated for 15 minutes. Absorbance was then read at 595nm. Using 
the calculated concentration, 20 g of each sample was used for the 
digestion steps. 
To prepare protein samples for digestion, samples were first incubated 
with 1 L 5mM dithiothreitol reducing agent for 30 minutes at 37ºC. 1 L 
of 25mM iodoacetamide was then added to each sample and 
incubated in the dark for 20 minutes at room temperature. Digestion 
of protein samples was performed with Endoproteinase Lys-C 
(Promega, V1071) at a ratio of 100:1, protein to enzyme, ie. 20μg of 
protein was digested with 0.2ug of Endoproteinase Lys-C. Samples 
were incubated at 37ºC for 3 hours to allow the digestion to occur. 
Samples were subsequently digested with trypsin. 7.5 L of trypsin and 
80 L of 50mM ammonium bicarbonate was added to each sample 
and incubated overnight at 37ºC. Following overnight incubation, 2% 
trifluoroacetic acid (TFA) and 20% acetonitrile were added to each 
sample to stop the trypsin digestion. 
 
4.1.2 Label-free liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS) 
 
Following the preparation of serum samples by ProteoMiner™, label-
free liquid chromatography coupled to tandem mass spectrometry 
(LC-MS/MS) was performed for analysis of peptide composition in 
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these samples. LC-MS/MS measures the peptide constituents rather 
than intact proteins, as peptides are more suitable for LC analysis and 
have better ionization properties.  
Label-free LC-MS/MS does not utilise isotopic labelling of proteins. 
Instead, signal intensities are directly compared between LC-MS/MS 
runs. Label-free LC-MS/MS is now being used more frequently where 
previously 2D DIGE (two-dimensional difference in gel electrophoresis) 
gels were used as standard for biomarker discovery (143). 2D DIGE 
gels have several limitations, including insufficient resolving power to 
fully separate peptides in the gel, difficulty in analysing hydrophobic 
proteins, restricted sample throughput, complex sample preparation, 
incomplete labelling, as well as high costs (144). Label-free LC-MS 
overcomes these issues while allowing increased proteome coverage 
compared to gel based techniques (145).  
LC is the most commonly used method for separating peptides before 
downstream mass spectrometry analysis (144) 
The mass spectrometer consists of three main components: the 
ionisation source which converts the eluting peptides into the gas 
phase; the mass analyser which separates the ions based on the mass 
to charge ratio (m/z); the detector which registers relative abundance 
of ions (144). 
In this study, tandem mass spectrometry was employed. This 
incorporates several mass analysers in series, which enables ions from 
the first analyser (parent ions) to undergo collision induced 
dissociation  to generate product ions; these are then separated 
based on m/z in the subsequent mass analysers. Detection of parent 
and daughter ions allows extra confidence in peptide identification. 
MS/MS spectral files from the mass spectrometer, containing m/z 
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information of parent and product ions of each peptide, can be 
compared to identify differentially abundant ions or peptides which 
can be directly searched against a database of proteins which have 
been digested in silico. 
To prepare the samples for mass-spectrography analysis, digested 
peptides were processed using PepClean C-18 Spin Columns (Pierce, 
89870) according to manufacturer’s instructions to remove interfering 
contaminants and chemicals. Peptide samples were eluted in 80 L of 
80% acetonitrile (ACN) dried down using a speed-vac (MAXI dry plus) 
and stored at -20ºC until required.  
When ready for MS analysis, peptide samples were re-solubilised in 
80 L of LC-MS grade water with 0.1% TFA and 2% ACN. 40 L was then 
transferred to glass vials, and then to autosampler on the MS 
instrument. Peptides were first submitted to the nano-LCMS/MS using 
an Ultimate 3000 system (Dionex) coupled to an LTQ-Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific) operating in positive mode 
with a spray voltage of 1.6kV. 6.5μL of each sample was injected onto 
a C18 pre-column (300μm inner diameter x 5mm; Dionex) at 25μL/min 
in 5% ACN, 0.05% TFA. After a 3 minute desalting step, the pre-column 
was switched on line with the analytical column (75μm inner diameter 
x 25cm PepMap C18; Dionex) equilibrated in 98% solvent A (2% ACN, 
0.05% TFA) and 2% solvent B (98% ACN. 0.04% FA). Peptides were 
eluted using a 10-35% gradient of solvent B during 150 minutes at a 
300nL/min flow rate.  
Data were acquired with Xcalibur software version 2.0.7 (Thermo Fisher 
Scientific). The mass spectrometer was operated in the data-
dependent mode and was externally calibrated. Survey MS scans 
were acquired in the Orbitrap in the 300-2000m/z range with the 
resolution set to a value of 60,000 at m/z 400. Up to seven of the most 
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intense multiply charged ions (1+, 2+ and 3+) per scan were CID 
fragmented in the linear ion trap. A dynamic exclusion window was 
applied within 40s. All tandem mass spectra were collected using 
normalised collision energy of 35%, an isolation window of 3m/z, and 
one microscan.  
Data analysis was performed using Progenesis LC-MS software 
available from Non-Linear Dynamics. Raw MS data files were imported 
to Progenesis LC-MS software package. A reference run is selected as 
the sample which is most representative of the data; all additional 
sample runs are then aligned to the reference sample run. Alignment 
of sample runs allows correction of variable peptide retention times 
during chromatographic separation and hence allows comparison of 
different sample runs. Once sample runs have been aligned, the 
software is then able to detect features in each run. Detected 
features are then filtered based on an ANOVA p-value of less than 0.2; 
this cut-off value was chosen so as not to exclude too many peptides 
from the analysis, as subsequent identified proteins would be filtered 
with more stringent criteria at a later stage. From this list of filtered 
features a principal component analysis (PCA) plot is generated.  
Principal component analysis is a statistical technique used for finding 
patterns in data of high dimension. The MS/MS data from this list of 
filtered features is then exported into the external search engine 
MASCOT to match these identified features to known peptides, using 
the following search criteria: database-Swissprot/UniProt, enzyme-
trypsin, allow up to 2 missed cleavages, taxonomy-homo sapiens, 
fixed modifications carbamidomethyl(C), variable modifications-
oxidation (M), peptide tolerance-10ppm, MS/MS tolerance-0.8Da, and 
peptide charge-2+, 3+ and 4+. Once identifications have been 
assigned, this information is then imported to progenesis. Various 
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statistical criteria can then be applied to identified peptides to 
generate a list of proteins. For this experiment, a statistical criterion of 
ANOVA p-value less than 0.05, and peptide number greater than one 
was applied to generate lists of differentially expressed proteins 
 
4.1.3 Validation of proteomic targets 
ELISAs were used for validation of targets identified from the 
proteomic profiling study. Validation was performed on the same 8 
newly diagnosed type 1 diabetes (T1DM new), established diabetes 
(T1DM old), and matched controls (control new and control old) 
serum specimens used for the profiling experiment, as well as an 
additional 22 T1DM old and control old specimens.  
 
4.1.3.1 Vitronectin 
A vitronectin ELISA kit was sourced from American Diagnostica GmbH 
(803). Serum specimens were diluted by a factor of 4,000 using dilution 
buffer. Standards were reconstituted as per manufacturer’s 
instructions using dilution buffer. 100μL of diluted samples or standards 
were added to each well, and incubated for 1 hour at room 
temperature on a shaker at 250rpm. The plate was then washed 4 
times using wash buffer and excess liquid was removed from the plate 
by tapping on absorbent paper 4-5 times between each wash step. 
100μL of detection antibody was added to each well and incubated 
for 1 hour at room temperature on a shaker at 250rpm. The plate was 
then washed 4 times using wash buffer, and excess liquid was 
removed after each wash step by tapping the plate on absorbent 
paper. 100μL of substrate was added and incubated for 5 minutes at 
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room temperature. 50μL stop solution was added and plate was read 
at 450nm. A polynomial standard curve was plotted using the 
absorbance of the standards. Using the equation of the line the 
vitronectin concentration was calculated for each sample. 
 
4.1.3.2 Clusterin 
A clusterin ELISA was sourced from Phoenix Pharmaceuticals (EK-018-
35). Serum specimens were diluted by a factor of 6,000 using assay 
buffer. Standards were reconstituted as per manufacturer’s 
instructions using assay buffer. 300μL assay buffer was added to each 
well of the ELISA plate and allowed to stand for 5 minutes; buffer was 
then removed and plate tapped on absorbent paper to remove 
excess liquid. 100μL of diluted samples or standards were added to 
each well and incubated for 2 hours at room temperature on a shaker 
at 350rpm. The plate was washed four times using assay buffer and 
tapped on absorbent paper to remove excess liquid between each 
wash step. 100μL of detection antibody was added to each well and 
incubated for 2 hours at room temperature on a plate shaker at 
350rpm. The plate was then washed four times, tapping on absorbent 
paper between each wash. 100μL substrate solution was added and 
incubated for 30 minutes at room temperature on a shaker at 350rpm. 
100μL stop solution was added and absorbance was read at 450nm 
on a plate reader. A standard curve was plotted as log concentration 
versus log absorbance. The equation of the line was used for 
calculation of clusterin concentration in serum specimens. 
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4.1.3.3 Vitamin K-dependent protein S 
A vitamin K-dependent protein S ELISA was sourced from USCN Life 
Science Inc. (E1971h). Serum specimens were diluted by a factor of 10 
using sample diluent. Standards were reconstituted as per the 
manufacturer’s instructions using sample diluent. 50μL of diluted 
samples or standards were added to each well, followed by 50μL of 
detection reagent A, and incubated for 1 hour at 37ºC. The plate was 
washed three times using wash buffer, and tapped on absorbent 
paper after the last wash to remove excess liquid. 100μL of detection 
reagent B was added and incubated for 45 minutes at 37ºC. The plate 
was washed five times with wash buffer, and tapped on absorbent 
paper after the last wash. 90μL of substrate solution was added to 
each well and incubated at 37ºC for 30 minutes. 50μL of stop solution 
was added and absorbance read at 450nm on a plate reader. A 4–
parameter logistic standard curve was plotted and using the equation 
of the line vitamin K-dependent protein S concentration in serum 
specimens was calculated. 
4.1.3.4 Apolipoprotein L1 
An apolipoprotein L1 ELISA kit was sourced from USCN Life Science Inc. 
(E9374Hu). Serum specimens were diluted by a factor of 5 using PBS. 
Standards were reconstituted as per the manufacturer’s instructions 
using standard diluent. 100μL of diluted samples or standards were 
added to each well and incubated for 2 hours at 37ºC. Liquid was 
removed from the wells, and without washing, 100μL of detection 
reagent A was added and incubated for 1 hour at 37ºC. The plate 
was washed three times using wash solution and tapped on 
absorbent paper after each wash to remove excess liquid. 100μL of 
detection reagent B was added to each well and incubated for 30 
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minutes at 37ºC. The plate was washed five times using wash solution 
and tapped on absorbent paper after each wash. 90μL of substrate 
solution was added to each well and incubated for 15 minutes at 
37ºC. 50μL stop solution was added to each well and absorbance 
read at 450nm on a plate reader. 
 Mass-spectrography instrument was run and lists of differentially 
expressed proteins generated by Dr. Paul Dowling. ELISAs were run by 
Dr Erica Hennessy.  
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4.2 Results 
4.2.1 Subjects 
 
4.2.1.1 Patients with newly-diagnosed type 1 diabetes 
 
We recruited 8 patients with type 1 diabetes diagnosed within six 
months prior to entering the study. They were instructed to come in 
fasting (defined as no food from midnight on the day before). They 
were instructed not to take any insulin on the morning of the test. The 
last ‘allowed’ insulin dose was the long acting insulin the night before. 
If they were taking the long-acting insulin in the morning, they were 
instructed to take it after the test visit. . Their results were compared to 
their age/sex/BMI-matched controls.  
The characteristics of the patients with newly-diagnosed type 1 
diabetes and their healthy controls are presented in table 4.2.1.   
 
4.2.1.2 Patients with established type 1 diabetes  
 
From the cohort of patients with established diabetes type 1, we 
recruited 8 patients with long-term type 1 diabetes, defined as 18 
months and more, with average duration of disease of 14±9 years 
(range 5-26 years). The characteristics of these patients are presented 
in table 4.2.2. 
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The patients were instructed to come in fasting (defined as no food 
from midnight). They were instructed not to take any insulin on the 
morning of testing. The last ‘allowed’ insulin dose was long-acting 
insulin the night before.  
The results of proteomic analysis were validated by extending ELISA 
validation on the whole cohort of 30 patients with established type 1 
diabetes, recruited using same inclusion/exclusion criteria. 
Characteristics of the whole cohort of 30 patients with established 
type 1 diabetes and their healthy controls are presented in table 4.2.3
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Table 4.2.1 Characteristics of patients with newly-diagnosed type 1 diabetes (n=8) and their 
healthy controls (n=8) 
 T1DM new (n=8)  Controls (n=8) p 
Age [years  (±SD)] 26 (±5.1) 27.3(± 2.2) 0.49 
Sex (F:M) 1:7 1:7 1 
BMI [kg/m (±SD)] 24.6 (±4.21) 24.2 (±2.61) 0.86 
BP systolic [mmHg (±SD)] 118 (±8.3) 123.7 (±11.3) 0.29 
BP diastolic [mmHg (±SD)] 71.8 (±12.8) 81.3 (±9.2) 0.12 
Heart rate (beats/min)* 63.6 (±6.5) 63.7 (±10.7) 0.99 
Waist/ hip ratio (±SD) 0.84 (±0.05) 0.92 (±0.07) 0.29 
Duration of diabetes  
[months (±SD)] 
3 (±2.4) N/A -- 
Cigarette smoking [pack-years (±SD)] 1.38 (±2.26) 0.11 (±0.28) 0.16 
Alcohol [units/wk (±SD) 5.88 (±6.55) 14.29 (±12.72) 0.12 
Exercise [min/wk (±SD) 188.13 (±201) 120 (±115.4) 0.44 
HbA1C [% (±SD)] 7.68 (±1.95) 5.15 (±0.3) <0.01 
Fasting glucose  
[mmol/L (±SD)] 
6.48 (±3.06) 4.48 (±0.37) 0.10 
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 T1DM new (n=8)  Controls (n=8) p 
Fasting insulin [mU/L (±SD)] 44.45 (±60.78) 5.64 (±2.86) 0.02 
HOMA IR (±SD) ----- 1.02 (±0.09) --- 
Total cholesterol 
[mmol/L (±SD)] 
4.2 (±0.55) 5.05 (±0.43) 0.01 
LDL [mmol/L (±SD)] 2.53 (±0.41) 3.19 (±0.55) 0.02 
HDL [mmol/L (±SD)] 1.24 (±0.42) 1.35 (±0.39) 0.62 
Insulin daily dose (units) 0-60; 32.75 (± 20.4) N/A --- 
Long-acting insulin daily dose (units) 15.4 (±9.1) N/A --- 
Short-acting insulin daily dose (units) 17.4 (±11.5). N/A --- 
Insulin daily requirement (unit/kg of 
body weight) 
0.81 (±0.44) N/A --- 
Legend: N/A not applicable, HOMA-IR not calculated in T1DM as taking exogenous insulin; *no 
subjects were taking medications that could affect the heart rate. 
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Table 4.2.2 Characteristics of patients with established type 1 diabetes (T1DM old, n=8)  and their 
controls (n=8). 
 T1DM old (n=8) Controls (n=8) P 
Age [years  (±SD)] 44.7 (±12.84) 42.25 (±4.8) 0.61 
BMI [kg/m (±SD)] 28.45 (±4.35) 28.36 (±4.87) 0.97 
BP systolic [mmHg (±SD)] 125.3 (±10.9) 126 (±6.2) 0.89 
BP diastolic [mmHg (±SD)] 80.5 (±5.8) 78.3 (±8.9) 0.58 
Heart rate (beats/min) 73.4 (±5.8) 65.1 (±7.7) 0.03 
Subjects taking beta-blockers 1/8 0/8 0.3 
Waist/ hip ratio (±SD) 0.89 (±0.1) 0.93 (±0.08) 0.52 
Duration of diabetes  
[years (±SD)] 
14.38 (±9.89) --- n/a 
Cigarette smoking  
[pack-years (±SD) 
11.38 (±17.94) 9.88 (±10.32) 0.84 
Alcohol [units/wk (±SD) 2.75 (±3.65) 14.63 (±20.96) 0.13 
Exercise [min/wk (±SD) 57.5 (±87.1) 224.3 (±361.4) 0.22 
HbA1C [% (±SD)] 7.99(±1.28) 5.38(±0.23) <0.01 
Fasting glucose  
[mmol/L (±SD)] 
11 (±5.6) 4.8 (±0.38) <0.01 
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 T1DM old (n=8) Controls (n=8) P 
Fasting insulin [mU/L (±SD)] 5.35 (±6.33) 5.36 (±3.19) 0.99 
HOMA IR (±SD) ---- 0.81 (±0.51) --- 
Total cholesterol 
[mmol/L (±SD)] 
3.95 (±0.66) 5.18 (±0.53) <0.01 
LDL [mmol/L (±SD)] 1.91 (±0.29) 2.74 (±1.09) 0.056 
HDL [mmol/L (±SD)] 1.56 (±0.39) 1.45 (±0.17) 0.49 
Insulin daily dose (units) 74 (±19.3) N/A --- 
Long-acting insulin daily dose 
(units) 
42.2 (±12.1) N/A --- 
Short-acting insulin daily dose 
(units) 
31.7 (±10.4) N/A --- 
Insulin daily requirement 
(unit/kg of body weight) 
0.86 (±1.71) N/A --- 
Legend: N/A, not applicable 
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Table 4.2.3 Characteristics of patients with established type 1 diabetes (T1DM old, n=30) and their 
controls (n=30) 
 T1DM old (n=30) Controls (n=30) P 
Age [years  (±SD)] 40.23±10.03 43.17±8.80 0.23 
BMI [kg/m (±SD)] 26.52±3.38 27.94±4.18 0.15 
BP systolic [mmHg (±SD)] 129.3±19.29 127.87±12.47 0.73 
BP diastolic [mmHg (±SD)] 79.53±7.86 80.47±8.72 0.66 
Heart rate (beats/min) 74.8 (±12.4) 70.2 (±11.6) 0.14 
Waist/ hip ratio (±SD) 0.90±0.09 0.92±0.08 0.35 
Duration of diabetes  
[years (±SD)] 
16.86±12.9 --- N/A 
Cigarette smoking  
[pack-years (±SD) 
9.34±13.55 11.25±11.58 0.56 
Alcohol [units/wk (±SD) 5.38±6.15 11±15.01 0.06 
Exercise [min/wk (±SD) 145±179 216±246 0.47 
HbA1C [% (±SD)] 7.61±1.08 5.35±0.66 <0.001 
Fasting glucose  
[mmol/L (±SD)] 
9.78±4.75 4.94±0.41 <0.001 
Fasting insulin* [mU/L (±SD)] 23.98 7.53 N/A* 
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 T1DM old (n=30) Controls (n=30) P 
HOMA IR*(±SD) --- 0.91±0.74 N/A* 
Total cholesterol 
[mmol/L (±SD)] 
4.39±0.76 5.3±0.66 <0.001 
LDL [mmol/L (±SD)] 2.31±0.56 3.09±0.85 <0.01 
HDL [mmol/L (±SD)] 1.55±0.46 1.40±o.33 0.18 
Insulin daily dose (units) 61.8±27.8 --- N/A 
Long-acting insulin daily dose 
(units) 
33.5±19.3 --- N/A 
Short-acting insulin daily dose 
(units) 
28.9±14.2 --- N/A 
Insulin daily requirement 
(unit/kg of body weight) 
0.75±0.33 --- N/A 
Legend: N/A, not applicable, *Even though patients with diabetes were instructed to omit their 
morning dose, there is an obvious spill-over, most likely from the background insulin; therefore 
HOMA-IR was not calculated for them. 
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4.2.2 All-group analysis 
 
Eight serum samples per group (patients with newly-established type 1 
diabetes, their matched controls, patients with established type 1 
diabetes, and their matched controls) were included in this 
experiment. One control sample (DS-171/ U30) was incompatible for 
alignment with any reference sample selected. This may be due to 
sub-optimal sample handling or a problem associated with the LC-MS 
run, therefore this sample could not be used in the data analysis. All 
other sample runs aligned with reference run without any problems.  
LC-MS data for all samples from each group were imported to the 
Progenesis software (excluding control sample DS-171/U30). After 
successful alignment and filtering of detected features (ANOVA p-
value < 0.2), a principal component analysis (PCA) plot was 
generated. 
Figure 4.2.1 shows PCA plot for all sample groups. For brevity, patients 
with established diabetes are labelled as type 1 old (T1DM old); 
patients with newly diagnosed diabetes as type 1 new (T1DM new) 
and their respective controls as controls old and controls new.  
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Figure 4.2.1 PCA plot for all sample groups. Pink spots represent T1DM new samples, blue spots represent T1DM old samples, purple spots represent control new samples, 
orange spots represent control old sample and the cyan spots represent the autoimmune samples
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The pink spots represent the samples of patients with newly-diagnosed 
type 1 diabetes, while the purple spots represent their respective 
controls.  While they did not form distinctly separate clusters, spots 
belonging to subjects from the healthy control group (those matched 
to newly diagnosed type 1 diabetes) were clustered quite closely on 
the bottom right part of the PCA plot.  
Spots representing patients with newly-diagnosed type 1 diabetes, 
while not as closely clustered, were mainly located in the top left 
corner of the plot.  
The autoimmune/ inflammatory disease serum specimens were 
represented by the cyan spots. These showed a very similar clustering 
pattern to the samples of patients with newly-diagnosed type 1 
diabetes.  
The samples from patients with established type 1 diabetes were 
represented by the blue spots, while their respective healthy controls’ 
samples were represented by the orange spots. Spots belonging to 
patients with established type 1 diabetes were mainly located in the 
right portion of the plot while spots belonging to their healthy controls 
were located in the left of the plot.  
While each sample group did not result in the formation of distinctly 
separate clusters, each sample group clustered in a separate area of 
the plot. The loose filter criteria for peptide identification (ANOVA p-
value 0.2) would also contribute to the samples not clustering as 
tightly. That said, we did not want to apply so stringent a criterion at 
this stage as to exclude peptides from the analysis, as identified 
proteins would be filtered using more stringent criteria at a later stage. 
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4.2.3 Results of proteomic analysis in patients with 
newly-diagnosed type 1 diabetes compared to 
their matched healthy controls  
 
Progenesis analysis was performed in triplicate for all comparisons 
analysed, using a different reference sample for each replicate. 
Samples with the highest number of detected features were chosen 
as reference samples. Therefore, three lists of differentially expressed 
proteins were generated for each comparison analysed. Proteins 
common to all three lists were then identified.  
For the comparison of patients with newly diagnosed type 1 diabetes 
and their respective controls, the first replicate was performed with a 
sample belonging to a newly-diagnosed type 1 diabetes patient (DS-
169, T1N8) as reference sample, the second replicate with a ‘control 
new’ sample (DS- 175, U35) and the third replicate with another 
‘control new’ sample (DS-178, U36)(Raw data in Appendix A, Tables 1, 
2 & 3)  
Proteins that were common to all three lists were: complement C5, 
clusterin, inter-alpha-trypsin inhibitor heavy chain H3, C-reactive 
protein, POTE ankyrin domain family member E and β-actin-like protein 
3 (Table 4.2.4).  
A PCA plot was generated for each analysis performed. Figure 4.2.2  
shows a very clear distinction between the ‘T1DM new’ and ‘control 
new’ sample clusters, Samples belonging to patients with newly-
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diagnosed type 1 diabetes are shown in pink, while their respective 
control samples are shown in blue. 
117 
 
 
Table 4.2.4 Summary of proteins differentially expressed in patients with newly-diagnosed type 1 diabetes and their matched healthy controls 
   
      Average normalised 
abundances 
Accession Description Reference run 
used 
Fold Anova (p) Peptides T1DM new Matched 
controls 
P01031 Complement C5  
 
OS=Homo sapiens GN=C5 PE=1 SV=4 
DS-169  1.65 0.03 20 1.88E+006 1.14E+006 
DS-175  1.74 0.00451 20 2.24E+006 1.28E+006 
DS-178 1.63 0.04 9 4.70E+005 2.88E+005 
P10909 Clusterin  DS-169  1.72 0.04 13 1.78E+007 1.03E+007 
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      Average normalised 
abundances 
Accession Description Reference run 
used 
Fold Anova (p) Peptides T1DM new Matched 
controls 
 
OS=Homo sapiens GN=CLU PE=1 SV=1 
DS-175  1.68 0.01 12 2.68E+007 1.59E+007 
DS-178 1.57 0.02 4 8.49E+005 5.41E+005 
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3  
 
OS=Homo sapiens GN=ITIH3 PE=1 SV=2 
DS-169  2.43 0.01 3 9.40E+004 3.88E+004 
DS-175  2.7 0.00792 5 1.53E+005 5.66E+004 
DS-178 2.5 0.02 2 8.37E+004 3.34E+004 
P02741 C-reactive protein  DS-169  6.09 0.02 6 1.22E+006 2.00E+005 
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      Average normalised 
abundances 
Accession Description Reference run 
used 
Fold Anova (p) Peptides T1DM new Matched 
controls 
 
OS=Homo sapiens GN=CRP PE=1 SV=1 
DS-175  6.22 0.01 4 1.24E+006 1.99E+005 
DS-178 8.05 0.02 4 4.21E+005 5.23E+004 
Q6S8J3 POTE ankyrin domain family member E  
 
OS=Homo sapiens GN=POTEE PE=1 SV=3 
DS-169  1.97 0.02 3 5.39E+004 1.06E+005 
DS-175  1.92 0.03 2 6.34E+004 1.22E+005 
DS-178 2.02 0.03 3 6.91E+004 1.40E+005 
Q9BYX7 Β-actin-like protein 3  DS-169  1.98 0.02 2 4.86E+004 9.63E+004 
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      Average normalised 
abundances 
Accession Description Reference run 
used 
Fold Anova (p) Peptides T1DM new Matched 
controls 
 
OS=Homo sapiens GN=ACTBL3 PE=1 SV=1 
DS-175  1.92 0.03 2 6.34E+004 1.22E+005 
DS-178 2.03 0.03 2 6.31E+004 1.28E+005 
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Figure 4.2.2  PCA plot for samples from patients with newly-diagnosed diabetes and their matched healthy controls. DS-175/U35 sample was used as reference run. Pink 
spots indicate the ‘T1DM new’ samples while the blue spots indicate the ‘control new’ samples. 
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4.2.4 Results of proteomic analysis in patients with 
established type 1 diabetes compared to their 
matched healthy controls 
 
The analysis of these groups was performed in triplicate using a 
different reference sample for each replicate. The first replicate was 
performed with a sample belonging to a patient with established type 
1 diabetes (DS-84/ T1O10) as reference sample, the second replicate 
with sample from the pool of matched healthy controls with a 
BMI>30kg/m2 (DS- 162/M16) and the third replicate with another 
sample from the pool of matched healthy controls, with a BMI of 
<30kg/m2 (DS-39/U14) as reference sample (Raw data in appendix A)  
A PCA plot was generated (Figure 4.2.3), showing two distinct clusters. 
However, one of the samples belonging to a patient with established 
type 1 diabetes (pink) clustered with the matched controls’ samples 
(blue), rather than with the other established type 1 diabetes samples.  
Proteins that were common to all three lists were identified. These 
included: antithrombin III, apolipoprotein E, apolipoprotein C-II, 
vitronectin, ficolin-2, ceruloplasmin, vitamin K-dependent protein S, 
apolipoprotein A-1, transthyretin, C4b binding protein alpha chain, 
serum amyloid A-4 protein, mannan-binding lectin serine protease 1, 
apolipoprotein L1,platelet factor 4, apolipoprotein C-IV, von 
Willebrand factor, complement component C8 β chain, actin- 
cytoplasmic 2, complement factor H related protein 1, POTE ankyrin 
domain family member E and β-actin-like protein 3 (Table 4.2.8). 
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Figure 4.2.3 PCA plot for patients with established type 1 diabetes (T1DM old) and their matched controls’ samples. DS-84/ T1O10 ‘type 1 old’ sample was used as reference 
run. Pink spots indicate the’ T1DM old’ samples while the blue spots indicate the ‘control old’ samples 
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Table 4.2.5 Summary of proteins differentially expressed in patients with established type 1 diabetes versus their matched controls. 
         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
P01008 Antithrombin-III  
OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 
DS-84 2.55 0.05 18 6.43E+007 1.64E+008 
DS-162 2.31 0.03 17 3.15E+007 7.27E+007 
DS-39 2.37 0.03 16 2.79E+007 6.63E+007 
P02649 Apolipoprotein E  
OS=Homo sapiens GN=APOE PE=1 SV=1 
DS-84 2.19 0.02 12 1.46E+007 3.20E+007 
DS-162 2.05 0.02 15 1.07E+007 2.19E+007 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
DS-39 2.05 0.02 15 1.05E+007 2.16E+007 
P02655 Apolipoprotein C-II  
OS=Homo sapiens GN=APOC2 PE=1 SV=1 
DS-84 2.41 0.01 4 4.06E+006 9.79E+006 
DS-162 2.25 0.01 5 3.13E+006 7.05E+006 
DS-39 2.5 7.13E-003 5 2.76E+006 6.88E+006 
P04004 Vitronectin  
OS=Homo sapiens GN=VTN PE=1 SV=1 
DS-84 1.72 0.03 5 2.55E+007 4.39E+007 
DS-162 1.62 0.03 5 1.71E+007 2.77E+007 
DS-39 1.57 0.03 6 1.76E+007 2.77E+007 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
Q15485 Ficolin-2  
OS=Homo sapiens GN=FCN2 PE=1 SV=2 
DS-84 3 0.02 5 5.81E+005 1.75E+006 
DS-162 2.81 0.02 7 4.37E+005 1.23E+006 
DS-39 2.88 0.02 6 4.10E+005 1.18E+006 
P00450 Ceruloplasmin  
OS=Homo sapiens GN=CP PE=1 SV=1 
DS-84 1.7 0.03 6 5.53E+005 3.25E+005 
DS-162 1.44 0.04 8 4.51E+005 3.13E+005 
DS-39 1.6 0.03 7 5.17E+005 3.23E+005 
P07225 Vitamin K-dependent protein S  DS-84 2.47 0.05 7 1.52E+006 3.75E+006 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
OS=Homo sapiens GN=PROS1 PE=1 SV=1 
DS-162 2.13 6.32E-003 4 4.03E+005 8.59E+005 
DS-39 2.24 5.34E-003 6 4.03E+005 9.04E+005 
P02647 Apolipoprotein A-I  
OS=Homo sapiens GN=APOA1 PE=1 SV=1 
DS-84 1.9 0.05 5 2.66E+007 5.06E+007 
DS-162 1.76 0.04 4 1.99E+007 3.50E+007 
DS-39 1.75 0.05 5 1.96E+007 3.44E+007 
P02766 Transthyretin  
OS=Homo sapiens GN=TTR PE=1 SV=1 
DS-84 2.69 0.04 4 2.14E+006 5.74E+006 
DS-162 2.39 0.03 3 1.63E+006 3.91E+006 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
DS-39 2.46 0.04 3 1.51E+006 3.71E+006 
P04003 C4b-binding protein alpha chain  
OS=Homo sapiens GN=C4BPA PE=1 SV=2 
DS-84 2.62 0.04 3 5.67E+006 1.49E+007 
DS-162 2.39 0.03 3 4.23E+006 1.01E+007 
DS-39 2.4 0.03 4 4.16E+006 9.97E+006 
P35542 Serum amyloid A-4 protein  
OS=Homo sapiens GN=SAA4 PE=1 SV=1 
DS-84 2.34 0.02 2 8.40E+005 1.97E+006 
DS-162 2.25 0.02 2 5.16E+005 1.16E+006 
DS-39 2.37 0.01 3 5.00E+005 1.19E+006 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
P48740 Mannan-binding lectin serine protease 1 
 OS=Homo sapiens GN=MASP1 PE=1 SV=3 
DS-84 1.97 5.95E-003 4 4.04E+005 7.95E+005 
DS-162 1.95 2.11E-003 4 2.82E+005 5.49E+005 
DS-39 1.91 2.59E-003 4 2.79E+005 5.35E+005 
O14791 Apolipoprotein L1  
OS=Homo sapiens GN=APOL1 PE=1 SV=5 
DS-84 4.07 3.71E-003 2 7.27E+004 2.96E+005 
DS-162 2.44 0.03 3 7.75E+004 1.89E+005 
DS-39 2 0.02 3 1.25E+005 2.49E+005 
P02776 Platelet factor 4  DS-84 2.1 0.05 2 7.12E+005 1.49E+006 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
OS=Homo sapiens GN=PF4 PE=1 SV=2 
DS-162 1.98 0.05 2 5.30E+005 1.05E+006 
DS-39 1.97 0.05 2 5.22E+005 1.03E+006 
P63261 Actin, cytoplasmic 2  
OS=Homo sapiens GN=ACTG1 PE=1 SV=1 
DS-84 3.42 0.03 4 1.28E+005 4.38E+005 
DS-162 3.14 0.02 4 1.45E+005 4.56E+005 
DS-39 3.09 0.03 4 1.52E+005 4.71E+005 
Q9BYX7 Β-actin-like protein 3  
OS=Homo sapiens GN=ACTBL3 PE=1 SV=1 
DS-84 3.99 0.01 3 6.77E+004 2.70E+005 
DS-162 3.72 9.51E-003 3 4.79E+004 1.78E+005 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
DS-39 3.63 0.02 3 5.17E+004 1.88E+005 
Q6S8J3 POTE ankyrin domain family member E  
OS=Homo sapiens GN=POTEE PE=1 SV=3 
DS-84 3.99 0.01 3 6.77E+004 2.70E+005 
DS-162 3.72 9.51E-003 3 4.79E+004 1.78E+005 
DS-39 3.63 0.02 3 5.17E+004 1.88E+005 
P55056 Apolipoprotein C-IV  
OS=Homo sapiens GN=APOC4 PE=1 SV=1 
DS-84 2.9 0.02 2 5.04E+004 1.46E+005 
DS-162 3.53 3.89E-03 2 2.86E+004 1.01E+005 
DS-39 3.03 4.00E-003 2 3.58E+004 1.08E+005 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
P04275 von Willebrand factor  
OS=Homo sapiens GN=VWF PE=1 SV=3 
DS-84 4.42 0.02 2 1.76E+004 7.80E+004 
DS-162 3.51 0.01 2 1.67E+004 5.87E+004 
DS-39 3.9 0.01 2 1.41E+004 5.50E+004 
Q03591 Complement factor H-related protein 1  
OS=Homo sapiens GN=CFHR1 PE=1 SV=2 
DS-84 1.88 6.65E-003 3 2.30E+006 4.34E+006 
DS-162 1.74 0.02 3 1.42E+006 2.47E+006 
DS-39 1.74 0.03 2 1.34E+006 2.33E+006 
P07358 Complement component C8 β chain  DS-84 1.46 0.01 3 8.24E+004 5.64E+004 
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         Average normalised abundances 
Accession Description Reference run used Fold Anova (p) Peptides T1DM old Matched controls 
OS=Homo sapiens GN=C8B PE=1 SV=3 
DS-162 1.86 1.57E-003 2 6.35E+004 3.41E+004 
DS-39 1.91 5.89E-004 2 6.34E+004 3.31E+004 
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4.2.5 Results of proteomics analysis in patients with 
newly-diagnosed type 1 diabetes compared to 
patients with established type 1 diabetes 
 
The analysis of this comparison was performed in triplicate using a 
different reference sample for each replicate. The first replicate was 
performed with a sample belonging to a patient with newly-
diagnosed diabetes (DS-169/T1N8) as reference sample, the second 
replicate with sample belonging to a patient with established type 1 
diabetes (DS-74/T1O7) and the third replicate with another sample 
belonging to a patient with established type 1 diabetes (DS-
90/T1O12). A list of differentially expressed proteins was also generated 
for each replicate analysis performed (Raw data presented in 
Appendix A) 
 PCA plot was generated for this comparison (Figure 4.2.4.), showing 
two distinct clusters. However, one of the samples belonging to a 
patient with established type 1 diabetes,- DS-29/T1O4 (blue), clustered 
slightly closer to the samples belonging to patients with newly-
diagnosed type 1 diabetes (pink), rather than with the other samples 
from patients with established diabetes. 
Proteins that were common to all three lists were identified in table 
4.2.6. These included: complement C4-B, prothrombin, clusterin, Ig mu 
chain C region, antithrombin III, Ig kappa chain C region, vitronectin, 
vitamin K-dependent protein and apolipoprotein C-1.
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Figure 4.2.4 PCA plot for T1DM new and T1DM old. DS-169 control sample was used as reference run. Pink spots indicate the T1DM new samples while the blue spots 
indicate the T1DM old samples.  
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Table 4.2.6 Summary of proteins differentially expressed in patients with newly-diagnosed type 1 diabetes compared to patients with established type 1 diabetes. 
         Av normalised abundances 
Accession Description Reference 
run used 
Fold Anova (p) Peptid
es 
T1DM new T1DM old 
P0C0L5 Complement C4-B  
 
OS=Homo sapiens GN=C4B PE=1 SV=1 
DS-169 1.35 0.02 47 1.11E+08 8.23E+07 
DS-74 1.45 0.01 46 1.56E+08 1.08E+08 
DS-90 1.48 0.01 44 1.62E+08 1.09E+08 
P00734 Prothrombin  
 
OS=Homo sapiens GN=F2 PE=1 SV=2 
DS-169 1.39 0.05 19 3.08E+07 2.22E+07 
DS-74 1.4 0.05 15 4.57E+07 3.27E+07 
DS-90 1.42 0.03 17 4.69E+07 3.31E+07 
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         Av normalised abundances 
Accession Description Reference 
run used 
Fold Anova (p) Peptid
es 
T1DM new T1DM old 
P10909 Clusterin  
 
OS=Homo sapiens GN=CLU PE=1 SV=1 
DS-169 1.43 0.005 7 2.10E+07 1.47E+07 
DS-74 1.42 3.88E-03 9 3.31E+07 2.34E+07 
DS-90 1.45 3.08E-03 10 3.35E+07 2.31E+07 
P01871 Ig mu chain C region  
 
OS=Homo sapiens GN=IGHM PE=1 SV=3 
DS-169 1.57 0.04 4 6.61E+06 4.21E+06 
DS-74 1.57 0.04 5 1.26E+07 8.04E+06 
DS-90 1.55 0.03 6 1.43E+07 9.25E+06 
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         Av normalised abundances 
Accession Description Reference 
run used 
Fold Anova (p) Peptid
es 
T1DM new T1DM old 
P01008 Antithrombin-III  
 
OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 
DS-169 1.44 6.47E-03 10 2.35E+07 1.63E+07 
DS-74 1.43 0.01 13 3.12E+07 2.18E+07 
DS-90 1.46 7.92E-03 13 4.18E+07 2.87E+07 
P01834 Ig kappa chain C region  
 
OS=Homo sapiens GN=IGKC PE=1 SV=1 
DS-169 1.54 0.03 4 6.15E+06 4.00E+06 
DS-74 1.55 0.02 5 9.42E+06 6.07E+06 
DS-90 1.58 0.02 4 9.56E+06 6.06E+06 
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         Av normalised abundances 
Accession Description Reference 
run used 
Fold Anova (p) Peptid
es 
T1DM new T1DM old 
P04004 Vitronectin  
 
OS=Homo sapiens GN=VTN PE=1 SV=1 
DS-169 1.45 0.03 4 1.72E+07 1.18E+07 
DS-74 1.46 0.03 5 2.57E+07 1.76E+07 
DS-90 1.42 0.03 4 3.39E+07 2.38E+07 
P07225 Vitamin K-dependent protein S  
 
OS=Homo sapiens GN=PROS1 PE=1 SV=1 
DS-169 1.71 7.49E-03 4 6.27E+05 3.67E+05 
DS-74 1.49 9.13E-04 5 6.24E+05 4.18E+05 
DS-90 2.2 3.38E-03 2 6.16E+05 2.80E+05 
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         Av normalised abundances 
Accession Description Reference 
run used 
Fold Anova (p) Peptid
es 
T1DM new T1DM old 
P02654 Apolipoprotein C-I  
 
OS=Homo sapiens GN=APOC1 PE=1 SV=1 
DS-169 1.55 4.51E-03 4 2.59E+06 1.67E+06 
DS-74 1.56 2.43E-03 2 3.78E+06 2.42E+06 
DS-90 1.59 2.83E-03 3 3.88E+06 2.45E+06 
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4.2.6 Target protein selection for follow-up 
 
Proteins for follow up were selected based on their potential interest in 
both newly-diagnosed type 1 diabetes and established type 1 
diabetes studies.  
Clusterin was identified as being up-regulated in samples of patient 
with newly-diagnosed type 1 diabetes relative to their matched 
healthy controls and relative to patients with established type 1 
diabetes (tables 4.2.4and 4.2.6) 
Vitronectin was down-regulated in samples of patients with 
established type 1 diabetes relative to their matched healthy controls, 
as well as relative to patients with newly-diagnosed diabetes (tables 
4.2.5 and 4.2.6). Vitronectin was also up-regulated in two of the three 
replicates for comparison of samples from patients with newly-
diagnosed diabetes and their matched healthy controls (Appendix 
A). 
Vitamin K-dependent protein S levels showed the same pattern as 
vitronectin. This protein was down-regulated in samples of patients 
with established type 1 diabetes relative to their healthy controls 
(table 4.2.5) and to patients with newly-diagnosed diabetes (table 
4.2.6). It was also up-regulated in two of the three replicate 
comparisons of samples from patients with newly-diagnosed diabetes 
and their matched healthy controls (Appendix A). 
Apolipoprotein L1 was down-regulated in samples of patients with 
established type 1 diabetes relative to their healthy controls (table 
142 
 
4.2.5), while it was also down-regulated in one of the replicates for 
T1DM old versus T1DM new comparisons (Appendix A)  
These proteins were also selected on the basis that they had no 
conflicting identified peptides. Conflicting peptides are peptides that 
are not unique to the named protein, and may be present in a 
number of other different proteins. Performing each comparison in 
triplicate with different reference samples, assigning filter criteria of 
ANOVA p-value less than 0.05, as well as analysing proteins with no 
conflicting peptides allowed identification of the most robustly 
differentially expressed proteins in the samples analysed.  
Using these criteria, clusterin, vitronectin, apolipoprotein L1 and 
vitamin K-dependent protein S were selected for follow-up validation 
in a larger cohort of patient samples.  
Samples from healthy controls matched to newly-diagnosed patients 
and controls matched to patients with established type 1 diabetes 
were compared to determine if protein changes seen in disease vs. 
control samples were related to disease phenotype or to control 
samples’ variation.  
A PCA plot of ‘control new’ and ‘control old’ samples was generated 
(Figure 4.2.5). This indicated that DS-7/U3 was a slight outlier for the 
‘control old’ group. Differentially expressed protein lists were 
generated with and without the DS-7 outlier sample (Apendix A) 
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Figure 4.2.5 PCA plot for comparison of controls matched to newly-diagnosed patients with controls matched to patients with established type 1 diabetes. Sample DS-
178/U36 was used  as reference run. Blue spots indicate the ‘control old’, while pink spots indicate ‘control new’ samples. ‘Old control’ sample DS-7 is a slight outlier 
relative to the rest of the control old group. 
 
144 
 
 
Apolipoprotein L1 and vitronectin were unchanged in the 
comparison of two control samples’ sets with and without outlier 
DS-7 sample included in analysis. This indicates that changing 
levels of these proteins are due to the disease phenotype.  
Clusterin and vitamin K-dependent protein S were seen to be up-
regulated in the ‘control old’ samples relative to the ‘control new’ 
samples in comparisons including and excluding outlier sample DS-
7 (Appendix A). However, as these proteins were also identified as 
being differentially expressed in samples belonging to patients with 
newly-diagnosed type 1 diabetes versus samples belonging to 
patients with established type 1 diabetes, (table 4.2.6 ), we 
conclude that their differential expression is not due only to the 
difference in control samples.  
Protein changes between autoimmune (n=8) and control samples 
(n=16) were also analysed, to determine if protein targets 
identified in the T1DM study were type 1 diabetes-related, or if they 
were related to autoimmunity or inflammation per se. This analysis 
was limited by the fact that we unfortunately had no data on 
glucose values or medication use in autoimmune subjects. Various 
medications used for treatement of autoimmune conditions have 
an effect on insulin sensitivity and glucose handling in those 
subjects.  
Three lists of differentially expressed proteins were generated for 
comparison of samples from patients with autoimmune diseases vs 
healthy controls used in our studies. Samples DS-175/U35, DS-
178/U36 and DS-39/U14 were used as a reference run (complete 
lists shown in Appendix A) 
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No changes in vitronectin, clusterin or vitamin K-dependent protein 
S were seen in any of the ‘autoimmune’ versus ‘control’ 
comparisons, indicating that changes in these protein levels in the 
type 1 diabetes study could be specifically diabetes-related.  
One of the three comparisons (where control sample DS-178 was 
used as reference run, Appendix A.) showed decreased levels of 
apolipoprotein L1 in ‘autoimmune’ samples. Therefore, it is possible 
that decreased levels of apolipoprotein L1 in samples of patients 
with established type 1 diabetes could be related to a general 
autoimmune or inflammatory response. However, as 
apolipoprotein L1 was increased in patients with newly-diagnosed 
type 1 diabetes, this protein was selected for validation studies. 
 
4.2.7 ELISA validation of target proteins 
Protein targets identified in label-free LC-MS study were validated 
using ELISA technology. Validation was performed on the same 
samples of 8 patients with newly-diagnosed type 1 diabetes (T1DM 
new), 8 patients with established type 1 diabetes (T1DM old) and 
the samples of their respective controls (8 subjects in each, ‘control 
new’, ‘control old’) which were used in the label-free study, as well 
as in additional 22 samples of patients with established type 1 
diabetes (T1DM old) and their respective healthy controls (control 
old) samples. 
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4.2.7.1 Vitronectin 
 
4.2.7.1.1 Vitronectin in samples of patients with newly-diagnosed 
type 1 diabetes compared to their healthy controls 
 
Label-free proteomics analysis showed vitronectin levels to be 
significantly increased in samples of patients with newly-diagnosed 
type 1 diabetes compared to their respective controls by 
approximately 1.44 fold.  
An ELISA kit was sourced from American Diagnostica GmbH 
(catalogue number 803) for validation of this target protein 
(protocol outlined in section 4.1.3.1).  
ELISA detection of vitronectin in the same samples from patients 
with newly-diagnosed type 1 diabetes and their matched controls 
showed no significant difference in vitronectin levels between the 
groups (116.54±21.18 vs. 113.63±15.95 μg/mL, respectively, p=0.76), 
with a fold change of 1.02 (Figure 4.2.6).  
 
 Looking at each individual matched pair separately (Figure 4.2.7), 
vitronectin levels were higher in the T1DM new specimens in four of 
the eight matched pairs.  
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Figure 4.2.6 Mean vitronectin concentration (μg/mL) in patients with newly diagnosed type 1 
diabetes and their healthy controls. Error bars delineate 95% confidence intervals. 
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Figure 4.2.7.Vitronectin serum concentration shown for pairs of patients with newly-
diagnosed type 1 diabetes (T1DM new) and their respective healthy controls.  
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4.2.7.1.2 Vitronectin in samples of patients with established type 1 
diabetes compared to their healthy controls 
In the label-free proteomic experiment, vitronectin was shown to 
be significantly reduced in patients with established type 1 
diabetes compared to their healthy controls by approximately 1.64 
fold.  
Validation of this target was performed in a larger cohort of 30 
T1DM old samples, including the samples used for the label-free 
proteomics experiment. 
ELISA validation confirmed reduced vitronectin levels (1.14 fold) in 
samples of patients with established type 1 diabetes compared to 
matched controls (119.52±28.27 vs. 135.94±32.82 μg/mL, p=0.038) 
(Figure 4.2.8). 
 
Figure 4.2.8. Mean vitronectin concentration in patients with established type 1 diabetes  and 
their healthy controls. Error bars delineate 95% confidence intervals.  
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Looking at each individual matched pair, reduced vitronectin 
levels in patients with established T1DM is seen in 23 of the 30 
matched pairs (figure 4.2.9). 
 
Figure 4.2.9 Vitronectin levels in matched pairs of patients with established type 1 diabetes 
(T1DM old)  and their healthy controls. 
 
There was no correlation between vitronectin levels and markers of 
inflammation (ESR, FBC) or markers of glycaemic control (HbA1C). 
 
4.2.7.1.3 Vitronectin in samples of patients with newly-diagnosed 
type 1 diabetes compared to patients with established 
type 1 diabetes 
 
In the label-free proteomics experiment vitronectin levels were 
significantly decreased in samples of patients with established type 
1 diabetes compared to patients with newly-diagnosed specimens 
by approximately 1.44 fold.  
On expansion of the T1DM old sample cohort to 30 specimens, 
vitronectin levels were not significantly different between patients 
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with established type 1 diabetes (T1DM old) and newly-diagnosed 
type 1 diabetes (119.15±28.28 vs. 116.55±21.18 μg/mL, p=0.81) 
(Figure 4.2.10).  
 
Figure 4.2.10 Vitronectin levels in patients with with established type 1 diabetes (T1DM old, 
n=30) and in patients with newly-diagnosed type 1 diabetes (T1DM new, n=8). Error bars 
delineate 95% confidence intervals. 
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4.2.7.2 Clusterin 
4.2.7.2.1 Clusterin in samples of patients with newly-diagnosed 
type 1 diabetes compared to their healthy controls 
Clusterin protein levels were found to be significantly up-regulated 
(1.66 fold) in samples from patients with newly-diagnosed type 1 
diabetes (n=8) when compared to their healthy controls (n=8) in 
the label-free proteomics experiment.  
Attempted validation of this target was performed using a clusterin 
ELISA sourced from Phoenix pharmaceuticals (catalogue number 
EK-018-35) in the same samples used in label-free proteomics 
experiment (protocol outlined in section 4.1.3.2). There was no up-
regulation of clusterin in samples from newly-diagnosed type 1 
diabetes when compared to healthy controls (186.77±80.19 vs. 
212.94±31.09 μg/mL, p=0.40) (Figure 4.2.11).  
  
Figure 4.2.11  Clusterin concentration in patients with newly-diagnosed type 1 diabetes 
compared to the healthy controls. Error bars delineate 95% confidence intervals. 
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 Looking at the ELISA results of each matched pair individually 
(Figure 4.2.12), 6 of the 8 sets of matched pairs show reduced 
clusterin levels in T1DM new sample compared to control.  
The increased clusterin expression detected in the label-free 
experiment may have been skewed by the outlier T1DM new 
sample in pair 1 (Figure 4.2.12), which shows almost double the 
level of clusterin compared to the other T1DM new samples 
analysed. 
 
Figure 4.2.12  Clusterin serum concentrations in matched pairs of patients with newly-
diagnosed type 1 diabetes and their healthy controls. 
As clusterin shows an association with inflammation and lipid 
transport and its expression appears to be stimulated by glucose in 
the liver, we investigated correlations of clusterin level and 
parameters of metabolic health in our patients with newly 
diagnosed type 1 diabetes (BMI, blood pressure, smoking in pack-
years, exercise in minutes/week, heart rate, waist/hip ratio, fasting 
glucose, insulin, HbA1C, HOMA indices and lipid levels).  There was 
no significant correlation found with any parameter of metabolic 
health (146).  
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4.2.7.2.2 Clusterin in samples of patients with established type 1 
diabetes compared to their healthy controls 
In label-free proteomic analysis, there was no significant difference in 
clusterin levels between patients with established type 1 diabetes and 
their healthy controls. This bore true in ELISA validation as well. The 
levels in patients with established type 1 diabetes did not differ 
significantly when compared to their healthy controls (215.59±59.20 vs. 
231.48±60.01 μg/mL, p=0.30; Figure 4.2.13).  
 
Figure 4.2.13  Levels of clusterin serum concentration in patients with established type 1 diabetes 
(T1DM old, n=30) and their matched controls (n=30). Error bars delineate 95% confidence 
intervals.  
 
Looking at the matched pairs individually (Figure 4.2.14), large 
variation in clusterin expression was seen in both control and T1DM old 
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serum specimens. Sixteen out of thirty matched pairs showed lower 
clusterin levels in samples of patients with established type 1 diabetes 
relative to their healthy controls, with the remaining 14 pairs showing 
higher clusterin levels in the T1DM old samples (Figure 4.2.14). 
 
There was no significant correlation between clusterin levels and 
markers of dyslipidaemia (levels of total cholesterol, HDL, LDL, 
triglycerides), BMI or markers of glycaemic control (fasting glucose, 
HbA1C).  
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Figure 4.2.14  Levels of clusterin in matched pairs of patients with established type 1 diabetes and their healthy controls. 
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4.2.7.2.3 Clusterin in samples of patients with newly diagnosed type 1 
diabetes compared to patients with established type 1 
diabetes 
Clusterin expression was significantly up-regulated by 1.43 fold in 
patients with newly-diagnosed type 1 diabetes compared to patients 
with established type 1 diabetes, as established by the label-free 
proteomics analysis. Attempted validation of clusterin expression by 
ELISA in 30 samples of patients with established type 1 diabetes and 
the same 8 samples from patients with newly-diagnosed type 1 
diabetes used in the initial analysis showed no significant difference in 
clusterin expression (215.59±59.2 VS. 186.76±80.19 μg/mL, p=0.26) 
(Figure 4.2.15).  
 
Figure 4.2.15 Clusterin levels in patients with established type 1 diabetes vs. patients with newly-
diagnosed type 1 diabetes. Error bars delineate 95% confidence intervals. 
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4.2.7.3 Vitamin K-dependent protein S  
4.2.7.3.1 Vitamin K-dependent protein S in samples of patients with 
newly-diagnosed type 1 diabetes compared to their healthy 
controls 
 
Vitamin K-dependent protein S was found to be significantly up-
regulated in serum of patients with newly diagnosed type 1 diabetes, 
compared to their matched healthy controls, by approximately 1.42 
fold, in the label free proteomics experiment. 
 An ELISA kit was sourced from USCN Life Science Inc. (catalogue 
number E1971h) for attempted validation of this target protein 
(protocol outlined in section 4.1.3.3).  
On ELISA in the same eight samples of patients with newly-diagnosed 
type 1 diabetes and their eight healthy controls, vitamin K-dependent 
protein S was significantly down-regulated in samples of patients with 
newly-diagnosed type 1 diabetes by 1.24 fold when compared to 
their healthy controls (360.93±79.92 vs. 448.48±68.13 ng/mL, p= 0.03; 
Figure 4.2.16). 
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Figure 4.2.16 Vitamin K-dependent protein S concentration in patients with newly-diagnosed type 
1 diabetes (T1DM new) and their healthy controls. Error bars delineate 95% confidence intervals. 
 
Figure 4.2.17 shows the individual levels of vitamin K-dependent 
protein S in each of the matched pairs. Lower levels of vitamin K-
dependent protein S are seen in samples of patients with newly 
diagnosed type 1 diabetes for 6 of the 8 matched pairs. One 
matched pair shows no change, while one pair shows higher vitamin 
K-dependent protein S levels in the T1DM new specimen.  
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Figure 4.2.17 Concentration of vitamin K-dependent protein S in patients with newly-diagnosed 
type 1 diabetes (T1DM new) and their matched controls. 
 
There was no significant correlation between vitamin K-dependent 
protein S and markers of glycaemic control (fasting glucose, HbA1C) 
or markers of lipaemic control (total cholesterol, HDL, LDL, Tg).  
 
4.2.7.3.2 Vitamin K-dependent protein S in samples of patients with 
established type 1 diabetes compared to their healthy 
conrols 
 
Vitamin K-dependent protein S was significantly down-regulated in 
patients with established type 1 diabetes when compared to their 
healthy controls in label free proteomic analysis, by approximately 
2.28 fold.  
ELISA validation of this target was performed using an expanded 
cohort of 30 T1DM old and 30 control old samples, but no significant 
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difference in vitamin K-dependent protein S was found between the 
groups (358.49±118.22 vs. 388.44±122.16 ng/mL, p=0.33; Figure 4.2.18)  
 
 
Figure 4.2.18 Vitamin K-dependent protein S in patients with established type 1 diabetes (n=30) 
and their matched controls (n=30). Error bars delineate 95% confidence interval.  
 
Looking at each matched pair individually (Figure 4.2.19), no 
consistent change was seen in vitamin K-dependent protein S 
expression. This target was present at lower levels in serum of patients 
with established type 1 diabetes in 15 of the 30 matched pairs, in 
higher levels in 14 of 30 matched pairs, and no change in one pair.  
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Figure 4.2.19 Vitamin K-dependent protein S in patients with established type 1 diabetes and their matched healthy controls.
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4.2.7.3.3 Vitamin K-dependent protein S in samples of patients with 
newly-diagnosed type 1 diabetes compared to patients with 
established type 1 diabetes 
 
Label-free proteomics analysis identified vitamin K-dependent protein 
S as being significantly up-regulated in serum of patients with newly-
diagnosed type 1 diabetes, compared to patients with established 
type 1 diabetes.  However, on expansion of the established type 1 
diabetes cohort, ELISA quantification of vitamin K-dependent protein S 
found no significant difference in levels of this target between sera of 
patients with newly-diagnosed and established type 1 diabetes 
(358.49 vs. 360.79 ng/mL, p=0.95; Figure 4.2.20) 
 
Figure 4.2.20 Vitamin K-dependent protein S concentration in patients with established type 1 
diabetes (n=30) compared to patients with newly-diagnosed type 1 diabetes (n=8).  
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4.2.7.4 Apolipoprotein L1  
 
Label free proteomics analysis showed a significant 2.84 fold 
decrease in apolipoprotein L1 in sera of patients with established 
type 1 diabetes when compared to their matched healthy controls. 
It also showed a 1.88 fold decrease when sera of patients with 
established type 1 diabetes were compared to sera of patients with 
newly-diagnosed type 1 diabetes.  
The human apolipoprotein L1 ELISA used for this validation study was 
sourced from USCN Life Science Inc. (catalogue number E9374Hu). 
However, no suggested serum dilutions were included in this kit. 
Therefore, an apolipoprotein L1 concentration estimation was 
performed using two serum samples (T1DM old sample DS-100 and 
T1DM new sample DS-170), and three dilutions of each sample, at 
1:10, 1:500 and 1:5,000, as well as the lowest and highest points of 
the standard curve. The apolipoprotein L1 ELISA used for this 
experiment is based on a sandwich ELISA technique (protocol 
outlined in section 2.2.6.4). Therefore higher concentrations of 
apolipoprotein L1 should lead to high absorbance readings at 
450nm. For each sample analysed, the 1:10 dilution showed the 
highest absorbance, with a lower absorbance reading for the 1:500 
dilutions, as expected. However, absorbance readings for 1:5,000 
dilutions showed higher absorbance reading than the 1:500 dilutions 
for both samples tested (Table 4.2.7). As the lowest dilution (1:10) 
absorbance readings were only marginally above the lowest 
standard curve reading, therefore a 1:5 dilution was chosen to 
perform ELISA on all remaining samples. 
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Samples from eight patients with newly diagnosed type 1 diabetes 
and their controls as well as thirty samples from patients with 
established type 1 diabetes and their controls were diluted at 1:5 
before performing the apolipoprotein L1 ELISA.  
Table 4.2.7 Apolipoprotein L1 serum concentration estimation. Absorbance values measured at 
450nm for two serum samples (DS-100 and DS-170), serially diluted to 1:10, 1:500 and 1:5000 
Sample Absorbance 
1.25ng/mL standard 0.21 
80ng/mL standard Too high 
DS-100 1:10 dilution 0.349 
DS-100 1:500 dilution 0.120 
DS-100 1:5000 dilution 0.262 
DS-170 1:10 dilution 0.297 
DS-170 1:500 dilution 0.138 
DS-170 1:5000 dilution 0.251 
All sample absorbances were below the lowest point on the 
standard curve, therefore apolipoprotein L1 concentrations could 
not be deduced. DS-100 and DS-170 samples which were used for 
the concentration estimation were also diluted 1:5 and assayed 
again with all other samples. However, the absorbance reading was 
lower than the lowest point on the standard curve for DS-170, and 
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the DS-100 absorbance reading was lower than the blank 
absorbance reading of the standard diluent solution. 
The low absorbance readings of serum samples may indicate that 
apolipoprotein L1 levels were below the level of detection. 
However, as more dilute samples showed higher absorbance 
readings during the concentration estimate, this may indicate that 
these pre-coated ELISA plates may not have been uniformly coated 
with the anti-apolipoprotein L1 capture antibody.  
 
4.2.8 Summary of proteomic biomarker study 
 
Label-free proteomics and ELISA validation results for each target 
analysed are shown in table 4.2.23.  Only two comparisons reached 
statistical significance when validated using ELISA technology, 1) 
vitamin K-dependent protein S, in the comparison of sera from 
patients with newly-diagnosed type 1 diabetes and their matched 
controls and 2) vitronectin, in the comparison of sera from patients 
with established type 1 diabetes with their matched controls.  
ELISA validation experiments were performed by Dr Erica Hennessy.  
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Table 4.2.8 Summary of proteomic studies. Legend:’ T1DM new’, patients with newly-diagnosed type 1 diabetes; ‘control new’ healthy controls matched to patients with 
newly-diagnosed type 1 diabetes; ‘T1DM old’, patients with established type 1 diabetes; ‘control old’, healthy controls matched to patients with established type 1 diabetes 
 T1DM new vs control new T1DM old vs control old T1DM new vs T1DM old 
 Proteomics (n=8) ELISA (n=8) Proteomics (n=8) ELISA (n=30) Proteomics (n=8) ELISA (T1DM N=8, 
T1DMO=30) 
Vitronectin 1.45 fold up in 
T1DM new (2/3) 
No change  1.64 fold down in 
T1DM old 
1.14 fold down in 
T1DM old (significant) 
1.44 fold up in T1DM 
new 
No change  
Clusterin  1.66 fold up in 
T1DM new 
No change  No change No change  1.43 fold up in T1DM 
new 
No change  
Vitamin K-
dependent 
protein S 
1.42 fold up in 
T1DM new (2/3) 
1.24 fold down 
in T1DM new  
(significant) 
2.28 fold down in 
T1DM old 
No change  1.80 fold up in T1DM 
new 
No change  
Apolipoprotein 
L1 
No change Unmeasurable 2.84 fold down in 
T1DM old 
Un-measurable 1.88 fold up in T1DM 
new (1/3) 
Unmeasurable 
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4.3 Discussion on findings of 
proteomics serum analysis 
 
While in the past the majority of research was hypothesis-driven, 
hypothesis-free global approaches, such as microarray-based 
transcriptional profiling or quantitative proteome analysis, have the 
advantage of investigating the whole complexity of an organism. 
Thus, evidence for patterns of changes can be provided and, 
potentially, new hypotheses generated. The transcriptomic and 
proteomic approaches are complementary as changes in mRNA 
levels do not necessarily mirror changes in the abundance of the 
proteins encoded by these genes, and potentially important post-
translational modifications can only be detected by proteomics (107).  
 Serum is an obvious choice for proteomic profiling due to ease of 
access. As initial proteomic investigations in diabetes were on tissues, 
we are comparing our data to those.   
In our study, from the four proteins identified on label-free serum 
proteomic analysis as being differentially expressed in type 1 diabetes 
(vitronectin, clusterin, apolipoprotein 1 and vitamin K-dependent 
protein S), only two proteins were significantly differentially expressed 
when validated by ELISA studies (Table 4.2.8). Vitronectin was down-
regulated by 1.14 fold in established type 1 diabetes patients 
compared to their healthy controls, while vitamin K-dependent 
protein S was 1.24 fold down-regulated in patients with newly-
diagnosed type 1 diabetes compared to their healthy controls. 
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4.3.1 Vitronectin 
 
Vitronectin was 1.45 fold up-regulated in two thirds of patients with 
newly diagnosed type 1 diabetes in initial label-free proteomic 
experiment; this was not confirmed on ELISA. It was 1.64 down-
regulated in patients with established type 1 diabetes compared to 
their healthy controls and that was upheld by ELISA validation.  
Vitronectin is an adhesive glycoprotein which plays a role in 
attachment of cells to their surrounding matrix and may be involved in 
regulation of cell differentiation, proliferation, migration and 
morphogenesis (147). Vitronectin expression on angiogenic 
endothelial retinal cells contributes to diabetic retinopathy (148). In 
our group, there was no difference in vitronectin levels between 
patients with type 1 diabetes who had retinopathy when compared 
to those who did not have retinopathy (data not shown).  
Vitronectin levels are increased in regulation of complement 
activation and blood coagulation (147). It is possible that an elevation 
in newly-diagnosed type 1 diabetes on label-free proteomics, albeit 
not confirmed on ELISA, is a remnant of autoimmune destructive 
processes as our patients were recruited on average around three 
months after diagnosis. Unfortunately, no coagulation testing was 
performed in our patient cohort.  
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4.3.2 Clusterin 
 
Clusterin was 1.66 fold increased in newly diagnosed patients with 
type 1 diabetes, when compared to healthy controls on label-free 
proteomic analysis, but this did not hold on ELISA validation. There was 
no difference in clusterin between samples of established type 1 
diabetes and their controls, or between the samples of patients with 
newly-diagnosed and established diabetes.  
 
Clusterin is a stress-response protein involved in various biological 
processes, including cell proliferation, apoptosis, tissue differentiation, 
inflammation and lipid transport (146). Clusterin gene polymorphisms 
were found to be associated with type 2 diabetes in Japanese 
population and hepatic clusterin expression is increased by glucose 
stimulation (146, 149). It is also associated with metabolic changes of 
type 2 diabetes: high levels of circulating clusterin and LDL-bound 
clusterin were found in patients with type 2 diabetes (150). In another 
study of men only with type 2 diabetes, clusterin level was increased 
when LDL-associated proteins were analysed with mass spectrometry, 
2-DIGE and ELISA (151). Same positive association between clusterin 
and LDL and total cholesterol was found in healthy young males (152) 
. Clusterin was also found to be low in the protein HDL of men with 
reduced insulin sensitivity and higher BMI (153) . In our study there was 
no association of clusterin with BMI, total cholesterol, LDL, HDL or 
triglycerides.   
Reduced levels of clusterin were found in the vitreous fluid of patients 
with proliferative diabetic retinopathy in type 2 diabetes (112). 
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In type 1 diabetes, there is a significant paucity of data on clusterin. In 
the only available previous serum study, serum levels of clusterin were 
lower in patients with newly-diagnosed type 1 diabetes (within 14 days 
of starting insulin treatment) when compared to controls, while in our 
study, higher levels initially identified on label-free proteomics were not 
confirmed on ELISA validation (103).  
 
4.3.3 Vitamin K-dependent protein S 
 
Vitamin K-dependent protein S is an anticoagulant factor. It is a 
cofactor to activated protein C in the degradation of coagulation 
factors Va and VIIIa (154). It is secreted by hepatocytes, 
megakaryocytes and endothelial cells as well as osteoblasts; it 
stimulates fibrinolysis and is involved in serum-stimulated phagocytosis 
of apoptotic cells (155, 156). About 40% of the protein S in plasma is in 
the free form, whereas the remaining 60% is associated in a 1:1 
complex with C4b-binding protein (C4bBP). Both forms bind strongly to 
negatively charged phospholipids exposed on the surface of 
activated platelets. Free protein S (although having no strong 
inhibitory effect on FVa or FVIIIa itself) forms a calcium- dependent 
complex with activated protein C, helping to orient its active site 
above the phospholipid surface and enhancing its anticoagulant 
activity (157). 
Increased coagulation was described in type 1 diabetes, due to 
increased concentration of coagulation factor VII and to increased 
platelet adhesiveness, activation of the coagulation system, and 
decreased plasma fibrinolytic potential (158, 159). It is known that 
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hypoglycaemia activated the coagulation system, partly by 
increasing the concentration of von Willebrand antigen (160).  
In our study, vitamin K-dependent protein S was down-regulated in 
patients with newly-diagnosed type 1 diabetes (which would be 
expected to promote coagulation) and up-regulated in patients with 
established type 1 diabetes (which would be expected to promote 
anticoagulation) on label-free proteomics. Only the down-regulation 
in newly-diagnosed type 1 patients was confirmed by ELISA validation.  
There was no history of thrombotic events or family history of 
thrombosis in our cohort of patients with newly-diagnosed type 1 
diabetes. Unfortunately, we have not collected any coagulation data 
on our patients. It is also known that hypoglycaemia promotes 
thrombosis; unfortunately, we have not collected data on 
hypoglycaemic episodes in this patient population. 
Increased levels of protein S have been described in poorly controlled 
newly diagnosed patients type 1 diabetes, with no evident clinical 
consequence (161). Decreased levels of protein S have been 
described in patients with type 2 diabetes and microvascular 
complications, in particular diabetic nephropathy, while conflicting 
data exists on patients with type 1 diabetes with various degrees of 
diabetic nephropathy—increased protein S levels were found in 
patients with increased urinary albumin excretion and yet, a surgical 
study analysing prothrombotic defects in patients with type 1 diabetes 
undergoing pancreas/kidney transplant found a significant number of 
patients suffering from protein S deficiency (12/47, 25%); this had not 
affected their surgical thrombosis risk (162, 163).  
It would certainly be interesting to assess the vitamin K-dependent 
protein S level in a larger sample of patients with newly-diagnosed 
172 
 
and established type 1 diabetes, particularly with detailed assessment 
of coagulation function.  
 
4.3.4 Apolipoprotein L1 
 
Apolipoprotein L1 is a HDL-associated lipoprotein. While label-free 
proteomics showed a down-regulation in established type 1 diabetes, 
apolipoprotein L1 was not measurable on ELISA validation. A different 
method would be needed to establish if there is a real difference in 
apolipoprotein L1 in established type 1 diabetes.  
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5 Metabolomic analysis in patients 
with newly-diagnosed type 1 
diabetes 
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5.1 Materials and methods 
 
Metabolites can vary greatly in their physical properties; as of yet no 
single technique is capable of detecting and quantifying such a 
diverse range of compounds. 
 The diagnostic company Metabolon incorporate three independent 
analysis platforms in their procedure for metabolite profiling, in order to 
get maximum separation of the different types of biochemicals 
present in the samples (164, 165).  
Two separate ultra-high performance liquid chromatography / 
tandem mass spectrometry (UHPLC/MS/MS) injections and one gas 
chromatography/mass spectrometry (GC/MS) injection are performed 
per sample. One UHPLC/MS/MS injection was optimised for detection 
of positive ions while the second injection was optimised for negative 
ion detection; GC/MS platform allows for better separation of 
carbohydrates which are difficult to detect with LC methods.  
Each detected biochemical is automatically compared to a 
reference standard in the company’s database, using retention index 
and mass spectrum. The result is a broad range of biochemicals 
identified including amino acids, carbohydrates, lipids, nucleic acids 
and cofactors. The service provides two types of data: 1)biochemical 
data file, which contains information about each sample processed: 
biochemical name, super pathway, sub pathway, KEGG ID (Kyoto 
Encyclopaedia of Genes and Genomes) , HMDB ID (Human 
Metabolome Database ID), and amount detected; the data is 
provided in two forms, raw and imputed, and 2) statistical heat map--
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statistical analysis of the data, which shows the fold change of each 
biochemical, grouped by super and sub pathway, and colour coded 
in terms of increase or decrease relative to control (164).  
This type of metabolomic profiling is a non-targeted one, meaning 
that it allows for detection of new metabolites, not yet documented in 
the reference library (166). 
 
Following an overnight fast, whole blood specimens were collected 
from newly diagnosed type 1 diabetes patients (n=8) and 
age/BMI/gender matched healthy controls (n=8). Samples were 
processed as detailed in the introduction. Resulting serum specimens 
were stored at -80ºC until required. Serum specimens (500μL) were 
shipped on dry ice to Metabolon Inc., North Carolina, USA, where the 
metabolomic profiling was performed. 
The samples were re-labelled by Metabolon, ED for patients with 
newly-diagnosed diabetes (‘disease’) and EN (‘control’).  
Metabolon incorporates three independent complimentary analysis 
platforms to maximise the number of small molecules and metabolites 
that the combined systems can identify and measure. Two 
independent ultra-high performance liquid chromatography / 
tandem mass spectrometry (UHPLC/MS/MS2) injections (one optimised 
for basic compounds, and the other for acidic compounds) and one 
GC/MS injection per sample are performed. 
Firstly, small molecules were extracted from serum specimens using 
methanol to allow precipitation of proteins. The extract supernatant 
was then split into four equal aliquots; two for UHPLC/MS, one for 
GC/MS and one reserve aliquot. Aliquots were then dried overnight to 
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remove solvent. For the UHPLC methods, one aliquot was 
reconstituted in 50μL 0.1% formic acid and the other in 50μL 6.5mM 
ammonium bicarbonate pH 8.0. For GC/MS analysis, aliquots were 
derivatised using equal parts N,O-bistrimethylsilyltrifluoroacetamide 
and a solvent mixture of acetonitrile:dichloromethane:cyclohexane 
(5:4:1) with 5% triethylamine at 60ºC for 1 hour. All reconstitution 
solvents contained instrument internal standards used to monitor 
instrument performance. 
UHPLC/MS was carried out using a Waters Acquity UHPLC coupled to 
an LTQ mass spectrometer equipped with an electrospray ionization 
source. Two independent UHPLC/MS injections were performed on 
each sample. The acidic injections were monitored for positive ions 
and the basic injections were monitored for negative ions. The 
derivatised samples for GC/MS were analyzed on a Thermo-Finnigan 
Trace DSQ fast-scanning single-quadrupole MS.  
The resulting MS/MS2 data was then searched against Metabolon’s 
reference standard library. This library was generated from 1500 
standards and contains the retention time/index, mass to charge 
(m/z), and MS/MS spectral data for all molecules in the library, 
including their associated adducts, in-source fragments, and 
multimers. The library allows identification of experimentally detected 
metabolites based on a multiparameter match basis. All 
identifications and quantifications were subjected to QC to verify the 
quality of the identification and peak integration.  
An internal standard was added to each sample before injection onto 
the mass spectrometers. Instrument variability was determined by 
calculating the median relative standard deviation (RSD) for the 
internal standard; median of measured RSD was 4%. A small amount 
of each study sample was also used to create a homogenous pool 
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called the client matrix. Technical replicates of this client matrix were 
used to determine overall process variability by calculating the 
median relative standard deviation of all endogenous metabolites, 
which amounted to 11%. Process variability as measured by median 
RSD passed Metabolon’s quality control criteria. Metabolon 
recommend an RSD cut off value of 13% to ensure minimum process 
variability.  
 
5.1.1 Validation of metabolomic target fibrinopeptide A 
 
ELISA validation of metabolite target was performed on the same 
eight samples of patients with newly-diagnosed type 1 diabetes and 
their controls as well as 30 samples of patients with established type 1 
diabetes and their matched controls.  
Fibrinopeptide A (FPA) ELISA was sourced from Hyphen BioMed 
(catalogue number RK016A). Serum specimens to be analysed were 
diluted by a factor of 1500 using sample diluent. Standards were 
reconstituted as per the manufacturer’s instructions using sample 
diluent. 100μL of anti-FPA antibodies were added to 1mL diluted 
samples or standards in an Eppendorf tube, and incubated at 37ºC for 
1 hour. 200 μL of sample/antibody or standard/antibody mix was 
added to each well of the ELISA plate, and incubated for 1 hour at 
room temperature. The plate was washed five times using wash 
solution. 200μL antibody conjugate solution was added to each well 
and incubated for 1 hour at room temperature. The plate was washed 
five times using wash solution. 200μL substrate solution was added to 
each well and incubated for 5 minutes at room temperature. 50μL 
stop solution was added and incubated for 10 minutes, and then 
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absorbance was read at 450nm. The standard curve was plotted as 
log concentration versus log absorbance, and the FPA concentration 
of samples was calculated using the equation of the line. 
 
5.2 Results of metabolomic profiling 
In this study, we sent the samples from eight patients with newly-
diagnosed type 1 diabetes and their matched healthy controls 
(characteristics described in section 2.1.3 and table 4.2.1) on dry ice 
(sample preparation described in section 5.1) to Metabolon Inc., 
North Carolina, USA, for metabolic profiling. The samples were re-
labelled by Metabolon, ED for patients with newly-diagnosed diabetes 
(‘disease’) and EN (‘control’).  
Overall, 302 biochemicals were detected in the serum samples. 
Biochemical data was analysed using two different methods--Welch’s  
two-sample t-test was used to compare disease group versus control 
group as a whole, while matched pairs t-test was used to analyse the 
individual matched pairs. A p-value of less than or equal to 0.05 was 
used as a cut-off for identification of significantly different 
biochemicals. 
Comparing disease group to control group, 19 biochemicals reached 
statistical significance, with 5 biochemicals at higher levels and 14 
biochemicals at lower levels in the disease group relative to control. A 
further 13 biochemicals were just beyond the level of significance and 
were termed ‘approaching significance’, with p-value greater than 
0.05 but less than 0.1. Of the 13 biochemicals approaching 
significance, 4 were present at higher levels and 9 at lower levels in 
disease versus control specimens (Table 5.2.1). 
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The matched pairs’ analysis showed very similar results to the group 
analysis. 21 biochemicals were significantly different, 5 of which were 
at higher levels and 16 at lower levels in disease versus control. 11 
biochemicals were in the approaching significance group, 6 of which 
were at higher levels and 5 at lower levels in disease group (Table 
5.2.1)  
 
Table 5.2.1  Biochemicals detected at significantly altered levels in  patients with newly-diagnosed 
type 1 diabetes and their matched healthy controls. 
 Welch’s two-sample 
t-test 
Matched pairs t-
test 
Biochemical with p ≤ 0.05 19 21 
Biochemicals (↑↓) 5|14 5|16 
Biochemicals approaching significance 
0.05<p>0.10 
13 11 
Biochemicals (↑↓) 4|9 6|5 
 
Table 5.2.2 lists all biochemicals which were identified as significantly 
different either by Welch’s two-sample analysis or by matched pair 
analysis. The fold change for the matched pair analysis is reported as 
the average fold changes for each of the individual matched pairs. 
Direction of fold change for all biochemicals in table 5.2.2 is 
consistent, whether analysed with Welch’s two sample analysis or 
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matched pair analysis, although in a limited number of cases the 
biochemical only reaches statistical significance with one of analysis 
methods. Box and whisker plots of all significantly different 
biochemicals are shown in figure 5.1.1. 
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Table 5.2.2 Significantly altered biochemicals in newly diagnosed type 1 diabetes specimens compared to healthy controls. : Red boxes indicate biochemicals which are 
present at significantly higher levels in newly diagnosed type 1 diabetes serum specimens. Green boxes indicate biochemicals which are present at lower levels in type 1 
diabetes serum specimens compared to control specimens (derived from the ‘heat map’ produced by Metabolon Inc.)  
Metabolite 
Group analysis Matched pairs analysis 
Fold change P-value  Average fold change P-value 
1,5-anhydroglucitol  2.85 0.0036 2.7 0.0063 
Fibrinogen cleavage peptide  2.67 0.0085 5.01 0.012 
Caffeine 2.5 0.0439 1.96 0.0156 
Isovalerylcarnitine 1.92 0.0081 1.69 0.0138 
Theophylline 1.89 0.059 1.61 0.0316 
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Metabolite 
Group analysis Matched pairs analysis 
Fold change P-value  Average fold change P-value 
1-pentadecanoylglycerophosphocholine 1.82 0.0038 1.67 0.0053 
Paraxanthine 1.78 0.0962 1.51 0.0358 
Malate  1.72 0.0036 1.61 0.0022 
3-carboxy-4-methyl-5-propyl-2-furanpropanoate 1.72 0.0847 1.67 0.0176 
1,7-dimethylurate 1.67 0.0424 1.43 0.0474 
2-methylbutyroylcarnitine 1.64 0.0214 1.41 0.0469 
Glucose  1.58 0.0162 1.59 0.0175 
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Metabolite 
Group analysis Matched pairs analysis 
Fold change P-value  Average fold change P-value 
Arginine  1.56 < 0.001 1.59 < 0.001 
N-acetyl threonine 1.54 0.0337 1.35 0.0659 
Hexanoylcarnitine 1.49 0.0256 1.33 0.0746 
Catechol sulphate 1.49 0.0099 1.59 0.0027 
Sebacate 1.47 0.0081 1.41 0.0239 
Propionylcarnitine 1.39 0.0335 1.33 0.0209 
Succinylcarnitine 1.37 0.0445 1.33 0.0441 
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Metabolite 
Group analysis Matched pairs analysis 
Fold change P-value  Average fold change P-value 
1,3-dimethylurate 1.37 0.0345 1.28 0.0223 
Urate 1.23 0.0758 1.22 0.0281 
5-oxyproline 1.16 0.0225 1.16 0.0082 
Glutamine 1.14 0.0339 1.14 0.0361 
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Figure 5.2.1. Box and whisker plots of all significantly different biochemicals in disease- newly diagnosed type 1 diabetes, compared to control- healthy specimens. Box and 
whisker plots show the distribution of the dataset. The median indicates the middle of the data, with 50% of the data being above and 50% below this value. Upper quartile 
indicates 25% of the data is above this value, while the lower quartile indicates that 25% of the data is below this value.  
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5.2.1 Validation of metabolomic targets 
We picked the metabolite with the strongest fold difference in 
expression on metabolomic studies, fibrinogen cleavage peptide/ 
fibrinopeptide A, and attempted to validate it with ELISA studies.  
Fibrinogen cleavage peptide/ fibrinopeptide A (FPA) levels were 
increased in T1DM new samples according to the metabolomics 
analysis by 2.67 and 5.01 fold in the groups and matched pairs’ 
analysis, respectively. Levels of this peptide were assessed in the same 
samples of patients with newly-diagnosed type 1 diabetes and their 
matched controls using an ELISA (Hyphen BioMed catalogue number 
RK016A) (protocol outlined in section 2.2.7.1). ELISA confirmed a 
significant increase (1.8 fold) in FPA levels in samples of patients with 
newly-diagnosed type 1 diabetes when compared to samples of 
healthy controls (31.035 ± 6.058 vs 17.536 ± 4.819 μg/mL, p<0.001) 
(figure 5.2.2). 
 
Figure 5.2.2 Fibrinopeptide A concentrations in patients with newly-diagnosed type 1 diabetes 
(T1DM new) and their matched controls. Error bars delineate 95% confidence intervals.  
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Figure 5.2.3 shows ELISA quantification of FPA in individual matched 
pairs. Fold change for pair 2 and pair 3 was 10 and 14 fold, 
respectively, according to metabolomics analysis. However, 
according to ELISA quantification, fold changes for these pairs was 
1.37 and 1.49, respectively. 
 
 
Figure 5.2.3. FPA concentrations in matched pairs of patients with newly-diagnosed type 1 
diabetes (T1DM new) and their matched controls.  
To test whether increased FPA levels was specifically seen in patients 
with newly-diagnosed type 1 diabetes or this was a more general 
diabetes-related event, FPA levels were assessed in patients with 
established type 1 diabetes. No difference in FPA levels was seen in 
patients with established type 1 diabetes (n=30) when compared to 
their matched controls (n=30) (Figure 5.2.4.).  
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Figure 5.2.4. Fibrinopeptide A levels in patients with established type 1 diabetes  and their 
matched controls. Error bars delineate 95% confidence intervals.  
 
Figure 5.2.5.  shows FPA levels in individual matched pairs of patients 
with established type 1 diabetes and their controls. FPA was down-
regulated in patients with established type 1 diabetes in 11 of 30 
matched pairs, while it was up-regulated in 17 of 30 matched pairs.
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Figure 5.2.5.  FPA concentration in patients with established type 1 diabetes (T1DM old) and their matched controls.
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FPA levels were assessed in T1DM new (n=8) compared to T1DM old 
(n=30) serum specimens, however, no significant change in expression 
levels was seen in these groups (Figure  5.2.6).  
 
Figure 5.2. 6 . FPA concentration in patients with newly-diagnosed type 1 diabetes and patients 
with established type 1 diabetes. Error bars delineate 95% confidence intervals. 
 
Fibrinopeptide levels were decreased significantly in samples of 
healthy controls of patients with newly-diagnosed type 1 diabetes 
when compared to patients with newly-diagnosed diabetes (17.536 ± 
4.819 vs. 31.035 ± 6.058 μg/mL, p<0.001) and controls to patients with 
established type 1 diabetes samples (17.536 ± 4.819 vs. 31.120 ± 19.907, 
p<0.001) (Figure 5.2.7). Therefore, differential expression seen between 
samples of patients with newly-diagnosed type 1 diabetes and their 
controls seems to be related to the control samples used rather than 
change due to the disease. 
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Figure 5.2.7.  Concentrations of fibrinopeptide A in patients with established type 1 diabetes 
IT1DM old), their matched controls (control old), patients with newly-diagnosed diabetes (T1DM 
new)  and their matched controls (control new), *p<0.01 
ELISA validation experiment was performed by Dr Erica Hennessy.  
 
5.2.2 Summary of metabolomic biomarkers study 
results 
Twenty-one different metabolites were differentially expressed in 
metabolomic studies; five metabolites were higher in patients than in 
controls and sixteen were lower in patients with newly-diagnosed type 
1 diabetes than in controls. However, the strongest differential 
expression of a metabolite, fibrinogen cleavage peptide/ 
fibrinopeptide A, was found to be due to a difference in the samples 
of the healthy controls, rather than in levels in patients with newly-
diagnosed type 1 diabetes.  
195 
 
5.3 Discussion 
Overall, 19 substances were significantly differentially expressed 
between patients with newly-diagnosed type 1 diabetes and their 
matched controls. Of those, 5 were more expressed in patients and 14 
were less expressed in patients.  
 
5.3.1 Carbohydrate metabolism 
 
1.5-anhydroglucitol (1,5-AG) was the most significantly differentially 
expressed metabolite from the carbohydrate metabolism; it was 2.85-
fold lower in group analysis and 2.7-fold lower in matched pair 
analysis.  
This was an expected change: 1,5-anhydroglucitol is a serum 
monosaccharide that is excreted in the urine at an accelerated rate 
in the presence of glycosuria (167) (Figure 5.3.1).   
1,5-AG is a naturally occurring 1-deoxy form of glucose, discovered in 
1888 (168).  Most of 1,5-AG is thought to originate from the diet, soy 
being the largest food source, while rice and pasta contain smaller 
quantities (169). A negligible amount is produced de novo (169). Its 
function in the human metabolism is still unknown.   
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Figure 5.3.1 Competitive tubular reabsorption of glucose and 1, 5-anhydroglucitole (1,5-AG) in 
hyperglycaemia [Adapted from Dungan, 2008 (169)].  
1, 5-AG intake is balanced by urinary excretion and nearly 99.9% is 
absorbed by the kidney (170). It appears to be transported through 
the SGLT4 transporter (sodium-glucose co-transporter 4) (169). After 
1,5-AG is filtered through the kidney, it competes with glucose for 
reabsorption in the kidney tubule (168).  When circulating levels of 
glucose increase the above the renal threshold for glucose (around 10 
mmol/L) even temporarily, 1,5-anhydroglucitol is lost in the urine and 
circulating levels fall, hence poor glycaemic control is associated with 
low serum levels of 1,5-AG (169).   
1,5-AG reflects glycaemic status over the preceding 48 hours to 2 
weeks and it has been used in Japan for over a decade to ascertain 
short-term diabetes control  (168). 1, 5-AG appears to correlate better 
than HbA1C with extent of glycaemic excursions and to be more 
successful at identifying patients with great fluctuations in glucose 
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levels despite similar HbA1C levels (170). It is not, however, as good as 
fasting glucose and HbA1c at establishing the diagnosis of diabetes 
due to poor sensitivity and specificity (168, 171). Recently it was 
successfully used to identify people at risk of cardiovascular disease 
development (172).  
There were no other metabolites involved in glucose metabolism 
which were significantly differently expressed.  
 
Malate and succynilcarnitine, metabolites from the Krebs cycle (citric 
acid cycle, tricarboxylic acid cycle, TCA) were less expressed in 
patients with newly-diagnosed type 1 diabetes (Figure 4.3.2). 
Succynilcarnitine is derived from succinyl-coenzyme A, which is 
derived from pyruvate in the Krebs cycle, while malate is part of the 
Krebs cycle metabolites (Figures 5.3.2 & 5.3.3). We hypothesise that 
reduction of levels of these two metabolites was due to a possible 
relative pyruvate deficiency in patients with type 1 diabetes, as 
pyruvate level reduction per se did not reach statistical significance in 
our study. It was previously shown in a study with radiolabelled carbon 
on Krebs cycle metabolites in type 1 diabetes that relative 
contribution of pyruvate oxidation to TCA cycle flux was decreased by 
approximately 30% in patients with type 1 diabetes (173).  
Pyruvate, the starting point of the Krebs cycle, is the end product of 
glycolysis. While glucose levels were high in our patients with newly-
diagnosed type 1 diabetes (table 5.2.1), in order for glucose to enter 
the cell and enter the glycolytic pathway, insulin needs to be present. 
Our patients were fasting and had very variable levels of insulin on 
board, having been instructed not to take any insulin that morning; 
the only insulin present being the long-acting preparation taken the 
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night before. Hence, their insulin levels may not have been high 
enough to transport sufficient amount of glucose across the cell 
membrane at the time of testing. This would account for lower 
pyruvate and consequently lower succinylcarnitine and malate. This 
pattern of reduced citric acid cycle metabolites was previously 
described in proteomic analyses of sera of patients with type 2 
diabetes (174). 
 
Figure 5.3.2  Citric acid cycle, positions of malate and succynil-coenzyme A visible (Adapted from 
Murray et al. Harper's Illustrated Biochemistry, 29th ed.) 
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Figure 5.3.3 Citric acid cycle, pathway to synthesis of succinylcarnitine [Adapted from Carrozo et al 
(175)] 
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5.3.2 Lipid metabolism 
 
On routine blood tests, controls had higher total cholesterol and 
higher LDL; this was despite the fact that none of our patients with 
type 1 diabetes was on statin treatment (Table 4.2.1). Considering that 
both patients and controls were rather young, there is most likely no 
pathological reason and it is due to chance that controls have less 
healthy lipid profiles. That said, controls to newly-diagnosed type 1 
diabetes patients were all medical interns; we could possibly 
extrapolate that being a medical intern is not the healthiest of 
lifestyles.  
When the metabolome was analysed, several components of lipid 
metabolism were differentially expressed: sebacate, 3-carboxy-4-
methyl-5-propyl-2-furanpropanoate  (CMPF) (only on matched pairs 
mean ratio analysis), propionylcarnitine, hexanoylcarnitine (Welch 
two-sample T-test only), and 1-pentadecanolglycerophosphocholine 
(Table 5.2.2).  
Sebacate and CMPF, both fatty acid dicarboxylates, were decreased 
in serum of patients with newly-diagnosed diabetes (Table 5.2.2). This 
is, at least in part, great news for our patients as CMPF is a known 
uremic toxin, which induces cell damage to proximal tubular cells via 
the generation of a radical intermediate (176). 
Reduced levels of fatty acids in fasting patients with type 1 diabetes 
could be connected to decreased lipolysis, which would fit in with 
relatively good glycaemic control of our patients (mean HbA1C of 
7.68%), meaning that they were mostly able to satisfy the energy 
metabolism requirements from glucose metabolism, rather than 
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needing to recruit energy creation from fat. Reduced levels of fatty 
acids could be also due to inappropriately high insulin from their basal 
(background, long acting) insulin  
Lipolysis involves the hydrolysis of triglycerides stored in adipose tissue 
into free fatty acids (FFA) in the fasted state, when hormone-sensitive 
lipase is stimulated by glucagon and cortisol. FFAs can then pass into 
the blood stream and travel to sites of energy requirements. β-
oxidation is the breakdown of FFAs to acetyl coenzyme-A (CoA), 
which can enter the TCA cycle to generate energy. β-oxidation of 
FFAs occurs in the mitochondrial matrix and in order for FFAs to access 
the mitochondrial matrix they must be transported via a carnitine 
shuttle (Figure 5.3.4). Firstly FFAs undergo conjugation to CoA 
generating fatty acyl-CoA. Fatty acyl-CoA is then transiently attached 
to carnitine via a transesterification reaction to form fatty acyl-
carnitine, which can then be translocated into the mitochondrial 
matrix via the acyl-carnitine transporter. Once inside the 
mitochondrial matrix, the fatty acyl-CoA is regenerated, while the 
carnitine molecule is released and transported back into the 
intermembrane space ready to transport the next fatty acyl-CoA 
molecule (177).  
In this study, a number of fatty acylcarnitine compounds were present 
at lower levels in the patients with newly-diagnosed type 1 diabetes 
compared to controls. Propionylcarnitine and hexanoylcarnitine levels 
were significantly lower 1.39 and 1.47 fold, respectively. A decrease in 
free carnitine and increase of acylcarnitine has previously been 
reported in sera of young patients with poorly controlled type 1 
diabetes (178).  
The decrease in fatty acylcarnitine compounds could be related to 
reduced β-oxidation in our patients—as carnitine shuttle-mediated 
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transportation of fatty acyl-CoA molecules into the mitochondrial 
matrix is the rate limiting step of fatty acid β-oxidation, lower levels of 
free carnitine would lead to lower levels of fatty acid β-oxidation, and 
subsequently lower levels of fatty acid dicarboxylates. This could also 
be due to the lower level of fatty acids due to decreased lipolysis.  
 
Figure 5.3.4 Transport of fatty acids through carnitine shuttle and link to FFA β oxidation, Krebs 
cycle and respiratory chain (Adapted from Murray et al, Harper’s Illustrated Biochemistry, 29
th
 e 
d(177)  
 
The lysolipid- 1-pentadecanolglyerophosphocholine was also present 
at significantly lower levels (1.82 fold) in serum of patients with newly-
diagnosed type 1 diabetes compared with controls. Lysolipids are 
involved in the formation of lipid bilayers of cell membranes.  
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Of the 16 lysolipids detected in this study, 1-
pentadecanoylglycerophosphocholine is the only lysolipid which is 
significantly reduced in sera of patients with newly diagnosed 
diabetes. No obvious trend was seen in the other lysolipids analysed 
and the patophysiology behind this result remains a mystery to us. 
Lipid metabolite changes identified in this study cannot be 
conclusively determined to be related to type 1 diabetes. As control 
subjects’ cholesterol was significantly higher than that of patients with 
type 1 diabetes and the control subjects overall exhibited a less 
healthy cholesterol profile, with higher LDL cholesterol, it is plausible 
that results of our lipid metabolism analysis were thus skewed. 
  
5.3.3 Amino acid metabolism 
 
The aminoacids arginine and glutamine were present at increased 
levels in samples of patients with newly diagnosed diabetes 
compared to control, 1.56 and 1.14 fold respectively.  
Arginine and glutamine are gluconeogenic aminoacids; after 
degradation of gluconeogenic amino acids, their carbon skeleton is 
diverted to gluconeogenesis (Figure 5.3.5). Arginine is also a urea 
cycle intermediate further indicating an increase in proteolysis, as the 
urea cycle functions to convert ammonia from amino acid oxidation 
to urea for excretion (Figure 5.3.6 A).  Glutamine is also a major 
component of amino acid oxidation (Figure 5.3.6 B). Ammonia 
generated from amino acid oxidation is toxic to tissues; therefore, it is 
combined with glutamate to yield glutamine, which can then be 
transported safely to the liver or kidneys for excretion. Increased levels 
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of glutamine therefore also suggest increased activity of the amino 
acid degradation pathway.  
Newly presenting patients with type 1 diabetes and patients with 
poorly controlled established diabetes typically exhibit increased 
protein catabolism and muscle wasting (30). As our patients were well 
controlled, this would explain a small difference in gluconeogenic 
amino acid level between patients and controls, indicating they were 
not suffering from significant levels of muscle wasting and proteolysis.  
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Figure 5.3.5 The pathway of gluconeogenesis includes 11 enzymatic steps, which form one 
molecule of glucose from two molecules of pyruvate. Reactions and enzymes specific only to 
gluconeogenesis are shown in red. Irreversible reactions specific for glycolysis are shown in green. 
Additional substrates for gluconeogenesis are shown in blue and may also enter gluconeogenesis 
as denoted by the associated arrows. (Adapted from Naik P: Biochemistry, 3
rd
 edition, Jaypee 
Brothers Medical Publishers Ltd, 2009, published in Janson (179) ) 
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Figure 5.3.6 A. The urea cycle converts two amino groups (NH3) from glutamate and aspartate into 
urea as part of the body's nitrogen balance. Glutamate donates the first nitrogen atom via the 
molecule carbamoyl phosphate that is synthesized via the regulated enzyme carbamoyl phosphate 
synthetase (CPS-1). This enzyme is activated by increased glutamate, N-acetylglutamic acid, 
and/or arginine concentrations [indicated by (+)]. Carbamoyl phosphate then enters the urea cycle 
by combination with ornithine via ornithine transcarbamoylase. Aspartate donates the second 
nitrogen. Other amino acids contribute amino groups after conversion into glutamate or 
aspartate. Adapted from Janson et al, (179). 
 
 
 
Figure 5.3.6 B. α-ketoglutarate/glutamate/glutamine Ammonia Buffering System. The 
interconversion of -ketoglutarate to/from glutamate to/from glutamine offers the body an 
important system to utilise, generate, and/or store ammonia. Adapted from Janson et al (179). 
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Other amino acid-related metabolites less expressed in sera of 
patients with newly-diagnosed type 1 diabetes were 
isovalerylcarnitine, 2-methylbutyorylcarnitine, N-acetilthreonine. 
Isovalerylcarnitine and 2-methylbutyorylcarnitine come from the 
valine/leucine/isoleucine metabolism pathway.  
As valine, leucine and isoleucine are essential amino acids, and 
cannot by synthesised in the body, metabolites of these amino acids 
are an indication of amino acid oxidation rather than amino acid 
synthesis. Valine, leucine and isoleucine amino acids contain aliphatic 
side chains and are therefore known as the branched chain amino 
acids (BCAA). BCAAs have previously been reported to be of 
significance in diabetes, with raised BCAA levels presenting prior to 
autoantibody positivity in children which later develop type 1 diabetes 
(18). Similar pattern of reduced alanine, leucine, isoleucine, valine, 
,methionine, proline, lysine, tyrosine, histine and glutamine was 
previously seen in metabolomic analysis of sera of type 2 diabetes 
patients (174). Increased levels of BCAAs have previously been seen in 
studies of patients with poorly controlled type 1 diabetes (180, 181). 
The reduced level of BCAAs in our well patient cohort could be due to 
good metabolic and glycaemic control.  
 
N-acetyl threonine, involved in threonine metabolism, another 
essential amino acid, was also down regulated in samples of patients 
with newly-diagnosed type 1 diabetes.  5-oxyproline, involved in 
glutathione metabolism was also down regulated in patients with 
newly diagnosed type 1 diabetes. There is no known association 
between these amino acid metabolites and diabetes. . 
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5.3.4  Peptide metabolism 
On metabolomic analysis, the only significantly differently expressed 
peptide between patients with newly-diagnosed type 1 diabetes and 
controls was fibrinogen cleavage peptide/fibrinopeptide A (FPA). FPA 
was significantly increased in samples of patients with newly-
diagnosed type 1 diabetes. This was proven during ELISA validation to 
be due to the differentially expressed FPA in control samples matched 
to patients with type 1 diabetes, rather than to up-regulation in 
patients with newly diagnosed type 1 diabetes (Section 5.2.1) 
FPA is produced during the clotting process, when thrombin cleaves 
fibrinogen to produce fibrin and fibrinopeptide. Up-regulation of FPA 
has previously been reported in type 1 diabetes (182). Raised levels of 
FPA have previously been linked to increased alcohol consumption 
(183). While control subjects consumed more alcohol per week than 
patients with type 1 diabetes in our study, the difference was not 
statistically significant.  
 
5.3.5 Nucleotide metabolism 
Urate levels were significantly decreased in samples of patients with 
newly diagnosed type 1 diabetes when compared to control subjects, 
by 1.23 fold.  
Urate is formed from the degradation of purine-containing nucleotides 
(adenine and guanine), and is excreted in the urine (36). Low levels of 
urate could indicate reduced activity of nucleotide catabolism, due 
to either reduced purine intake in the diet, or reduced proteolysis. 
Increased uric acid levels have been reported to be associated with 
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increased risk of microvascular complications in patients with type 1 
diabetes (184). Our patients were newly diagnosed and hence, 
complication-free.   
As urate was the only differently expressed metabolite of eleven 
nucleotide-related metabolites detected, we conclude that changes 
in nucleotide metabolism were minor.  
 
5.3.6 Xenometabolites 
Caffeine, paraxantine, theophylline, cathecol sulphate and 1,3 
dimethylurate are xenometabolites, meaning that they are 
substances with no role in organism’s metabolism.  
In our study, caffeine, paraxantine and 1, 3-dimethylurate were 
present at a lower level in patients with type 1 diabetes than in control 
subjects.  
They are all caffeine metabolites, which would indicate that the 
control subjects, medical interns, consumed a lot more caffein-
containing products than the patients with type 1 diabetes 
Cafestol, the diterpene present in coffee, previously described as the 
most potent cholesterol-elevating compound in human diet,  was not 
found in sera of patients or controls. 
Cathecol sulphate was increased in patients with newly-diagnosed 
type 1 diabetes. Cathecol sulphate is a benzoate metabolite and 
benzoates are food preservatives used in acidic juices and soft drinks, 
indicating that patients with type 1 diabetes consumed more soft 
drinks than medical interns.  
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5.3.7  Summary of metabolomic studies 
 
In the snapshot of metabolome, our patients with newly-diagnosed 
type 1 diabetes were found to have less 1,5-anhydroglucitol, 
consistent with higher glucose levels than controls.  
Krebs cycle metabolites malate and succinylcarnitine were less 
expressed in patients with newly-diagnosed type 1 diabetes, possibly 
due to relative pyruvate deficiency, or decreased flux of pyruvate into 
TCA cycle.  
Fatty acylcarnitine compounds were present at lower levels in patients 
with newly-diagnosed type 1 diabetes when compared to controls; 
this may be related to reduced β-oxidation of fatty acids in our 
patients. 
Gluconeogenic aminoacids arginine and glutamine were present at 
significantly increased levels in sera of patients with newly-diagnosed 
type 1 diabetes, most likely due to increased muscle catabolism in 
patients with diabetes in fasting state.  
Branched chain aminoacids were also less expressed in patients with 
newly-diagnosed type 1 diabetes.    
Peptide and nucleotide metabolism were not significantly different 
between patients and controls.  
 
Xenometabolites derived from caffeine were more expressed in 
control subjects, while xenometabolites derived from sodium 
benzoate were more expressed in control subjects. 
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6 Conclusion 
6.1 Serum mRNA studies 
 
Based on previous cell line work from our Dublin City University 
colleagues, several mRNA targets were investigated with qRT-PCR. Of 
those, two were found in the sera of our patients with newly 
diagnosed type 2 diabetes and their healthy controls, thioredoxin-
interacting protein (Txnip)  and early growth factor 1 (Egr1). No 
significant difference of expression was found in Txnip expression levels 
between patients with newly-diagnosed diabetes and their controls, 
contrary to findings of previous muscle biopsy studies.  
 
Considering Txnip’s mode of action through arrestin-mediated 
supression of glucose uptake, it would be interesting ot extend this 
study to other groups of patients, particularly those with impaired 
fasting glucose and impaired glucose tolerance as well as patients 
with poorly controlled diabetes mellitus, as initially planned when 
devising this study. We hope that financial constraints which 
prevented us from performing these analyses at the time will be 
overcome in the future.  
Egr1 mRNA was significantly more expressed in patients with newly 
diagnosed type 2 diabetes when compared to controls. In cell 
cultures, Egr1 expression is reported to be both inducible and 
repressed by insulin and glucose induces Egr1 mRNA in various β-cell 
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models; in the only human serum study known to us, it was inducible 
by oral glucose load (83). It has been proposed that Egr1 
overexpression is the mechanism by which hyperinsulinism induces 
insulin resistance in adipocytes (185).  
In our study, no relationship between Egr1 expression and insulin or 
fasting glucose levels was observed, so we have no data to support or 
refute the above theory.  
As Egr1 is a major transcription factor in atherosclerosis, even though 
our patients had no history of atherosclerosis or atherosclerosis-related 
events, it would be interesting to follow this cohort in the future and 
record the occurance of cardiovascular events, to investigate if 
increased Egr1 transcription could have had pathological 
consequences (138). 
 
6.2 Serum proteomics studies 
 
Proteomic profiling was performed on sera of patients with newly 
diagnosed type 1 diabetes and their healthy controls as well as 
patients with established type 1 diabetes and their healthy controls.  
Initial label-free proteomic analysis identified four targets as 
differentially expressed: vitronectin, clusterin, vitamin K-dependent 
protein S and apolipoprotein A.  
Label-free proteomics results were validated by ELISA for each target 
analysed.  Only two comparisons reached statistical significance 
when validated using ELISA technology: vitamin K-dependent protein 
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S, which was decreased in sera from patients with newly-diagnosed 
type 1 diabetes when compared to their matched controls; and 
vitronectin, which was decreased in sera from patients with 
established type 1 diabetes when compared with their matched 
controls.  
While the decrease in anticoagulant protein S in our patients with type 
1 diabetes would have reasonably been expected to have a 
prothrombotic effect, no such events were reported by patients with 
newly diagnosed type 1 diabetes. While we had not performed any 
coagulation testing, the usual screening tests, prothrombin time and 
activated partial thromboplastin time, would not have been much 
use as they do not assess the propensity of organism to clotting 
adequately. It would be interesting to perform additional detailed 
thrombophilia studies on patients with newly diagnosed type 1 at 
diagnosis,  including protein C, antithrobin levels, activated protein C 
resistance assay and factor V Leyden mutation, if necessary, as well as 
prothrombin G-20210-A mutation, lupus anticoagulant studies, 
anticardiolipin and β2-glycoprotein 1 antibody, to exclude any known 
thrombophilia which could have started a coagulation process, 
leading to consumption of protein S in  clot formation.  
As one of the shortcomings of this study was that data on 
hypoglycaemia was not collected, this would need to be included in 
any further studies expanding on this finding, possibly coupled with 
continuous glucose monitoring to investigate the relationship of 
decreased protein S to hypoglycaemic events.  
Regarding vitronectin, while our patients with established type 1 
diabetes with reduced serum vitronectin levels did not have an 
increased prevalence of retinopathy, it would be interesting to follow 
this group for development of retinopathy in the future.  
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6.3 Serum metabolomics studies 
 
In the snapshot of metabolome, there were not many unexpected 
findings. Patients with newly-diagnosed type 1 diabetes were found to 
have less 1,5-anhydroglucitol, consistent with higher glucose levels 
than controls.  
Krebs cycle metabolites malate and succinylcarnitine were less 
expressed in patients with newly-diagnosed type 1 diabetes, possibly 
due to relative pyruvate deficiency, or decreased flux of pyruvate into 
TCA cycle.  
Fatty acylcarnitine compounds were present at lower levels in patients 
with newly-diagnosed type 1 diabetes when compared to controls; 
this may be related to reduced β-oxidation of fatty acids in our 
patients. 
Gluconeogenic aminoacids arginine and glutamine levels were 
higher in patients  with newly-diagnosed type 1 diabetes, most likely 
due to increased muscle catabolism in patients with diabetes in 
fasting state.  
Branched chain aminoacids were also less expressed in patients with 
newly-diagnosed type 1 diabetes.    
Peptide and nucleotide metabolism were not significantly different 
between patients and controls.  
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Xenometabolites derived from caffeine were more expressed in 
control subjects, while xenometabolites derived from sodium 
benzoate were more expressed in patients with type 1 diabetes: 
medical interns drank more coffee, patients more minerals, one would 
be led to believe.  
Unfortunately, metabolomic analysis of patients with newly diagnosed 
type 1 diabetes as far as we can observe did not yield any new 
insights into the patophysiology of the disease. It would be possibly 
beneficial to perform metabolomic analyses in the acute setting, at 
the very diagnosis of type 1 diabetes, but, based on experience from 
this study and low interest in newly diagnosed patients with type 1 
diabetes, overwhelmed by the sudden change in their life, I would 
expect that study to be difficult to recruit for and perform.  
217 
 
List of tables 
Table 3.1.1 qRT-PCR primer and their assay ID used for serum study .... 68 
Table 3.1.2 Reagents for Taqman® qRT-PCR reaction. ........................... 69 
Table 3.2.1 Characteristics of newly diagnosed type 2 patients (T2DM) 
and their controls .......................................................................................... 71 
Table 3.2.2 Txnip expression in patients with newly diagnosed type 2 
diabetes (T2DM) and their healthy controls. ............................................ 74 
Table 3.2.3 Egr1 expression in patients with newly diagnosed type 2 
diabetes and their healthy controls. .......................................................... 81 
Table 4.2.1 Characteristics of patients with newly-diagnosed type 1 
diabetes (n=8) and their healthy controls (n=8) .................................... 106 
Table 4.2.2 Characteristics of patients with established type 1 diabetes 
(T1DM old, n=8)  and their controls (n=8). ............................................... 108 
Table 4.2.3 Characteristics of patients with established type 1 diabetes 
(T1DM old, n=30) and their controls (n=30) ............................................. 110 
Table 4.2.4 Summary of proteins differentially expressed in patients with 
newly-diagnosed type 1 diabetes and their matched healthy controls
........................................................................................................................ 117 
Table 4.2.5 Summary of proteins differentially expressed in patients with 
established type 1 diabetes versus their matched controls. ................ 124 
Table 4.2.6 Summary of proteins differentially expressed in patients with 
newly-diagnosed type 1 diabetes compared to patients with 
established type 1 diabetes. ..................................................................... 136 
218 
 
Table 4.2.7 Apolipoprotein L1 serum concentration estimation. 
Absorbance values measured at 450nm for two serum samples (DS-
100 and DS-170), serially diluted to 1:10, 1:500 and 1:5000................... 164 
Table 4.2.8 Summary of proteomic studies. Legend:’ T1DM new’, 
patients with newly-diagnosed type 1 diabetes; ‘control new’ healthy 
controls matched to patients with newly-diagnosed type 1 diabetes; 
‘T1DM old’, patients with established type 1 diabetes; ‘control old’, 
healthy controls matched to patients with established type 1 diabetes
........................................................................................................................ 166 
Table 5.2.1  Biochemicals detected at significantly altered levels in  
patients with newly-diagnosed type 1 diabetes and their matched 
healthy controls. .......................................................................................... 179 
Table 5.2.2 Significantly altered biochemicals in newly diagnosed type 
1 diabetes specimens compared to healthy controls. : Red boxes 
indicate biochemicals which are present at significantly higher levels 
in newly diagnosed type 1 diabetes serum specimens. Green boxes 
indicate biochemicals which are present at lower levels in type 1 
diabetes serum specimens compared to control specimens (derived 
from the ‘heat map’ produced by Metabolon Inc.) ............................ 181 
 
219 
 
List of figures 
Figure 1.3.1  Mechanisms of protein kinase C activation of 
transcriptional factors involved in development of diabetes 
complications; SHP-1 protein tyrosine phosphatase, Akt, serine-
threonine kinase, ERK extracellular signal-regulated kinase; p38 MAPK 
mitogen-activated protein kinase; GSK-3β  glycogen synthase kinase 
β; VEGF-A vascular endothelial factor A; PDGF-B, platelet-derived 
growth factor β; ET-1 endothelin 1; CTGF, connective tissue growth 
factor; TGF-β, transforming growth factor β; VCAM, vascular cell 
adhesion molecule, ICAM, intercellular adhesion molecule; Egr-1, early 
growth response 1, NF-κB, nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1, SP1, specificity protein 1; NADPH oxidase, 
nicotinamide adenine dinucleotide phosphate oxidase; PLA2, 
phospholipase 2; eNOS, endothelial nitric oxid synthase; Na-K-ATPase, 
sodium-potassium-adenosine-triphosphatase; DAG, diacylglycerol; 
PKC, protein kinase C, AGE, advanced glycation products. Adapted 
from Geraldes (31). ....................................................................................... 27 
Figure 1.5.1  Role of TXNIP in the thioredoxin system. Thioredoxin (TXN) 
reduces oxidised cysteine residues (protein-S2) on cellular proteins. 
Reduced TXN (TXN-(SH)2) is regenerated via the action of thioredoxin 
reductase (TXR) at the expenditure of NADPH. When TXN reduces the 
oxidised form of thioredoxin peroxidise (TXP), the reduced enzyme 
(TXP-(SH)2) is available to scavenge reactive oxygen species (ROS) 
such as hydrogen peroxide (H2O2) and the superoxide anion (O2ꜙ). 
TXNIP binds and inhibits the reduced form of TXN, thereby functioning 
as a rheostat that modulates both redox status and ROS-mediated 
signalling to regulate metabolism and other cellular processes. 
220 
 
(Dashed lines indicate unknown processes) From Muoio, Cell 
Metabolism, 2007 (68) .................................................................................. 39 
Figure 1.5.2  Model of TXNIP regulation and action and its potential 
role in the pathogenesis of type 2 diabetes . A. Glucose induces the 
expression of TXNIP in a variety of cells and tissues. Insulin suppresses 
the expression of TXNIP. Forced expression of TXNIP results in reduced 
glucose uptake, while inhibition of TXNIP enhances glucose uptake. 
This suggests that TXNIP serves as a glucose- and insulin-sensitive 
homeostatic switch that regulates glucose uptake in the periphery. (B) 
Role of TXNIP in glucose toxicity in the β-cell and in impaired glucose 
uptake in the periphery. Insulin deficiency or hyperglycaemia can 
increase TXNIP levels in muscle, resulting in impaired peripheral 
glucose uptake. The pancreatic β-cell is initially able to compensate 
by secreting more insulin, but eventually the β-cell compensation fails. 
The resulting hyperglycaemia may then elevate pancreatic β-
cell TXNIP expression, which can induce apoptosis (80). The loss of β-
cells, in turn, results in decreased insulin production that further 
exacerbates peripheral IGT. The vicious cycle would eventually spiral 
to T2DM. Adapted from Parikh et al (79). .................................................. 41 
Figure 1.5.3. TXNIP expression in individuals with diabetes or at risk of 
developing diabetes.  A) TXNIP expression levels from males from 
Northern Europe with NGT, IGT, or T2DM. * p < 0.02; ** p < 0.01, Mann-
Whitney U-test. B) TXNIP expression levels from NGT individuals of 
Mexican-American descent with (FH+) or without (FH−) family history of 
T2DM, as well as individuals with T2DM; * p < 0.03, Mann-Whitney U-test. 
(Adapted from Parikh et al (79) .................................................................. 43 
Figure 1.5.4.  Insulin-mediated glucose uptake vs Txnip expression in a 
microarray in 43 males from Northern Europe with normal glucose 
tolerance (NGT, n=17), impaired glucose tolerance (IGT, n=8) and 
221 
 
type 2 diabetes (T2DM, n=18) who underwent euglycaemic-
hyperinsulinaemic pump studies;  a.u.-arbitrary units, i.e. relative 
numbers of Txnip expression normalised to cyclophilin A reference. 
Adapted from Parikh et al (79) ................................................................... 44 
Figure 3.1.1  RNA isolation using TriReagent from serum (Adapted with 
permission from Sweta Rani’s PhD Thesis, Investigation of molecular 
and cellular events associated with β cell function and elucidation of 
extracellular RNAs as potential biomarker for diabetes, Dublin City 
University, 2008) ............................................................................................. 65 
Figure 3.1.2 TaqMan qRT-PCR principle (Adapted from product insert).
.......................................................................................................................... 66 
Figure 3.2.1  Expression of Txnip in patients with newly-diagnosed type 
2 diabetes and their healthy controls. Error bars represent 95% 
confidence intervals. .................................................................................... 73 
Figure 3.2.2 Expression of mean ∆CtTxnip in patients with newly-
diagnosed type 2 diabetes depending on whether they were taking 
metformin (n=11) or were diet controlled (n=8). Error bars delineate 
95% confidence intervals. ............................................................................ 78 
Figure 3.2.3 Correlation between ΔCtTxnip and total cholesterol in 
patients with newly-diagnosed type 2 diabetes who were not on statin 
treatment........................................................................................................ 79 
Figure 3.2.4 Correlation between ΔCtTxnip and HDL in patients with 
newly diagnosed type 2 diabetes who were not taking statins ............ 79 
Figure 3.2.5 Mean Egr1 expression in patients with newly diagnosed 
type 2 diabetes vs. controls.Error bars delineate 95% confidence 
intervals. .......................................................................................................... 84 
222 
 
Figure 3.2.6 Correlation between ΔCtEgr1 and waist/hip ratio in 
patients with newly diagnosed type 2 diabetes. ..................................... 84 
Figure 3.2.7 Correlation of ΔCtEgr1 and systolic blood pressure in 
healthy controls. ............................................................................................ 85 
Figure 3.2.8 Correlation between ΔCtEgr1 and heart rate in healthy 
controls. .......................................................................................................... 85 
Figure 4.1.1. ProteoMiner™ technology. Each unique hexapeptide 
binds to a unique protein sequence. Because the bead capacity limits 
binding capacity, high-abundance proteins quickly saturate their 
ligands and excess protein is washed out. In contrast, low abundance 
proteins are concentrated on their specific ligands, thereby 
decreasing the dynamic range of proteins in the sample. When 
analysed in downstream applications, the number of proteins 
detected is dramatically increased. (Adapted from BIORAD 
ProteoMiner™ kit insert, available at 
http://wolfson.huji.ac.il/purification/PDF/AlbuminRemoval/BIORAD_Pro
teoMiner.pdf) ................................................................................................. 95 
Figure 4.2.1 PCA plot for all sample groups. Pink spots represent T1DM 
new samples, blue spots represent T1DM old samples, purple spots 
represent control new samples, orange spots represent control old 
sample and the cyan spots represent the autoimmune samples ...... 113 
Figure 4.2.2  PCA plot for samples from patients with newly-diagnosed 
diabetes and their matched healthy controls. DS-175/U35 sample was 
used as reference run. Pink spots indicate the ‘T1DM new’ samples 
while the blue spots indicate the ‘control new’ samples. .................... 121 
Figure 4.2.3 PCA plot for patients with established type 1 diabetes 
(T1DM old) and their matched controls’ samples. DS-84/ T1O10 ‘type 1 
223 
 
old’ sample was used as reference run. Pink spots indicate the’ T1DM 
old’ samples while the blue spots indicate the ‘control old’ samples123 
Figure 4.2.4 PCA plot for T1DM new and T1DM old. DS-169 control 
sample was used as reference run. Pink spots indicate the T1DM new 
samples while the blue spots indicate the T1DM old samples. ............ 135 
Figure 4.2.5 PCA plot for comparison of controls matched to newly-
diagnosed patients with controls matched to patients with established 
type 1 diabetes. Sample DS-178/U36 was used  as reference run. Blue 
spots indicate the ‘control old’, while pink spots indicate ‘control new’ 
samples. ‘Old control’ sample DS-7 is a slight outlier relative to the rest 
of the control old group. ............................................................................ 143 
Figure 4.2.6 Mean vitronectin concentration (μg/mL) in patients with 
newly diagnosed type 1 diabetes and their healthy controls. Error bars 
delineate 95% confidence intervals. ........................................................ 147 
Figure 4.2.7.Vitronectin serum concentration shown for pairs of 
patients with newly-diagnosed type 1 diabetes (T1DM new) and their 
respective healthy controls. ...................................................................... 147 
Figure 4.2.8. Mean vitronectin concentration in patients with 
established type 1 diabetes  and their healthy controls. Error bars 
delineate 95% confidence intervals. ........................................................ 148 
Figure 4.2.9 Vitronectin levels in matched pairs of patients with 
established type 1 diabetes (T1DM old)  and their healthy controls. . 149 
Figure 4.2.10 Vitronectin levels in patients with with established type 1 
diabetes (T1DM old, n=30) and in patients with newly-diagnosed type 
1 diabetes (T1DM new, n=8). Error bars delineate 95% confidence 
intervals. ........................................................................................................ 150 
224 
 
Figure 4.2.11  Clusterin concentration in patients with newly-diagnosed 
type 1 diabetes compared to the healthy controls. Error bars delineate 
95% confidence intervals. .......................................................................... 151 
Figure 4.2.12  Clusterin serum concentrations in matched pairs of 
patients with newly-diagnosed type 1 diabetes and their healthy 
controls. ........................................................................................................ 152 
Figure 4.2.13  Levels of clusterin serum concentration in patients with 
established type 1 diabetes (T1DM old, n=30) and their matched 
controls (n=30). Error bars delineate 95% confidence intervals. .......... 153 
Figure 4.2.14  Levels of clusterin in matched pairs of patients with 
established type 1 diabetes and their healthy controls. ...................... 155 
Figure 4.2.15 Clusterin levels in patients with established type 1 
diabetes vs. patients with newly-diagnosed type 1 diabetes. Error bars 
delineate 95% confidence intervals. ........................................................ 156 
Figure 4.2.16 Vitamin K-dependent protein S concentration in patients 
with newly-diagnosed type 1 diabetes (T1DM new) and their healthy 
controls. Error bars delineate 95% confidence intervals. ...................... 158 
Figure 4.2.17 Concentration of vitamin K-dependent protein S in 
patients with newly-diagnosed type 1 diabetes (T1DM new) and their 
matched controls. ....................................................................................... 159 
Figure 4.2.18 Vitamin K-dependent protein S in patients with 
established type 1 diabetes (n=30) and their matched controls (n=30). 
Error bars delineate 95% confidence interval. ........................................ 160 
Figure 4.2.19 Vitamin K-dependent protein S in patients with 
established type 1 diabetes and their matched healthy controls...... 161 
225 
 
Figure 4.2.20 Vitamin K-dependent protein S concentration in patients 
with established type 1 diabetes (n=30) compared to patients with 
newly-diagnosed type 1 diabetes (n=8). ................................................ 162 
Figure 5.3.1 Competitive tubular reabsorption of glucose and 1, 5-
anhydroglucitole (1,5-AG) in hyperglycaemia [Adapted from Dungan, 
2008 (169)]. ................................................................................................... 196 
Figure 5.3.2  Citric acid cycle, positions of malate and succynil-
coenzyme A visible (Adapted from Murray et al. Harper's Illustrated 
Biochemistry, 29th ed.) ............................................................................... 198 
Figure 5.3.3 Citric acid cycle, pathway to synthesis of succinylcarnitine 
[Adapted from Carrozo et al (175)] ......................................................... 199 
Figure 5.3.4 Transport of fatty acids through carnitine shuttle and link to 
FFA β oxidation, Krebs cycle and respiratory chain (Adapted from 
Murray et al, Harper’s Illustrated Biochemistry, 29th e d(177) ............... 202 
Figure 5.3.5 The pathway of gluconeogenesis includes 11 enzymatic 
steps, which form one molecule of glucose from two molecules of 
pyruvate. Reactions and enzymes specific only to gluconeogenesis 
are shown in red. Irreversible reactions specific for glycolysis are shown 
in green. Additional substrates for gluconeogenesis are shown in blue 
and may also enter gluconeogenesis as denoted by the associated 
arrows. (Adapted from Naik P: Biochemistry, 3rd edition, Jaypee 
Brothers Medical Publishers Ltd, 2009, published in Janson (179) ) ..... 205 
Figure 5.3.6 A. The urea cycle converts two amino groups (NH3) from 
glutamate and aspartate into urea as part of the body's nitrogen 
balance. Glutamate donates the first nitrogen atom via the molecule 
carbamoyl phosphate that is synthesized via the regulated enzyme 
carbamoyl phosphate synthetase (CPS-1). This enzyme is activated by 
226 
 
increased glutamate, N-acetylglutamic acid, and/or arginine 
concentrations [indicated by (+)]. Carbamoyl phosphate then enters 
the urea cycle by combination with ornithine via ornithine 
transcarbamoylase. Aspartate donates the second nitrogen. Other 
amino acids contribute amino groups after conversion into glutamate 
or aspartate. Adapted from Janson et al, (179). ................................... 206 
 
227 
 
  
228 
 
7 References 
1. WHO. Diabetes: key facts. 2011. 
2. Federation ID. Diabetes Atlas 2011 [30th August 2012]. 5th 
edition:[Available from: http://www.idf.org/diabetesatlas/5e/the-
global-burden. 
3. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new 
perspectives on disease pathogenesis and treatment. Lancet. 
2001;358(9277):221-9. 
4. Achenbach P, Bonifacio E, Koczwara K, Ziegler A-G. Natural 
History of Type 1 Diabetes. Diabetes. 2005;54(suppl 2):S25-S31. 
5. Van Belle TL, Coppieters KT, Von Herrath MG. Type 1 
Diabetes: Etiology, Immunology, and Therapeutic Strategies. 
Physiological Reviews. 2011;91(1):79-118. 
6. Concannon P, Rich SS, Nepom GT. Genetics of Type 1A 
Diabetes. New England Journal of Medicine. 2009;360(16):1646-54. 
7. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, 
Concannon P, et al. HLA DR-DQ Haplotypes and Genotypes and Type 
1 Diabetes Risk. Diabetes. 2008;57(4):1084-92. 
8. Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, 
Stevens HE, et al. Localization of type 1 diabetes susceptibility to the 
MHC class I genes HLA-B and HLA-A. Nature. 2007;450(7171):887-92. 
9. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, 
Erlich HA, et al. Genome-wide association study and meta-analysis 
find that over 40 loci affect risk of type 1 diabetes. Nature genetics. 
2009;41(6):703-7. 
10. German M. Pancreatic Hormones And Diabetes Mellitus. 
Greenspan’s Basic & Clinical Endocrinology. 2011(17). 
11. Siljander HTA, Simell S, Hekkala A, Lähde J, Simell T, Vähäsalo 
P, et al. Predictive Characteristics of Diabetes-Associated 
Autoantibodies Among Children With HLA-Conferred Disease 
Susceptibility in the General Population. Diabetes. 2009;58(12):2835-42. 
229 
 
12. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, 
Jackson RA, et al. Prediction of type I diabetes in first-degree relatives 
using a combination of insulin, GAD, and ICA512bdc/IA-2 
autoantibodies. Diabetes. 1996;45(7):926-33. 
13. Eisenbarth GS. Banting Lecture 2009: An Unfinished Journey: 
Molecular Pathogenesis to Prevention of Type 1A Diabetes. Diabetes. 
2010;59(4):759-74. 
14. Riley WJ, Maclaren NK, Krischer J, Spillar RP, Silverstein JH, 
Schatz DA, et al. A prospective study of the development of diabetes 
in relatives of patients with insulin-dependent diabetes. The New 
England journal of medicine. 1990;323(17):1167-72. 
15. Lönnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, 
et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in 
a prospectively observed birth cohort: the Finnish Diabetes Prediction 
and Prevention Study. Diabetes. 2000;49(8):1314-8. 
16. Littorin B, Blom P, Scholin A, Arnqvist HJ, Blohme G, Bolinder J, 
et al. Lower levels of plasma 25-hydroxyvitamin D among young adults 
at diagnosis of autoimmune type 1 diabetes compared with control 
subjects: results from the nationwide Diabetes Incidence Study in 
Sweden (DISS). Diabetologia. 2006;49(12):2847-52. 
17. Israni N, Goswami R, Kumar A, Rani R. Interaction of vitamin 
D receptor with HLA DRB1 0301 in type 1 diabetes patients from North 
India. PloS one. 2009;4(12):e8023. 
18. Orešič M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-
Laakso T, Parikka V, et al. Dysregulation of lipid and amino acid 
metabolism precedes islet autoimmunity in children who later progress 
to type 1 diabetes. The Journal of Experimental Medicine. 
2008;205(13):2975-84. 
19. Mehta D. Lysophosphatidylcholine: an enigmatic lysolipid. 
American Journal of Physiology - Lung Cellular and Molecular 
Physiology. 2005;289(2):L174-L5. 
20. Samuel Varman T, Shulman Gerald I. Mechanisms for Insulin 
Resistance: Common Threads and Missing Links. Cell. 2012;148(5):852-
71. 
21. PE M. Endocrine pancreas. Endocrine Physiology. 2010(7). 
22. Petersen KF, Shulman GI. Etiology of insulin resistance.  Am J 
Med. 119. United States2006. p. S10-6. 
230 
 
23. Wheeler E, Barroso I. Genome-wide association studies and 
type 2 diabetes.  Brief Funct Genomics. 10. England2011. p. 52-60. 
24. RH E. The Metabolic Syndrome. Harrison's Principles of 
Internal Medicine. 2012(242). 
25. Bosma M, Kersten S, Hesselink MKC, Schrauwen P. Re-
evaluating lipotoxic triggers in skeletal muscle: Relating 
intramyocellular lipid metabolism to insulin sensitivity. Progress in Lipid 
Research. 2012;51(1):36-49. 
26. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM 
occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 
1992;15(7):815-9. 
27. Implications of the United Kingdom Prospective Diabetes 
Study. Diabetes Care. 2002;25(suppl 1):s28-s32. 
28. The effect of intensive treatment of diabetes on the 
development and progression of long-term complications in insulin-
dependent diabetes mellitus. The Diabetes Control and Complications 
Trial Research Group. N Engl J Med. 1993;329(14):977-86. 
29. Hynes RO. Integrins: Bidirectional, Allosteric Signaling 
Machines. Cell. 2002;110(6):673-87. 
30. Greenspan's Basic & Clinical Endocrinology. 8 ed. David G. 
Gardner Md MS, Dolores Shoback MD, editors: The McGraw-Hill 
Companies, Inc.; 2007. 
31. Geraldes P, King GL. Activation of protein kinase C isoforms 
and its impact on diabetic complications.  Circ Res. 106. United 
States2010. p. 1319-31. 
32. Tesfamariam B. Free radicals in diabetic endothelial cell 
dysfunction. Free radical biology & medicine. 1994;16(3):383-91. 
33. Noh H, King GL. The role of protein kinase C activation in 
diabetic nephropathy.  Kidney Int Suppl. United States2007. p. S49-53. 
34. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes 
MW. Glycemic Control and Coronary Heart Disease Risk in Persons 
With and Without Diabetes: The Atherosclerosis Risk in Communities 
Study. Arch Intern Med. 2005;165(16):1910-6. 
35. Association AD. Diagnosis and Classification of Diabetes 
Mellitus. Diabetes Care. 2011;34(Supplement 1):S62-S9. 
231 
 
36. PJ K, VW. R. Proteins: Myoglobin & Hemoglobin. Harper's 
Illustrated Biochemistry. 2011. 
37. American Diabetes A. Diagnosis and Classification of 
Diabetes Mellitus. Diabetes Care. 2013;36(Supplement 1):S67-S74. 
38. Association AD. Standards of medical care in diabetes--
2012. Diabetes Care. 2012;35 Suppl 1:S11-63. 
39. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, 
Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a 
patient-centered approach: position statement of the American 
Diabetes Association (ADA) and the European Association for the 
Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79. 
40. Nathan DM, Rosenbaum C, Protasowicki VD. Single-void 
urine samples can be used to estimate quantitative microalbuminuria. 
Diabetes Care. 1987;10(4):414-8. 
41. Group. BDW. Biomarkers and surrogate endpoints: preferred 
definitions and conceptual framework. Clin Pharmacol Ther. 
2001;69(3):89-95. 
42. Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-
cell apoptosis prevents adaptive increase in beta-cell mass in mouse 
model of type 2 diabetes: evidence for role of islet amyloid formation 
rather than direct action of amyloid. Diabetes. 2003;52(9):2304-14. 
43. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet 
pathology and the pathogenesis of type 1 and type 2 diabetes 
mellitus revisited. Survey and synthesis of pathology research. 
1985;4(2):110-25. 
44. Rani S. Investigation of molecular and cellular events 
associated with beta cell function and elucidation of extracellular 
RNAs as potential biomarker for diabetes. Dublin: Dublin City University; 
2008. 
45. Rani S, Clynes M, O'Driscoll L. Detection of amplifiable mRNA 
extracellular to insulin-producing cells: potential for predicting beta 
cell mass and function. Clin Chem. 2007;53(11):1936-44. 
46. Miyazaki J-I, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki 
Y, et al. Establishment of a Pancreatic β Cell Line That Retains 
Glucose-Inducible Insulin Secretion: Special Reference to Expression of 
Glucose Transporter Isoforms. Endocrinology. 1990;127(1):126-32. 
232 
 
47. Lilla V, Webb G, Rickenbach K, Maturana A, Steiner DF, 
Halban PA, et al. Differential gene expression in well-regulated and 
dysregulated pancreatic beta-cell (MIN6) sublines. Endocrinology. 
2003;144(4):1368-79. 
48. O'Driscoll L, Gammell P, Clynes M. Engineering Vero cells to 
secrete human insulin. In Vitro Cell Dev Biol Anim. 2002;38(3):146-53. 
49. Wieczorek AJ, Sitaramam V, Machleidt W, Rhyner K, 
Perruchoud AP, Block LH. Diagnostic and Prognostic Value of RNA-
Proteolipid in Sera of Patients with Malignant Disorders following 
Therapy: First Clinical Evaluation of a Novel Tumor Marker. Cancer 
research. 1987;47(23):6407-12. 
50. Hasselmann DO, Rappl G, Tilgen W, Reinhold U. Extracellular 
tyrosinase mRNA within apoptotic bodies is protected from 
degradation in human serum. Clin Chem. 2001;47(8):1488-9. 
51. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) 
and cancer--a survey. Biochimica et biophysica acta. 
2007;1775(1):181-232. 
52. Li Y, St. John MAR, Zhou X, Kim Y, Sinha U, Jordan RCK, et al. 
Salivary Transcriptome Diagnostics for Oral Cancer Detection. Clinical 
Cancer Research. 2004;10(24):8442-50. 
53. Bryzgunova OE, Skvortsova TE, Kolesnikova EV, Starikov AV, 
Rykova EY, Vlassov VV, et al. Isolation and comparative study of cell-
free nucleic acids from human urine. Ann N Y Acad Sci. 2006;1075:334-
40. 
54. Kuligina EV, Semenov DV, Shevyrina ON, Richter VA. 
Ribonucleic acids of human milk. Nucleosides, nucleotides & nucleic 
acids. 2004;23(6-7):837-42. 
55. Schmidt B, Engel E, Carstensen T, Weickmann S, John M, Witt 
C, et al. Quantification of free RNA in serum and bronchial lavage: a 
new diagnostic tool in lung cancer detection? Lung Cancer. 
2005;48(1):145-7. 
56. O'Driscoll L KE, Villarreal M.P.D, Clynes M. Detection of 
specific mRNAs in culture medium conditioned by human tumour 
cells: Potential for new class of cancer biomarkers in serum. Cancer 
genomics & proteomics. 2005;2(1):43-52. 
57. Stroun M, Anker P, Beljanski M, Henri J, Lederrey C, Ojha M, 
et al. Presence of RNA in the nucleoprotein complex spontaneously 
233 
 
released by human lymphocytes and frog auricles in culture. Cancer 
research. 1978;38(10):3546-54. 
58. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of 
Tumor Messenger RNA in the Serum of Patients with Malignant 
Melanoma. Clinical Cancer Research. 1999;5(8):1961-5. 
59. Rykova EY, Wunsche W, Brizgunova OE, Skvortsova TE, 
Tamkovich SN, Senin IS, et al. Concentrations of circulating RNA from 
healthy donors and cancer patients estimated by different methods. 
Ann N Y Acad Sci. 2006;1075:328-33. 
60. Reddi KK, Holland JF. Elevated serum ribonuclease in 
patients with pancreatic cancer. Proceedings of the National 
Academy of Sciences. 1976;73(7):2308-10. 
61. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. 
Exosome-mediated transfer of mRNAs and microRNAs is a novel 
mechanism of genetic exchange between cells. Nat Cell Biol. 
2007;9(6):654-9. 
62. Miranda KC, Bond DT, McKee M, Skog J, Paunescu TG, Da 
Silva N, et al. Nucleic acids within urinary exosomes/microvesicles are 
potential biomarkers for renal disease.  Kidney international. 78. United 
States2010. p. 191-9. 
63. Sandhu HS, Butt AN, Powrie J, Swaminathan R. Measurement 
of circulating neuron-specific enolase mRNA in diabetes mellitus. Ann 
N Y Acad Sci. 2008;1137:258-63. 
64. Hamaoui K, Butt A, Powrie J, Swaminathan R. Concentration 
of circulating rhodopsin mRNA in diabetic retinopathy. Clin Chem. 
2004;50(11):2152-5. 
65. Butt A, Ahmad MS, Powrie J, Swaminathan R. Assessment of 
diabetic retinopathy by measuring retina-specific mRNA in blood. 
Expert opinion on biological therapy. 2012;12 Suppl 1:S79-84. 
66. Butt AN, Shalchi Z, Hamaoui K, Samadhan A, Powrie J, Smith 
S, et al. Circulating nucleic acids and diabetic complications.  Ann N Y 
Acad Sci. 1075. United States2006. p. 258-70. 
67. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, 
Nakamura H, et al. Identification of Thioredoxin-binding Protein-
2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of 
Thioredoxin Function and Expression. Journal of Biological Chemistry. 
1999;274(31):21645-50. 
234 
 
68. Muoio DM. TXNIP links redox circuitry to glucose control. 
(1932-7420 (Electronic)). 
69. Harel A, Dalah I, Pietrokovski S, Safran M, Lancet D. Omics 
Data Management and Annotation. In: Mayer B, editor. Bioinformatics 
for Omics Data. Methods in Molecular Biology. 719: Humana Press; 
2011. p. 71-96. 
70. Chen K-S, DeLuca HF. Isolation and characterization of a 
novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. 
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 
1994;1219(1):26-32. 
71. Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, 
Nilsson E, et al. One-month versus six-month therapy with oral 
anticoagulants after symptomatic deep vein thrombosis. Acta 
medica Scandinavica. 1985;218(3):279-84. 
72. Patwari P, Lee RT. An expanded family of arrestins regulate 
metabolism. Trends in Endocrinology &amp; Metabolism. 
2012;23(5):216-22. 
73. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, et al. 
Deficiency of a beta-arrestin-2 signal complex contributes to insulin 
resistance. Nature. 2009;457(7233):1146-9. 
74. Chutkow WA, Patwari P, Yoshioka J, Lee RT. Thioredoxin-
interacting protein (Txnip) is a critical regulator of hepatic glucose 
production. Journal of Biological Chemistry. 2008;283(4):2397-406. 
75. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. 
Hyperglycemia Promotes Oxidative Stress through Inhibition of 
Thioredoxin Function by Thioredoxin-interacting Protein. Journal of 
Biological Chemistry. 2004;279(29):30369-74. 
76. Dornan S, Sebestyen Z, Gamble J, Nagy P, Bodnar A, 
Alldridge L, et al. Differential association of CD45 isoforms with CD4 
and CD8 regulates the actions of specific pools of p56lck tyrosine 
kinase in T cell antigen receptor signal transduction. The Journal of 
biological chemistry. 2002;277(3):1912-8. 
77. Hui TY, Sheth SS, Diffley JM, Potter DW, Lusis AJ, Attie AD, et 
al. Mice lacking thioredoxin-interacting protein provide evidence 
linking cellular redox state to appropriate response to nutritional 
signals. The Journal of biological chemistry. 2004;279(23):24387-93. 
235 
 
78. Ørntoft TF, Thykjaer T, Waldman FM, Wolf H, Celis JE. 
Genome-wide study of gene copy numbers, transcripts, and protein 
levels in pairs of non-invasive and invasive human transitional cell 
carcinomas. Mol Cell Proteomics. 2002;1(1):37-45. 
79. Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard 
H, Poulsen P, et al. TXNIP regulates peripheral glucose metabolism in 
humans. PLoS medicine. 2007;4(5):e158. 
80. Minn AH, Hafele C, Shalev A. Thioredoxin-interacting protein 
is stimulated by glucose through a carbohydrate response element 
and induces beta-cell apoptosis. Endocrinology. 2005;146(5):2397-405. 
81. Brownlee M. Biochemistry and molecular cell biology of 
diabetic complications. Nature. 2001;414(6865):813-20. 
82. Garnett KE, Chapman P, Chambers JA, Waddell ID, Boam 
DS. Differential gene expression between Zucker Fatty rats and Zucker 
Diabetic Fatty rats: a potential role for the immediate-early gene Egr-1 
in regulation of beta cell proliferation.  Journal of molecular 
endocrinology. 35. England2005. p. 13-25. 
83. Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A, 
Dandona P. Glucose intake induces an increase in activator protein 1 
and early growth response 1 binding activities, in the expression of 
tissue factor and matrix metalloproteinase in mononuclear cells, and 
in plasma tissue factor and matrix metalloproteinase concentrations. 
The American journal of clinical nutrition. 2004;80(1):51-7. 
84. Zierath JR, Kawano Y. The effect of hyperglycaemia on 
glucose disposal and insulin signal transduction in skeletal muscle. Best 
practice & research Clinical endocrinology & metabolism. 
2003;17(3):385-98. 
85. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag 
S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative 
phosphorylation are coordinately downregulated in human diabetes. 
Nature genetics. 2003;34(3):267-73. 
86. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et 
al. Coordinated reduction of genes of oxidative metabolism in 
humans with insulin resistance and diabetes: Potential role of PGC1 
and NRF1. Proc Natl Acad Sci U S A. 2003;100(14):8466-71. 
87. Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. 
Thioredoxin-interacting protein A critical link between glucose toxicity 
and β-cell apoptosis. Diabetes. 2008;57(4):938-44. 
236 
 
88. Oslowski Christine M, Hara T, O'Sullivan-Murphy B, Kanekura 
K, Lu S, Hara M, et al. Thioredoxin-Interacting Protein Mediates ER 
Stress-Induced ² Cell Death through Initiation of the Inflammasome. 
Cell metabolism. 2012;16(2):265-73. 
89. Chai TF, Hong SY, He H, Zheng L, Hagen T, Luo Y, et al. A 
potential mechanism of metformin-mediated regulation of glucose 
homeostasis: Inhibition of Thioredoxin-interacting protein (Txnip) gene 
expression. Cellular signalling. 2012;24(8):1700-5. 
90. Kaimul AM, Nakamura H, Masutani H, Yodoi J. Thioredoxin 
and thioredoxin-binding protein-2 in cancer and metabolic syndrome. 
Free Radical Biology and Medicine. 2007;43(6):861-8. 
91. Rani S, Mehta JP, Barron N, Doolan P, Jeppesen PB, Clynes 
M, et al. Decreasing Txnip mRNA and protein levels in pancreatic MIN6 
cells reduces reactive oxygen species and restores glucose regulated 
insulin secretion.  Cell Physiol Biochem. 25. Switzerland: 2010 S. Karger 
AG, Basel.; 2010. p. 667-74. 
92. Keeton AB, Bortoff KD, Bennett WL, Franklin JL, Venable DY, 
Messina JL. Insulin-Regulated Expression of Egr-1 and Krox20: 
Dependence on ERK1/2 and Interaction with p38 and PI3-Kinase 
Pathways. Endocrinology. 2003;144(12):5402-10. 
93. Committee HGN.  [22 Oct 2012]. Available from: 
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3238. 
94. Thiel G, Mayer SI, Müller I, Stefano L, Rössler OG. Egr-1—A 
Ca2+-regulated transcription factor. Cell Calcium. 2010;47(5):397-403. 
95. Josefsen K, Sørensen LR, Buschard K, Birkenbach M. Glucose 
induces early growth response gene (Egr-1) expression in pancreatic 
beta cells. Diabetologia. 1999;42(2):195-203. 
96. Yao J, Mackman N, Edgington TS, Fan S-T. 
Lipopolysaccharide Induction of the Tumor Necrosis Factor-α Promoter 
in Human Monocytic Cells. Journal of Biological Chemistry. 
1997;272(28):17795-801. 
97. Shen N, Yu X, Pan F-Y, Gao X, Xue B, Li C-J. An Early 
Response Transcription Factor, Egr-1, Enhances Insulin Resistance in 
Type 2 Diabetes with Chronic Hyperinsulinism. Journal of Biological 
Chemistry. 2011;286(16):14508-15. 
237 
 
98. Eto K, Kaur V, Thomas MK. Regulation of Pancreas 
Duodenum Homeobox-1 Expression by Early Growth Response-1. 
Journal of Biological Chemistry. 2007;282(9):5973-83. 
99. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. 
Evaluation of two-dimensional gel electrophoresis-based proteome 
analysis technology. Proc Natl Acad Sci U S A. 2000;97(17):9390-5. 
100. Sundsten T, Ortsäter H. Proteomics in diabetes research. Mol 
Cell Endocrinol. 2009;297(1-2):93-103. 
101. Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, 
Hochstrasser D, et al. Approaching clinical proteomics: current state 
and future fields of application in fluid proteomics. Clin Chem Lab 
Med. 2009;47(6):724-44. 
102. Herder C, Karakas M, Koenig W. Biomarkers for the 
prediction of type 2 diabetes and cardiovascular disease. Clin 
Pharmacol Ther. 2011;90(1):52-66. 
103. Metz TO, Qian WJ, Jacobs JM, Gritsenko MA, Moore RJ, 
Polpitiya AD, et al. Application of proteomics in the discovery of 
candidate protein biomarkers in a diabetes autoantibody 
standardization program sample subset. Journal of proteome 
research. 2008;7(2):698-707. 
104. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, 
Smith C, et al. Mining biomarkers in human sera using proteomic tools. 
Proteomics. 2004;4(1):244-56. 
105. Hittel DS, Hathout Y, Hoffman EP, Houmard JA. Proteome 
analysis of skeletal muscle from obese and morbidly obese women. 
Diabetes. 2005;54(5):1283-8. 
106. Hojlund K, Wrzesinski K, Larsen PM, Fey SJ, Roepstorff P, 
Handberg A, et al. Proteome analysis reveals phosphorylation of ATP 
synthase beta -subunit in human skeletal muscle and proteins with 
potential roles in type 2 diabetes. The Journal of biological chemistry. 
2003;278(12):10436-42. 
107. Giebelstein J, Poschmann G, Hojlund K, Schechinger W, 
Dietrich JW, Levin K, et al. The proteomic signature of insulin-resistant 
human skeletal muscle reveals increased glycolytic and decreased 
mitochondrial enzymes. Diabetologia. 2012;55(4):1114-27. 
238 
 
108. Zhou JY, Dann GP, Liew CW, Smith RD, Kulkarni RN, Qian WJ. 
Unraveling pancreatic islet biology by quantitative proteomics. Expert 
review of proteomics. 2011;8(4):495-504. 
109. Zhi W, Purohit S, Carey C, Wang M, She JX. Proteomic 
technologies for the discovery of type 1 diabetes biomarkers. Journal 
of diabetes science and technology. 2010;4(4):993-1002. 
110. Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, Kim MR, et al. 
Proteome analysis of serum from type 2 diabetics with nephropathy. 
Journal of proteome research. 2007;6(2):735-43. 
111. Overgaard AJ, Hansen HG, Lajer M, Pedersen L, Tarnow L, 
Rossing P, et al. Plasma proteome analysis of patients with type 1 
diabetes with diabetic nephropathy. Proteome science. 2010;8:4. 
112. Wang H, Feng L, Hu JW, Xie CL, Wang F. Characterisation of 
the vitreous proteome in proliferative diabetic retinopathy.  Proteome 
science. 10. England2012. p. 15. 
113. Ahn BY, Song ES, Cho YJ, Kwon OW, Kim JK, Lee NG. 
Identification of an anti-aldolase autoantibody as a diagnostic marker 
for diabetic retinopathy by immunoproteomic analysis. Proteomics. 
2006;6(4):1200-9. 
114. Schlatzer D, Maahs DM, Chance MR, Dazard JE, Li X, Hazlett 
F, et al. Novel urinary protein biomarkers predicting the development 
of microalbuminuria and renal function decline in type 1 diabetes. 
Diabetes Care. 2012;35(3):549-55. 
115. Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, et 
al. HMDB: a knowledgebase for the human metabolome.  Nucleic 
acids research. 37. England2009. p. D603-10. 
116. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. 
HMDB 3.0--The Human Metabolome Database in 2013. Nucleic acids 
research. 2013;41(Database issue):D801-7. 
117. Li X, Xu Z, Lu X, Yang X, Yin P, Kong H, et al. Comprehensive 
two-dimensional gas chromatography/time-of-flight mass 
spectrometry for metabonomics: Biomarker discovery for diabetes 
mellitus. Analytica Chimica Acta. 2009;633(2):257-62. 
118. Levy J, Matthews D, Hermans M. Correct homeostasis model 
assessment (HOMA) evaluation uses the computer program. Diabetes 
Care. 1998;21(12):2191-2. 
239 
 
119. Unit DT. HOMA calculator The Oxford Centre for Diabetes, 
Endocrinology and Metabolism [cited 2012 Sep 6, 2012]. Available 
from: http://www.dtu.ox.ac.uk/homacalculator/index.php. 
120. Shaked M, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. 
AMP-Activated Protein Kinase (AMPK) Mediates Nutrient Regulation of 
Thioredoxin-Interacting Protein (TXNIP) in Pancreatic Beta-Cells. PloS 
one. 2011;6(12):e28804. 
121. Elgort MG, O’Shea JM, Jiang Y, Ayer DE. Transcriptional and 
Translational Downregulation of Thioredoxin Interacting Protein Is 
Required for Metabolic Reprogramming during G1. Genes & Cancer. 
2010;1(9):893-907. 
122. Patwari P, Chutkow WA, Cummings K, Verstraeten VL, 
Lammerding J, Schreiter ER, et al. Thioredoxin-independent regulation 
of metabolism by the alpha-arrestin proteins. The Journal of biological 
chemistry. 2009;284(37):24996-5003. 
123. Seo SK, Yang HI, Lee KE, Kim HY, Cho S, Choi YS, et al. The 
roles of thioredoxin and thioredoxin-binding protein-2 in endometriosis. 
Human Reproduction. 2010;25(5):1251-8. 
124. Kobayashi T, Uehara S, Ikeda T, Itadani H, Kotani H. Vitamin 
D3 up-regulated protein-1 regulates collagen expression in mesangial 
cells. Kidney international. 2003;64(5):1632-42. 
125. Shalev A, Pise-Masison CA, Radonovich M, Hoffmann SC, 
Hirshberg B, Brady JN, et al. Oligonucleotide microarray analysis of 
intact human pancreatic islets: identification of glucose-responsive 
genes and a highly regulated TGFbeta signaling pathway. 
Endocrinology. 2002;143(9):3695-8. 
126. Hirota T, Okano T, Kokame K, Shirotani-Ikejima H, Miyata T, 
Fukada Y. Glucose down-regulates Per1 and Per2 mRNA levels and 
induces circadian gene expression in cultured Rat-1 fibroblasts. The 
Journal of biological chemistry. 2002;277(46):44244-51. 
127. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. 
Hyperglycemia promotes oxidative stress through inhibition of 
thioredoxin function by thioredoxin-interacting protein. The Journal of 
biological chemistry. 2004;279(29):30369-74. 
128. Hansen L, Gaster M, Oakeley EJ, Brusgaard K, Damsgaard 
Nielsen EM, Beck-Nielsen H, et al. Expression profiling of insulin action in 
human myotubes: induction of inflammatory and pro-angiogenic 
pathways in relationship with glycogen synthesis and type 2 diabetes. 
240 
 
Biochemical and biophysical research communications. 
2004;323(2):685-95. 
129. Færch K, Borch-Johnsen K, Holst JJ, Vaag A. 
Pathophysiology and aetiology of impaired fasting glycaemia and 
impaired glucose tolerance: does it matter for prevention and 
treatment of type 2 diabetes? Diabetologia. 2009;52(9):1714-23. 
130. Bailey CJ. Biguanides and NIDDM. (0149-5992 (Print)). 
131. Bailey CJ, Turner RC. Metformin. N Engl J Med. 
1996;334(9):574-9. 
132. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. 
Role of AMP-activated protein kinase in mechanism of metformin 
action. J Clin Invest. 2001;108(8):1167-74. 
133. Qu H-Q, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. The 
Definition of Insulin Resistance Using HOMA-IR for Americans of 
Mexican Descent Using Machine Learning. PloS one. 2011;6(6):e21041. 
134. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. 
Diagnosing Insulin Resistance by Simple Quantitative Methods in 
Subjects With Normal Glucose Metabolism. Diabetes Care. 
2003;26(12):3320-5. 
135. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin 
inhibits the pro-inflammatory transcription factor early growth response 
gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces 
plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) 
concentrations. J Clin Endocrinol Metab. 2002;87(3):1419-22. 
136. Muller I, Lipp P, Thiel G. Ca2+ signaling and gene 
transcription in glucose-stimulated insulinoma cells.  Cell Calcium. 52. 
Netherlands: 2012 Elsevier Ltd; 2012. p. 137-51. 
137. Chai Tf Fau - Hong SY, Hong Sy Fau - He H, He H Fau - Zheng 
L, Zheng L Fau - Hagen T, Hagen T Fau - Luo Y, Luo Y Fau - Yu F-X, et al. 
A potential mechanism of metformin-mediated regulation of glucose 
homeostasis: inhibition of Thioredoxin-interacting protein (Txnip) gene 
expression. (1873-3913 (Electronic)). 
138. Blaschke F, Bruemmer D, Law RE. Egr-1 is a major vascular 
pathogenic transcription factor in atherosclerosis and restenosis.  
Reviews in endocrine & metabolic disorders. 5. United States2004. p. 
249-54. 
241 
 
139. McCaffrey TA, Fu C, Du B, Eksinar S, Kent KC, Bush H, Jr., et al. 
High-level expression of Egr-1 and Egr-1-inducible genes in mouse and 
human atherosclerosis. J Clin Invest. 2000;105(5):653-62. 
140. Gousseva N, Kugathasan K, Chesterman CN, Khachigian 
LM. Early growth response factor-1 mediates insulin-inducible vascular 
endothelial cell proliferation and regrowth after injury. Journal of 
cellular biochemistry. 2001;81(3):523-34. 
141. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, for 
the Conference P. Definition of Metabolic Syndrome. Circulation. 
2004;109(3):433-8. 
142. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, 
Rubinstein AM, et al. Heparanase Is Essential for the Development of 
Diabetic Nephropathy in Mice. Diabetes. 2012;61(1):208-16. 
143. Ong S-E, Pandey A. An evaluation of the use of two-
dimensional gel electrophoresis in proteomics. Biomolecular 
Engineering. 2001;18(5):195-205. 
144. Tuli L, Ressom HW. LC-MS Based Detection of Differential 
Protein Expression. Journal of proteomics & bioinformatics. 2009;2:416-
38. 
145. Sandin M, Krogh M, Hansson K, Levander F. Generic 
workflow for quality assessment of quantitative label-free LC-MS 
analysis. Proteomics. 2011;11(6):1114-24. 
146. Kim G, Kim GH, Oh GS, Yoon J, Kim HW, Kim MS, et al. SREBP-
1c regulates glucose-stimulated hepatic clusterin expression.  
Biochemical and biophysical research communications. 408. United 
States: 2011 Elsevier Inc; 2011. p. 720-5. 
147. Preissner KT, Jenne D. Vitronectin: a new molecular 
connection in haemostasis. Thrombosis and haemostasis. 
1991;66(2):189-94. 
148. Preissner KT, Kanse SM, Hammes HP. Integrin chatter and 
vascular function in diabetic retinopathy. Hormone and metabolic 
research = Hormon- und Stoffwechselforschung = Hormones et 
metabolisme. 1997;29(12):643-5. 
149. Daimon M, Oizumi T, Karasawa S, Kaino W, Takase K, Tada K, 
et al. Association of the clusterin gene polymorphisms with type 2 
diabetes mellitus. Metabolism. 2011;60(6):815-22. 
242 
 
150. Trougakos IP, Gonos ES. Regulation of 
clusterin/apolipoprotein J, a functional homologue to the small heat 
shock proteins, by oxidative stress in ageing and age-related diseases. 
Free radical research. 2006;40(12):1324-34. 
151. Pettersson C, Karlsson H, Stahlman M, Larsson T, Fagerberg B, 
Lindahl M, et al. LDL-associated apolipoprotein J and lysozyme are 
associated with atherogenic properties of LDL found in type 2 
diabetes and the metabolic syndrome. J Intern Med. 2011;269(3):306-
21. 
152. Aronis KN, Vamvini MT, Chamberland JP, Mantzoros CS. 
Circulating clusterin (apolipoprotein J) levels do not have any 
day/night variability and are positively associated with total and LDL 
cholesterol levels in young healthy individuals.  J Clin Endocrinol 
Metab. 96. United States2011. p. E1871-5. 
153. Hoofnagle AN, Wu M, Gosmanova AK, Becker JO, Wijsman 
EM, Brunzell JD, et al. Low clusterin levels in high-density lipoprotein 
associate with insulin resistance, obesity, and dyslipoproteinemia.  
Arterioscler Thromb Vasc Biol. 30. United States2010. p. 2528-34. 
154. Esmon CT. Protein S and protein C Biochemistry, physiology, 
and clinical manifestation of. Trends in cardiovascular medicine. 
1992;2(6):214-9. 
155. Maillard C, Berruyer M, Serre CM, Dechavanne M, Delmas 
PD. Protein-S, a vitamin K-dependent protein, is a bone matrix 
component synthesized and secreted by osteoblasts. Endocrinology. 
1992;130(3):1599-604. 
156. Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, 
Shacter E. Serum-derived protein S binds to phosphatidylserine and 
stimulates the phagocytosis of apoptotic cells. Nature immunology. 
2003;4(1):87-91. 
157. Green AR. Postgraduate Haematology. Hoffbrand AV, 
Catovsky D, Tuddenham EGD, editors: Wiley; 2010. 
158. Singh A, Boden G, Homko C, Gunawardana J, Rao AK. 
Whole-blood tissue factor procoagulant activity is elevated in type 1 
diabetes: effects of hyperglycemia and hyperinsulinemia. Diabetes 
Care. 2012;35(6):1322-7. 
159. Targher G, Chonchol M, Zoppini G, Franchini M. Hemostatic 
disorders in type 1 diabetes mellitus. Seminars in thrombosis and 
hemostasis. 2011;37(1):58-65. 
243 
 
160. Wieczorek I, Pell AC, McIver B, MacGregor IR, Ludlam CA, 
Frier BM. Coagulation and fibrinolytic systems in type I diabetes: 
effects of venous occlusion and insulin-induced hypoglycaemia. Clin 
Sci (Lond). 1993;84(1):79-86. 
161. Schernthaner G, Vukovich T, Knobl P, Hay U, Muller MM. The 
effect of near-normoglycaemic control on plasma levels of 
coagulation factor VII and the anticoagulant proteins C and S in 
insulin-dependent diabetic patients. British journal of haematology. 
1989;73(3):356-9. 
162. Wullstein C, Woeste G, Zapletal C, Trobisch H, Bechstein WO. 
Prothrombotic disorders in uremic type-1 diabetics undergoing 
simultaneous pancreas and kidney transplantation. Transplantation. 
2003;76(12):1691-5. 
163. Madan R, Gupt B, Saluja S, Kansra UC, Tripathi BK, Guliani BP. 
Coagulation profile in diabetes and its association with diabetic 
microvascular complications. The Journal of the Association of 
Physicians of India. 2010;58:481-4. 
164. Bonner-Weir S. Life and death of the pancreatic beta cells. 
Trends in endocrinology and metabolism: TEM. 2000;11(9):375-8. 
165. Metabolon Inc. homepage  [28 Oct 2012]. Available from: 
http://www.metabolon.com/services/mView.aspx. 
166. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. 
Integrated, nontargeted ultrahigh performance liquid 
chromatography/electrospray ionization tandem mass spectrometry 
platform for the identification and relative quantification of the small-
molecule complement of biological systems. Analytical chemistry. 
2009;81(16):6656-67. 
167. Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, 
Akanuma H. Urinary excretion of 1,5-anhydro-D-glucitol 
accompanying glucose excretion in diabetic patients. Diabetologia. 
1988;31(11):831-5. 
168. Kim W, Park C-Y. 1,5-Anhydroglucitol in diabetes mellitus. 
Endocrine. 2012:1-8. 
169. Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of 
short-term glycemic control and glycemic excursions. Expert review of 
molecular diagnostics. 2008;8(1):9-19. 
244 
 
170. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 
AG): new clinical marker for glycemic control. Diabetes Res Clin Pract. 
1994;24 Suppl:S261-8. 
171. Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto 
J, Gareeboo H. Is serum anhydroglucitol an alternative to the oral 
glucose tolerance test for diabetes screening? The Mauritius 
Noncommunicable Diseases Study Group. Diabet Med. 1993;10(1):56-
60. 
172. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto 
Y, Okamura T. Serum 1,5-anhydro-D-glucitol levels predict first-ever 
cardiovascular disease: an 11-year population-based cohort study in 
Japan, the Suita study.  Atherosclerosis. 216. Ireland: 2011 Elsevier 
Ireland Ltd; 2011. p. 477-83. 
173. Cline GW, Rothman DL, Magnusson I, Katz LD, Shulman GI. 
13C-nuclear magnetic resonance spectroscopy studies of hepatic 
glucose metabolism. J Clin Invest. 1994;94(6):2369-76. 
174. Zhang X, Wang Y, Hao F, Zhou X, Han X, Tang H, et al. 
Human Serum Metabonomic Analysis Reveals Progression Axes for 
Glucose Intolerance and Insulin Resistance Statuses. Journal of 
proteome research. 2009;8(11):5188-95. 
175. Carrozzo R, Dionisi-Vici C, Steuerwald U, Lucioli S, Deodato F, 
Di Giandomenico S, et al. SUCLA2 mutations are associated with mild 
methylmalonic aciduria, Leigh-like. Brain : a journal of neurology. 
2007;130(Pt 3):862-74. 
176. Miyamoto Y, Iwao Y, Mera K, Watanabe H, Kadowaki D, 
Ishima Y, et al. A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-
furanpropionate induces cell damage. Biochemical pharmacology. 
2012;84(9):1207-14. 
177. KM B, PA M. Oxidation of Fatty Acids: Ketogenesis. Harper's 
Illustrated Biochemistry. 2011(22). 
178. Evangeliou A, Gourgiotis D, Karagianni C, Markouri M, 
Anogianaki N, Mamoulakis D, et al. Carnitine status and lactate 
increase in patients with type I juvenile diabetes. Minerva pediatrica. 
2010;62(6):551-7. 
179. LW J, ME T. The Big Picture: Medical Biochemistry. New York: 
McGraw-Hill; 2012. 
245 
 
180. Tessari P, Biolo G, Inchiostro S, Sacca L, Nosadini R, Boscarato 
MT, et al. Effects of insulin on whole body and forearm leucine and KIC 
metabolism in type 1. The American journal of physiology. 1990;259(1 
Pt 1):E96-103. 
181. Vannini P, Marchesini G, Forlani G, Angiolini A, Ciavarella A, 
Zoli M, et al. Branched-chain amino acids and alanine as indices of 
the metabolic control in. Diabetologia. 1982;22(3):217-9. 
182. Gianazza E, Mainini V, Castoldi G, Chinello C, Zerbini G, 
Bianchi C, et al. Different expression of fibrinopeptide A and related 
fragments in serum of type 1. Journal of proteomics. 2010;73(3):593-
601. 
183. Nomura F, Tomonaga T, Sogawa K, Ohashi T, Nezu M, 
Sunaga M, et al. Identification of novel and downregulated 
biomarkers for alcoholism by surface. Proteomics. 2004;4(4):1187-94. 
184. Matheus AS, Tibirica E, da Silva PB, de Fatima Bevilacqua da 
Matta M, Gomes MB. Uric acid levels are associated with 
microvascular endothelial dysfunction in patients with Type 1 
diabetes. Diabet Med. 2011;28(10):1188-93. 
185. Yu X, Shen N, Zhang ML, Pan FY, Wang C, Jia WP, et al. Egr-1 
decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK 
signal balance in mice.  The EMBO journal. 30. England2011. p. 3754-
65. 
 
246 
 
 Appendix A 
 
Proteomics label-free LC-MS (raw data) 
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Patients with newly diagnosed type 1 diabetes vs their healthy controls 
List of differentially expressed protein for newly-diagnosed type 1 diabetes  and matched controls with DS-169/ T1N8sample used as reference run (raw data) 
Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
CO4A_HUMAN 43 4138.72 0.02 1.58 Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 1.56E+008 9.88E+007 
CO3_HUMAN 35 3123.37 0.05 1.55 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 4.95E+007 3.19E+007 
CO5_HUMAN 20 1427.52 0.03 1.65 Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 1.88E+006 1.14E+006 
APOA1_HUMAN 16 1126.05 0.03 1.53 Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 7.57E+007 4.94E+007 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
SV=1 
CLUS_HUMAN 13 988.6 0.04 1.72 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 1.78E+007 1.03E+007 
CO9_HUMAN 10 950.21 8.86E-003 1.79 Complement component C9 OS=Homo sapiens GN=C9 
PE=1 SV=2 
4.28E+006 2.39E+006 
VTNC_HUMAN 8 689.45 0.05 1.43 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 4.72E+007 3.30E+007 
APOA4_HUMAN 9 652.83 0.01 1.58 Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 
SV=3 
9.07E+006 5.74E+006 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
FBLN1_HUMAN 7 640.57 0.03 1.61 Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4 5.67E+006 3.53E+006 
ALBU_HUMAN 8 628.35 0.04 1.64 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 9.07E+006 5.54E+006 
LG3BP_HUMAN 8 581.72 0.05 1.58 Galectin-3-binding protein OS=Homo sapiens 
GN=LGALS3BP PE=1 SV=1 
1.77E+006 1.12E+006 
ITIH4_HUMAN 6 520.69 0.04 7.81 Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo 
sapiens GN=ITIH4 PE=1 SV=4 
1.23E+006 1.58E+005 
A1AT_HUMAN 6 490.95 0.02 1.78 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 8.31E+005 4.66E+005 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
SV=3 
LBP_HUMAN 4 392.67 0.02 2.29 Lipopolysaccharide-binding protein OS=Homo sapiens 
GN=LBP PE=1 SV=3 
5.66E+005 2.47E+005 
TSP1_HUMAN 6 368.73 8.49E-003 1.65 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 
SV=2 
3.03E+005 5.00E+005 
CRP_HUMAN 6 334.89 0.02 6.09 C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 1.22E+006 2.00E+005 
C1QB_HUMAN 3 279.59 0.03 1.59 Complement C1q subcomponent subunit B OS=Homo 
sapiens GN=C1QB PE=1 SV=2 
2.60E+006 1.63E+006 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
CO7_HUMAN 4 272.65 3.75E-003 2.24 Complement component C7 OS=Homo sapiens GN=C7 
PE=1 SV=2 
4.26E+005 1.90E+005 
C4BPA_HUMAN 3 270.68 0.03 1.51 C4b-binding protein alpha chain OS=Homo sapiens 
GN=C4BPA PE=1 SV=2 
3.63E+006 2.40E+006 
CERU_HUMAN 4 258.01 0.01 2.41 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 2.70E+005 1.12E+005 
ACTC_HUMAN 4 232.49 0.02 1.95 Actin, alpha cardiac muscle 1 OS=Homo sapiens 
GN=ACTC1 PE=1 SV=1 
9.88E+004 1.93E+005 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
PROS_HUMAN 4 218.74 0.03 1.51 Vitamin K-dependent protein S OS=Homo sapiens 
GN=PROS1 PE=1 SV=1 
3.45E+005 2.29E+005 
TRFL_HUMAN 3 205.82 0.04 1.74 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 3.86E+004 6.70E+004 
ITIH3_HUMAN 3 180.97 0.01 2.43 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo 
sapiens GN=ITIH3 PE=1 SV=2 
9.40E+004 3.88E+004 
POTEE_HUMAN 3 178.05 0.02 1.97 POTE ankyrin domain family member E OS=Homo sapiens 
GN=POTEE PE=1 SV=3 
5.39E+004 1.06E+005 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
CO8B_HUMAN 3 171.54 0.05 1.86 Complement component C8 β chain OS=Homo sapiens 
GN=C8B PE=1 SV=3 
5.52E+005 2.97E+005 
PROC_HUMAN 2 164.19 0.03 1.81 Vitamin K-dependent protein C OS=Homo sapiens 
GN=PROC PE=1 SV=1 
2.12E+005 1.17E+005 
ZPI_HUMAN 2 153.72 0.02 2.69 Protein Z-dependent protease inhibitor OS=Homo sapiens 
GN=SERPINA10 PE=1 SV=1 
1.97E+005 7.33E+004 
FBLN3_HUMAN 2 136.33 0.05 1.94 EGF-containing fibulin-like extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 PE=1 SV=2 
1.78E+005 9.16E+004 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
C1S_HUMAN 3 135.97 0.03 1.5 Complement C1s subcomponent OS=Homo sapiens 
GN=C1S PE=1 SV=1 
4.01E+004 2.67E+004 
ACTBL_HUMAN 2 117.48 0.02 1.91 Β-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 
SV=2 
5.31E+004 1.02E+005 
ACTBM_HUMAN 2 113.28 0.02 1.98 Β-actin-like protein 3 OS=Homo sapiens GN=ACTBL3 PE=1 
SV=1 
4.86E+004 9.63E+004 
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 List of differentially expressed protein for newly-diagnosed type 1 diabetes and matched controls with DS- 175/ U35 sample used as reference run (raw data)  
Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
CO4B_HUMAN 40 3836.35 5.87E-003 1.65 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 1.95E+008 1.18E+008 
CO3_HUMAN 42 3693.41 0.03 1.56 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 6.88E+007 4.41E+007 
CO5_HUMAN 20 1420.08 4.51E-003 1.74 Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 2.24E+006 1.28E+006 
APOA1_HUMAN 17 1233.71 0.02 1.57 Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 
SV=1 
8.52E+007 5.43E+007 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
CLUS_HUMAN 12 1010.99 0.01 1.68 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 2.68E+007 1.59E+007 
CO9_HUMAN 11 1000.43 3.22E-003 1.86 Complement component C9 OS=Homo sapiens GN=C9 PE=1 
SV=2 
4.93E+006 2.66E+006 
APOA4_HUMAN 14 972.98 5.23E-003 1.64 Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 
SV=3 
1.15E+007 7.06E+006 
ALBU_HUMAN 10 777.19 0.03 1.58 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 1.29E+007 8.20E+006 
VTNC_HUMAN 7 644.16 0.04 1.46 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 5.38E+007 3.70E+007 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
FBLN1_HUMAN 7 631.79 0.02 1.64 Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4 6.42E+006 3.93E+006 
LBP_HUMAN 5 541.79 0.02 2.29 Lipopolysaccharide-binding protein OS=Homo sapiens 
GN=LBP PE=1 SV=3 
1.30E+006 5.68E+005 
SAMP_HUMAN 7 530.8 0.04 1.48 Serum amyloid P-component OS=Homo sapiens GN=APCS 
PE=1 SV=2 
7.41E+006 5.02E+006 
CFAH_HUMAN 8 521.49 0.02 1.41 Complement factor H OS=Homo sapiens GN=CFH PE=1 
SV=4 
2.70E+006 1.92E+006 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
ANT3_HUMAN 9 512.66 0.05 1.47 Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 
SV=1 
2.75E+007 1.87E+007 
IGHM_HUMAN 7 500.95 0.05 1.42 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 
SV=3 
1.44E+007 1.02E+007 
TSP1_HUMAN 7 425.34 0.01 1.53 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 
SV=2 
5.18E+005 7.94E+005 
A1AT_HUMAN 5 412.2 4.59E-003 2.19 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 
SV=3 
9.02E+005 4.11E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
C4BPA_HUMAN 3 346.18 0.01 1.61 C4b-binding protein alpha chain OS=Homo sapiens 
GN=C4BPA PE=1 SV=2 
4.45E+006 2.77E+006 
PROS_HUMAN 5 297.77 0.02 1.33 Vitamin K-dependent protein S OS=Homo sapiens 
GN=PROS1 PE=1 SV=1 
1.22E+006 9.16E+005 
ITIH3_HUMAN 5 278.62 7.92E-003 2.7 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo 
sapiens GN=ITIH3 PE=1 SV=2 
1.53E+005 5.66E+004 
CO7_HUMAN 3 267.47 1.61E-003 2.35 Complement component C7 OS=Homo sapiens GN=C7 PE=1 
SV=2 
5.43E+005 2.31E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
ACTS_HUMAN 5 246.04 0.01 2.19 Actin, alpha skeletal muscle OS=Homo sapiens GN=ACTA1 
PE=1 SV=1 
1.11E+005 2.43E+005 
C1QA_HUMAN 2 241.96 0.02 1.47 Complement C1q subcomponent subunit A OS=Homo 
sapiens GN=C1QA PE=1 SV=2 
2.71E+006 1.84E+006 
CRP_HUMAN 4 236.68 0.01 6.22 C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 1.24E+006 1.99E+005 
ZPI_HUMAN 3 228.52 0.03 2.51 Protein Z-dependent protease inhibitor OS=Homo sapiens 
GN=SERPINA10 PE=1 SV=1 
3.81E+005 1.52E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
TRFL_HUMAN 3 218.44 0.02 2.26 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 4.63E+004 1.05E+005 
IGKC_HUMAN 2 210.45 0.05 1.5 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 
SV=1 
1.23E+007 8.18E+006 
FA5_HUMAN 3 200.05 0.04 1.63 Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=3 2.57E+005 1.57E+005 
C1QB_HUMAN 2 195.39 0.02 1.55 Complement C1q subcomponent subunit B OS=Homo 
sapiens GN=C1QB PE=1 SV=2 
1.68E+006 1.09E+006 
CO6_HUMAN 3 185.01 0.04 1.58 Complement component C6 OS=Homo sapiens GN=C6 PE=1 4.21E+005 2.66E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
SV=3 
C1S_HUMAN 2 124.24 0.03 1.7 Complement C1s subcomponent OS=Homo sapiens 
GN=C1S PE=1 SV=1 
2.47E+005 1.46E+005 
ACTBM_HUMAN 2 113.96 0.03 1.92 Β-actin-like protein 3 OS=Homo sapiens GN=ACTBL3 PE=1 
SV=1 
6.34E+004 1.22E+005 
POTEE_HUMAN 2 113.96 0.03 1.92 POTE ankyrin domain family member E OS=Homo sapiens 
GN=POTEE PE=1 SV=3 
6.34E+004 1.22E+005 
POTEF_HUMAN 2 113.96 0.03 1.92 POTE ankyrin domain family member F OS=Homo sapiens 6.34E+004 1.22E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM new Matched 
controls 
GN=POTEF PE=1 SV=2 
HRG_HUMAN 2 95.38 0.05 2.61 Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 
SV=1 
1.13E+004 2.94E+004 
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List of differentially expressed protein for patients with newly-diagnosed type 1 diabetes and matched controls with DS-178/ U36 sample used as a reference run (raw data)  
Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM 
new 
Matched 
controls 
CO4B_HUMAN 26 2000.08 0.05 3.01 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 4.46e+007 1.48e+007 
CO5_HUMAN 9 586.25 0.04 1.63 Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 4.70e+005 2.88e+005 
THRB_HUMAN 7 555.88 0.04 35.59 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 1.05e+007 2.96e+005 
ACTB_HUMAN 8 446.32 0.04 1.66 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 3.25e+005 5.40e+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM 
new 
Matched 
controls 
ACTC_HUMAN 7 357.51 9.94e-003 2.30 Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1 PE=1 
SV=1 
1.24e+005 2.84e+005 
ACTH_HUMAN 6 314.33 9.62e-003 2.23 Actin, gamma-enteric smooth muscle OS=Homo sapiens 
GN=ACTG2 PE=1 SV=1 
1.16e+005 2.60e+005 
CLUS_HUMAN 4 246.38 0.02 1.57 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 8.49e+005 5.41e+005 
CRP_HUMAN 4 196.23 0.02 8.05 C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 4.21e+005 5.23e+004 
POTEF_HUMAN 3 178.73 0.03 2.02 POTE ankyrin domain family member F OS=Homo sapiens 6.91e+004 1.40e+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM 
new 
Matched 
controls 
GN=POTEF PE=1 SV=2 
POTEE_HUMAN 3 178.73 0.03 2.02 POTE ankyrin domain family member E OS=Homo sapiens 
GN=POTEE PE=1 SV=3 
6.91e+004 1.40e+005 
IPSP_HUMAN 3 167.73 0.02 2.08 Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 
PE=1 SV=2 
2.81e+004 5.83e+004 
LG3BP_HUMAN 2 121.06 0.04 1.54 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 
SV=1 
4.31e+005 2.79e+005 
ITIH3_HUMAN 2 117.79 0.02 2.50 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens 8.37e+004 3.34e+004 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM 
new 
Matched 
controls 
GN=ITIH3 PE=1 SV=2 
ACTBL_HUMAN 2 117.48 0.03 1.87 Β-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 6.40e+004 1.20e+005 
ACTBM_HUMAN 2 113.96 0.03 2.03 Β-actin-like protein 3 OS=Homo sapiens GN=ACTBL3 PE=1 SV=1 6.31e+004 1.28e+005 
A2AP_HUMAN 2 111.80 0.03 1.58 Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 7.70e+004 1.22e+005 
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Patients with established type 1 diabetes vs their healthy controls 
List of all proteins expressed in samples from patients with established type 1 diabetes (raw data) vs. their  matched controls with DS-84/T1O10 as a reference run (raw 
data) 
Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
APOB_HUMAN 56 4308.27 0.05 2.5 Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1 7.65E+006 1.91E+007 
ANT3_HUMAN 18 1712.09 0.05 2.55 Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 6.43E+007 1.64E+008 
APOE_HUMAN 12 1248.2 0.02 2.19 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 1.46E+007 3.20E+007 
PROS_HUMAN 7 545.67 0.05 2.47 Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 1.52E+006 3.75E+006 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
PE=1 SV=1 
VTNC_HUMAN 5 491.62 0.03 1.72 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 2.55E+007 4.39E+007 
APOC2_HUMAN 4 456.03 0.01 2.41 Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 SV=1 4.06E+006 9.79E+006 
APOA1_HUMAN 5 429.1 0.05 1.9 Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 2.66E+007 5.06E+007 
CERU_HUMAN 6 412.71 0.03 1.7 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 5.53E+005 3.25E+005 
FCN2_HUMAN 5 406.23 0.02 3 Ficolin-2 OS=Homo sapiens GN=FCN2 PE=1 SV=2 5.81E+005 1.75E+006 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
TTHY_HUMAN 4 377.31 0.04 2.69 Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 2.14E+006 5.74E+006 
SAA4_HUMAN 2 245.71 0.02 2.34 Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1 
SV=1 
8.40E+005 1.97E+006 
MASP1_HUMAN 4 243.86 5.95E-003 1.97 Mannan-binding lectin serine protease 1 OS=Homo sapiens 
GN=MASP1 PE=1 SV=3 
4.04E+005 7.95E+005 
C4BPA_HUMAN 3 243.28 0.04 2.62 C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA 
PE=1 SV=2 
5.67E+006 1.49E+007 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
FHR1_HUMAN 3 227.79 6.65E-003 1.88 Complement factor H-related protein 1 OS=Homo sapiens 
GN=CFHR1 PE=1 SV=2 
2.30E+006 4.34E+006 
HV315_HUMAN 1 211.45 4.00E-002 2.78 Ig heavy chain V-III region WAS OS=Homo sapiens PE=1 SV=1 4.24E+005 1.18E+006 
HV313_HUMAN 1 211.45 4.00E-002 2.78 Ig heavy chain V-III region POM OS=Homo sapiens PE=1 SV=1 4.24E+005 1.18E+006 
PLF4_HUMAN 2 211.02 0.05 2.1 Platelet factor 4 OS=Homo sapiens GN=PF4 PE=1 SV=2 7.12E+005 1.49E+006 
ACTG_HUMAN 4 201.04 0.03 3.42 Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 1.28E+005 4.38E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
HEP2_HUMAN 3 189.86 0.04 1.98 Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3 2.49E+004 4.94E+004 
APOL1_HUMAN  2 189.67 3.71E-003 4.07 Apolipoprotein L1 OS=Homo sapiens GN=APOL1 PE=1 SV=5 7.27E+004 2.96E+005 
FHR2_HUMAN 2 168.18 0.02 1.88 Complement factor H-related protein 2 OS=Homo sapiens 
GN=CFHR2 PE=1 SV=1 
7.12E+005 1.34E+006 
CO8B_HUMAN 3 158.26 0.01 1.46 Complement component C8 β chain OS=Homo sapiens GN=C8B 
PE=1 SV=3 
8.24E+004 5.64E+004 
ACTBM_HUMAN 3 154.69 0.01 3.99 Β-actin-like protein 3 OS=Homo sapiens GN=ACTBL3 PE=1 SV=1 6.77E+004 2.70E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
POTEE_HUMAN 3 154.69 0.01 3.99 POTE ankyrin domain family member E OS=Homo sapiens 
GN=POTEE PE=1 SV=3 
6.77E+004 2.70E+005 
APOC4_HUMAN 2 135.66 0.02 2.9 Apolipoprotein C-IV OS=Homo sapiens GN=APOC4 PE=1 SV=1 5.04E+004 1.46E+005 
VWF_HUMAN 2 117.51 0.02 4.42 von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=3 1.76E+004 7.80E+004 
CO8A_HUMAN 2 98.35 0.03 1.73 Complement component C8 alpha chain OS=Homo sapiens 
GN=C8A PE=1 SV=2 
5.12E+004 2.96E+004 
A2MG_HUMAN 2 96.72 0.02 2.27 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=2 8.06E+004 3.55E+004 
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List of proteins expressed in samples from patients with established type 1 diabetes vs. their matched controls with DS-162/M16 as a reference run (raw data). 
Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
ANT3_HUMAN 17 1510.35 0.03 2.31 Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 3.15E+007 7.27E+007 
APOE_HUMAN 15 1226.65 0.02 2.05 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 1.07E+007 2.19E+007 
FCN2_HUMAN 7 544.62 0.02 2.81 Ficolin-2 OS=Homo sapiens GN=FCN2 PE=1 SV=2 4.37E+005 1.23E+006 
APOC2_HUMAN 5 518.44 0.01 2.25 Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 SV=1 3.13E+006 7.05E+006 
VTNC_HUMAN 5 446.27 0.03 1.62 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 1.71E+007 2.77E+007 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
CERU_HUMAN 8 445.18 0.04 1.44 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 4.51E+005 3.13E+005 
APOA1_HUMAN 4 347.03 0.04 1.76 Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 1.99E+007 3.50E+007 
PROS_HUMAN 4 337.83 6.32E-003 2.13 Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 
PE=1 SV=1 
4.03E+005 8.59E+005 
TTHY_HUMAN 3 335.64 0.03 2.39 Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 1.63E+006 3.91E+006 
ITIH1_HUMAN 4 298.01 0.01 2.14 Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens 
GN=ITIH1 PE=1 SV=3 
2.66E+005 5.69E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
MASP1_HUMAN 4 243.86 2.11E-003 1.95 Mannan-binding lectin serine protease 1 OS=Homo sapiens 
GN=MASP1 PE=1 SV=3 
2.82E+005 5.49E+005 
C4BPA_HUMAN 3 243.28 0.03 2.39 C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA 
PE=1 SV=2 
4.23E+006 1.01E+007 
HV304_HUMAN 1 211.45 0.05 2.5 Ig heavy chain V-III region TIL OS=Homo sapiens PE=1 SV=1 3.20E+005 8.00E+005 
PLF4_HUMAN 2 211.02 0.05 1.98 Platelet factor 4 OS=Homo sapiens GN=PF4 PE=1 SV=2 5.30E+005 1.05E+006 
SAA4_HUMAN 2 202.91 0.02 2.25 Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1 5.16E+005 1.16E+006 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
SV=1 
ACTG_HUMAN 4 201.04 0.02 3.14 Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 1.45E+005 4.56E+005 
APOL1_HUMAN 3 186.21 0.03 2.44 Apolipoprotein L1 OS=Homo sapiens GN=APOL1 PE=1 SV=5 7.75E+004 1.89E+005 
IPSP_HUMAN 2 184.05 0.05 2.01 Plasma serine protease inhibitor OS=Homo sapiens 
GN=SERPINA5 PE=1 SV=2 
5.14E+004 1.03E+005 
FHR1_HUMAN 3 160.96 0.02 1.74 Complement factor H-related protein 1 OS=Homo sapiens 
GN=CFHR1 PE=1 SV=2 
1.42E+006 2.47E+006 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
A2AP_HUMAN 3 159.38 0.03 3.54 Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 2.47E+004 8.74E+004 
POTEE_HUMAN 3 154.69 9.51E-003 3.72 POTE ankyrin domain family member E OS=Homo sapiens 
GN=POTEE PE=1 SV=3 
4.79E+004 1.78E+005 
POTEF_HUMAN 3 154.69 9.51E-003 3.72 POTE ankyrin domain family member F OS=Homo sapiens 
GN=POTEF PE=1 SV=2 
4.79E+004 1.78E+005 
ACTBM_HUMAN 3 154.69 9.51E-003 3.72 Β-actin-like protein 3 OS=Homo sapiens GN=ACTBL3 PE=1 SV=1 4.79E+004 1.78E+005 
CO8A_HUMAN 3 139.62 0.02 1.67 Complement component C8 alpha chain OS=Homo sapiens 4.30E+004 2.58E+004 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
GN=C8A PE=1 SV=2 
APOC4_HUMAN 2 135.66 3.89E-03 3.53 Apolipoprotein C-IV OS=Homo sapiens GN=APOC4 PE=1 SV=1 2.86E+004 1.01E+005 
A2MG_HUMAN 2 133.61 0.03 2.08 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=2 8.89E+004 4.28E+004 
APOC1_HUMAN 2 117.67 0.02 2.32 Apolipoprotein C-I OS=Homo sapiens GN=APOC1 PE=1 SV=1 1.37E+006 3.18E+006 
VWF_HUMAN 2 117.51 0.01 3.51 von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=3 1.67E+004 5.87E+004 
ACTC_HUMAN 2 108.97 0.01 3.64 Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1 PE=1 
SV=1 
4.64E+004 1.69E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
ACTS_HUMAN 2 108.97 0.01 3.64 Actin, alpha skeletal muscle OS=Homo sapiens GN=ACTA1 PE=1 
SV=1 
4.64E+004 1.69E+005 
VTDB_HUMAN 2 106.33 0.05 3.04 Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 2.71E+004 8.23E+004 
FHR2_HUMAN 2 101.35 0.02 1.71 Complement factor H-related protein 2 OS=Homo sapiens 
GN=CFHR2 PE=1 SV=1 
2.27E+005 3.89E+005 
CO8B_HUMAN 2 92.06 1.57E-003 1.86 Complement component C8 β chain OS=Homo sapiens GN=C8B 
PE=1 SV=3 
6.35E+004 3.41E+004 
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List of proteins expressed in samples from patients with established type 1 diabetes vs. their  matched controls with DS-39/U14 as a reference run (raw data).  
Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
ANT3_HUMAN 16 1381.27 0.03 2.37 Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 2.79E+007 6.63E+007 
APOE_HUMAN 15 1269.56 0.02 2.05 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 1.05E+007 2.16E+007 
APOC2_HUMAN 5 518.44 7.13E-003 2.5 Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 SV=1 2.76E+006 6.88E+006 
VTNC_HUMAN 6 501.23 0.03 1.57 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 1.76E+007 2.77E+007 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
FCN2_HUMAN 6 494.26 0.02 2.88 Ficolin-2 OS=Homo sapiens GN=FCN2 PE=1 SV=2 4.10E+005 1.18E+006 
CERU_HUMAN 7 477.04 0.03 1.6 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 5.17E+005 3.23E+005 
PROS_HUMAN 6 446.97 5.34E-003 2.24 Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 
PE=1 SV=1 
4.03E+005 9.04E+005 
APOA1_HUMAN 5 429.1 0.05 1.75 Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 1.96E+007 3.44E+007 
TTHY_HUMAN 3 335.64 0.04 2.46 Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 1.51E+006 3.71E+006 
283 
 
Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
C4BPA_HUMAN 4 316.54 0.03 2.4 C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA 
PE=1 SV=2 
4.16E+006 9.97E+006 
SAA4_HUMAN 3 287.7 0.01 2.37 Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1 
SV=1 
5.00E+005 1.19E+006 
IPSP_HUMAN 3 245.51 0.05 2.13 Plasma serine protease inhibitor OS=Homo sapiens 
GN=SERPINA5 PE=1 SV=2 
5.80E+004 1.24E+005 
MASP1_HUMAN 4 243.86 2.59E-003 1.91 Mannan-binding lectin serine protease 1 OS=Homo sapiens 
GN=MASP1 PE=1 SV=3 
2.79E+005 5.35E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
APOL1_HUMAN 3 233.39 0.02 2 Apolipoprotein L1 OS=Homo sapiens GN=APOL1 PE=1 SV=5 1.25E+005 2.49E+005 
ITIH1_HUMAN 3 224.52 7.72E-003 2.26 Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens 
GN=ITIH1 PE=1 SV=3 
2.13E+005 4.81E+005 
HV313_HUMAN 1 211.45 5.00E-002 2.51 Ig heavy chain V-III region POM OS=Homo sapiens PE=1 SV=1 3.13E+005 7.87E+005 
HV315_HUMAN 1 211.45 5.00E-002 2.51 Ig heavy chain V-III region WAS OS=Homo sapiens PE=1 SV=1 3.13E+005 7.87E+005 
PLF4_HUMAN 2 211.02 0.05 1.97 Platelet factor 4 OS=Homo sapiens GN=PF4 PE=1 SV=2 5.22E+005 1.03E+006 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
ACTG_HUMAN 4 201.04 0.03 3.09 Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 1.52E+005 4.71E+005 
POTEF_HUMAN 3 154.69 0.02 3.63 POTE ankyrin domain family member F OS=Homo sapiens 
GN=POTEF PE=1 SV=2 
5.17E+004 1.88E+005 
ACTBM_HUMAN 3 154.69 0.02 3.63 Β-actin-like protein 3 OS=Homo sapiens GN=ACTBL3 PE=1 
SV=1 
5.17E+004 1.88E+005 
POTEE_HUMAN 3 154.69 0.02 3.63 POTE ankyrin domain family member E OS=Homo sapiens 
GN=POTEE PE=1 SV=3 
5.17E+004 1.88E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
APOC4_HUMAN 2 135.66 4.00E-003 3.03 Apolipoprotein C-IV OS=Homo sapiens GN=APOC4 PE=1 SV=1 3.58E+004 1.08E+005 
HEP2_HUMAN 2 125.29 0.02 2.81 Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 
SV=3 
1.05E+004 2.95E+004 
VWF_HUMAN 2 117.51 0.01 3.9 von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=3 1.41E+004 5.50E+004 
ZPI_HUMAN 2 112.45 0.02 1.98 Protein Z-dependent protease inhibitor OS=Homo sapiens 
GN=SERPINA10 PE=1 SV=1 
3.47E+004 1.75E+004 
FA10_HUMAN 2 111.84 0.04 2.96 Coagulation factor X OS=Homo sapiens GN=F10 PE=1 SV=2 3.78E+004 1.12E+005 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
T1DM old Matched 
controls 
ACTC_HUMAN 2 108.97 0.02 3.59 Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1 
PE=1 SV=1 
4.97E+004 1.79E+005 
FHR1_HUMAN 2 106.76 0.03 1.74 Complement factor H-related protein 1 OS=Homo sapiens 
GN=CFHR1 PE=1 SV=2 
1.34E+006 2.33E+006 
VTDB_HUMAN 2 106.33 0.05 3.2 Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 
SV=1 
2.52E+004 8.07E+004 
CO8B_HUMAN 2 92.06 5.89E-004 1.91 Complement component C8 β chain OS=Homo sapiens 
GN=C8B PE=1 SV=3 
6.34E+004 3.31E+004 
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Patients with newly diagnosed type 1 diabetes vs. patients with established type 1 diabetes  
List of differentially expressed proteins in samples from type 1 newly diagnosed diabetes (T1DM new) and established type 1 diabetes (T1DM old) with DS-169/T1N8  
control sample used as reference run (raw data) 
Accession Peptides Score Anova 
(p)* 
Fold Description Av. normalised 
abundances 
T1DM 
new 
T1DM 
old 
CO4B_HUMAN 47 4330.13 0.02 1.35 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 1.11E+08 8.23E+07 
THRB_HUMAN 19 1580.52 0.05 1.39 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 3.08E+07 2.22E+07 
CERU_HUMAN 12 841.03 0.03 1.55 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 8.18E+05 1.27E+06 
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Accession Peptides Score Anova 
(p)* 
Fold Description Av. normalised 
abundances 
T1DM 
new 
T1DM 
old 
CLUS_HUMAN 7 766.66 5.00E-
03 
1.43 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 2.10E+07 1.47E+07 
IGHM_HUMAN 4 763.61 0.04 1.57 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 6.61E+06 4.21E+06 
CO5_HUMAN 13 749.38 0.03 1.59 Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 6.09E+05 3.83E+05 
ANT3_HUMAN 10 724.15 6.47E-
03 
1.44 Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 2.35E+07 1.63E+07 
ITIH2_HUMAN 9 697.1 0.02 1.47 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens 2.58E+06 1.76E+06 
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Accession Peptides Score Anova 
(p)* 
Fold Description Av. normalised 
abundances 
T1DM 
new 
T1DM 
old 
GN=ITIH2 PE=1 SV=2 
A1AT_HUMAN 8 586.08 0.05 1.49 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 5.32E+05 3.57E+05 
IGKC_HUMAN 4 483.7 0.03 1.54 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 6.15E+06 4.00E+06 
VTNC_HUMAN 4 375.94 0.03 1.45 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 1.72E+07 1.18E+07 
PROS_HUMAN 4 316.49 7.49E-
03 
1.71 Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 
PE=1 SV=1 
6.27E+05 3.67E+05 
ALBU_HUMAN 4 255.52 7.77E- 1.69 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 4.50E+05 2.66E+05 
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Accession Peptides Score Anova 
(p)* 
Fold Description Av. normalised 
abundances 
T1DM 
new 
T1DM 
old 
03 
PLMN_HUMAN 3 255.02 0.05 1.29 Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 3.79E+05 4.91E+05 
APOC1_HUMAN 4 213.76 4.51E-
03 
1.55 Apolipoprotein C-I OS=Homo sapiens GN=APOC1 PE=1 SV=1 2.59E+06 1.67E+06 
ITIH3_HUMAN 4 213.07 0.05 1.81 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens 
GN=ITIH3 PE=1SV=2 
1.03E+05 5.70E+04 
LCAT_HUMAN 3 183.51 0.05 1.24 Phosphatidylcholine-sterol acyltransferase OS=Homo sapiens 
GN=LCAT PE=1 SV=1 
5.96E+05 4.80E+05 
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Accession Peptides Score Anova 
(p)* 
Fold Description Av. normalised 
abundances 
T1DM 
new 
T1DM 
old 
TSP1_HUMAN 3 171.19 0.05 1.48 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 1.52E+05 2.24E+05 
FHR1_HUMAN 2 153.94 0.02 1.77 Complement factor H-related protein 1 OS=Homo sapiens 
GN=CFHR1 PE=1 SV=2 
6.05E+04 3.42E+04 
KV204_HUMAN 2 121.2 0.05 1.48 Ig kappa chain V-II region TEW OS=Homo sapiens PE=1 SV=1 2.07E+05 1.40E+05 
K2C1_HUMAN 2 96.61 0.04 4.01 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 
1.49E+04 3.72E+03 
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List of differentially expressed proteins for type 1 newly diagnosed diabetes (T1DM new) and established type 1 diabetes (T1DM old) with DS-74/T1O7 used as reference 
run (raw data) 
Accession Peptide
s 
Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM 
new 
T1DM 
old 
CO4B_HUMAN 46 4003.4
7 
0.01 1.45 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 1.56E+08 1.08E+08 
THRB_HUMAN 15 1402.2
7 
0.05 1.4 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 4.57E+07 3.27E+07 
IGHM_HUMAN 5 1006.7 0.04 1.57 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 1.26E+07 8.04E+06 
294 
 
Accession Peptide
s 
Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM 
new 
T1DM 
old 
3 
CLUS_HUMAN 9 889.94 3.88E-03 1.42 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 3.31E+07 2.34E+07 
ANT3_HUMAN 13 886.97 0.01 1.43 Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 3.12E+07 2.18E+07 
ITIH1_HUMAN 9 781.46 0.04 1.46 Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo 
sapiens GN=ITIH1 PE=1 SV=3 
2.25E+06 1.55E+06 
IGKC_HUMAN 5 524.66 0.02 1.55 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 
SV=1 
9.42E+06 6.07E+06 
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Accession Peptide
s 
Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM 
new 
T1DM 
old 
VTNC_HUMAN 5 437.98 0.03 1.46 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 2.57E+07 1.76E+07 
CO9_HUMAN 5 355.88 0.05 1.53 Complement component C9 OS=Homo sapiens GN=C9 PE=1 
SV=2 
2.39E+06 1.56E+06 
CFAH_HUMAN 4 287.58 0.04 1.57 Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 7.80E+05 4.96E+05 
PROS_HUMAN 5 259.26 9.13E-04 1.49 Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 
PE=1 SV=1 
6.24E+05 4.18E+05 
APOC1_HUMAN 2 123.48 2.43E-03 1.56 Apolipoprotein C-I OS=Homo sapiens GN=APOC1 PE=1 SV=1 3.78E+06 2.42E+06 
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 List of differentially expressed proteins for type 1 newly diagnosed diabetes (T1DM new) and established type 1 diabetes (T1DM old) with DS-90/T1O12 sample used as 
reference run (raw data). 
Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM 
new 
T1DM 
old 
CO4B_HUMAN 44 3766.11 1.00E-02 1.48 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 1.62E+08 1.09E+08 
THRB_HUMAN 17 1532.49 0.03 1.42 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 4.69E+07 3.31E+07 
IGHM_HUMAN 6 963.76 3.00E-02 1.55 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 
SV=3 
1.43E+07 9.25E+06 
CLUS_HUMAN 10 962.19 0.00308 1.45 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 3.35E+07 2.31E+07 
298 
 
Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM 
new 
T1DM 
old 
ITIH1_HUMAN 10 959.99 0.04 1.48 Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo 
sapiens GN=ITIH1 PE=1 SV=3 
2.56E+06 1.73E+06 
ANT3_HUMAN 13 912.25 7.92E-03 1.46 Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 
SV=1 
4.18E+07 2.87E+07 
ITIH2_HUMAN 10 766.5 9.83E-03 1.46 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo 
sapiens GN=ITIH2 PE=1 SV=2 
4.43E+06 3.04E+06 
VTNC_HUMAN 4 447.26 0.03 1.42 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 3.39E+07 2.38E+07 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM 
new 
T1DM 
old 
IGKC_HUMAN 4 418.25 0.02 1.58 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 
SV=1 
9.56E+06 6.06E+06 
PROS_HUMAN 2 190.82 0.00338 2.2 Vitamin K-dependent protein S OS=Homo sapiens 
GN=PROS1 PE=1 SV=1 
6.16E+05 2.80E+05 
LCAT_HUMAN 3 183.5 0.03 1.26 Phosphatidylcholine-sterol acyltransferase OS=Homo 
sapiens GN=LCAT PE=1 SV=1 
8.95E+05 7.09E+05 
APOC1_HUMAN 3 171.86 0.00283 1.59 Apolipoprotein C-I OS=Homo sapiens GN=APOC1 PE=1 
SV=1 
3.88E+06 2.45E+06 
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Accession Peptides Score Anova 
(p)* 
Fold Description Average normalised 
abundances 
T1DM 
new 
T1DM 
old 
APOL1_HUMAN 3 147.63 0.02 1.88 Apolipoprotein L1 OS=Homo sapiens GN=APOL1 PE=1 
SV=5 
1.43E+05 7.61E+04 
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Healthy controls to patients with newly diagnosed type 1 diabetes vs. healthy controls to patients 
with established type 1 diabetes  
 List of differentially expressed proteins for ‘new’ and ‘old’ controls. DS-162 ‘old’ control sample was used as reference run (raw data) 
Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Average Normalised Abundances 
control new control old 
APOE_HUMAN 9 844.42 0.02 2.35 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 8.81E+06 2.07E+07 
LG3BP_HUMAN 8 786.36 0.02 2.55 Galectin-3-binding protein OS=Homo sapiens 
GN=LGALS3BP PE=1 SV=1 
1.65E+06 4.22E+06 
IGHM_HUMAN 8 557.04 0.04 1.6 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 
SV=3 
5.71E+06 3.57E+06 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Average Normalised Abundances 
control new control old 
CLUS_HUMAN 6 516.52 0.05 2.33 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 7.93E+06 1.85E+07 
PROS_HUMAN 6 429.17 0.05 2.69 Vitamin K-dependent protein S OS=Homo sapiens 
GN=PROS1 PE=1 SV=1 
8.16E+05 2.19E+06 
APOC2_HUMAN 3 422.95 4.73E-03 2.61 Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 
SV=1 
2.76E+06 7.18E+06 
CRP_HUMAN 5 353.29 0.01 10.84 C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 2.18E+05 2.36E+06 
C4BPA_HUMAN 3 251.9 0.03 2.61 C4b-binding protein alpha chain OS=Homo sapiens 
GN=C4BPA PE=1 SV=2 
4.22E+06 1.10E+07 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Average Normalised Abundances 
control new control old 
FBLN3_HUMAN 2 212.06 0.04 2.35 EGF-containing fibulin-like extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 PE=1 SV=2 
1.62E+05 3.82E+05 
LBP_HUMAN 2 210.94 0.04 2.01 Lipopolysaccharide-binding protein OS=Homo sapiens 
GN=LBP PE=1 SV=3 
2.92E+05 5.88E+05 
MASP1_HUMAN 3 191.72 0.02 1.77 Mannan-binding lectin serine protease 1 OS=Homo 
sapiens GN=MASP1 PE=1 SV=3 
2.71E+05 4.79E+05 
ITIH3_HUMAN 3 178.07 0.01 2.21 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo 
sapiens GN=ITIH3 PE=1 SV=2 
4.41E+04 9.75E+04 
CFAH_HUMAN 2 176.85 3.73E-03 1.52 Complement factor H OS=Homo sapiens GN=CFH PE=1 1.12E+06 7.35E+05 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Average Normalised Abundances 
control new control old 
SV=4 
SAA4_HUMAN 2 173.1 0.03 2.34 Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 
PE=1 SV=1 
5.48E+05 1.28E+06 
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List of differentially expressed proteins for ‘new’ and ‘old’ controls. DS-178 ‘new’ control sample was used as reference run (raw data). 
Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Av. normalised 
abundances 
Control 
new 
Control 
old 
THRB_HUMAN 12 1100.82 0.05 2.31 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 2.30E+07 5.31E+07 
APOE_HUMAN 9 844.42 0.02 2.33 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 8.78E+06 2.05E+07 
LG3BP_HUMAN 6 676.81 5.44E-
03 
2.94 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP 
PE=1 SV=1 
1.40E+06 4.10E+06 
IGHM_HUMAN 9 612.42 0.04 1.57 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 7.37E+06 4.68E+06 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Av. normalised 
abundances 
Control 
new 
Control 
old 
CLUS_HUMAN 6 516.52 0.05 2.25 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 8.14E+06 1.83E+07 
ITIH2_HUMAN 7 512.82 0.04 1.39 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens 
GN=ITIH2 PE=1 SV=2 
8.33E+05 5.98E+05 
FIBA_HUMAN 6 507.25 0.01 2.34 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 4.72E+05 1.10E+06 
APOC2_HUMAN 3 422.95 8.61E-
03 
2.83 Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 SV=1 2.52E+06 7.13E+06 
CFAH_HUMAN 6 357.17 5.49E- 1.5 Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 1.54E+06 1.02E+06 
307 
 
Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Av. normalised 
abundances 
Control 
new 
Control 
old 
03 
CRP_HUMAN 5 353.28 0.01 10.73 C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 2.20E+05 2.37E+06 
FA5_HUMAN 3 263.39 0.02 2.58 Coagulation factor V OS=Homo sapiens GN=F5 PE=1 SV=3 1.80E+05 4.64E+05 
SAA4_HUMAN 3 260.7 0.01 2.21 Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1 
SV=1 
6.65E+05 1.47E+06 
ITIH3_HUMAN 4 259.04 0.01 2.32 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens 
GN=ITIH3 PE=1 SV=2 
4.72E+04 1.09E+05 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Av. normalised 
abundances 
Control 
new 
Control 
old 
C4BPA_HUMAN 3 251.9 0.03 2.51 C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA 
PE=1 SV=2 
4.33E+06 1.09E+07 
PROC_HUMAN 3 240.46 0.05 2.24 Vitamin K-dependent protein C OS=Homo sapiens GN=PROC 
PE=1 SV=1 
1.66E+05 3.72E+05 
MASP1_HUMAN 3 191.72 0.02 1.72 Mannan-binding lectin serine protease 1 OS=Homo sapiens 
GN=MASP1 PE=1 SV=3 
2.80E+05 4.81E+05 
FETUA_HUMAN 2 112.69 0.03 1.4 Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 
SV=1 
3.06E+05 2.19E+05 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description  Av. normalised 
abundances 
Control 
new 
Control 
old 
IGKC_HUMAN 2 106.69 0.03 1.79 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 4.31E+05 2.40E+05 
TSP1_HUMAN 2 105.63 0.05 1.72 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 7.02E+04 4.07E+04 
TRFL_HUMAN 2 100.03 0.02 3.19 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 1.88E+04 5.89E+03 
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List of differentially expressed proteins for ‘new’ and ‘old’ controls. DS-39 ‘old’ control sample was used as reference run. DS-7 was excluded from this analysis as protein 
expression pattern for this sample differed from other samples in the same group (raw data). 
Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description   Average normalised 
abundances 
Control 
new 
Control 
old 
CO4B_HUMAN 53 4906.7
4 
0.05 1.53 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 1.21E+08 1.85E+08 
APOE_HUMAN 15 1315.9
5 
0.02 1.71 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 1.13E+07 1.92E+07 
THRB_HUMAN 16 1221.3 0.05 1.34 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 2.48E+07 3.33E+07 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description   Average normalised 
abundances 
Control 
new 
Control 
old 
7 
LG3BP_HUMAN 12 964.88 0.02 1.73 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 
SV=1 
1.78E+06 3.08E+06 
CLUS_HUMAN 12 927.6 0.01 1.64 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 1.47E+07 2.41E+07 
PROS_HUMAN 8 566.62 0.05 1.55 Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 PE=1 
SV=1 
9.76E+05 1.52E+06 
C4BPA_HUMAN 7 503.36 5.92E-03 1.55 C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 
SV=2 
5.05E+06 7.83E+06 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description   Average normalised 
abundances 
Control 
new 
Control 
old 
APOC2_HUMAN 4 469.21 3.74E-03 1.99 Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 SV=1 2.91E+06 5.80E+06 
CFAH_HUMAN 5 446.31 1.17E-03 1.6 Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 1.90E+06 1.19E+06 
CERU_HUMAN 5 441.73 0.05 1.5 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 1.99E+05 3.00E+05 
CRP_HUMAN 5 353.29 0.03 10.3 C-reactive protein OS=Homo sapiens GN=CRP PE=1 SV=1 2.19E+05 2.25E+06 
FIBA_HUMAN 4 308.39 0.03 2.24 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 1.26E+05 2.81E+05 
SAA4_HUMAN 4 295.89 8.06E-03 1.66 Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1 SV=1 7.99E+05 1.32E+06 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description   Average normalised 
abundances 
Control 
new 
Control 
old 
KV302_HUMAN 3 226.98 0.04 1.5 Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 6.89E+05 4.60E+05 
MASP1_HUMAN 3 191.72 0.03 1.38 Mannan-binding lectin serine protease 1 OS=Homo sapiens 
GN=MASP1 PE=1 SV=3 
2.80E+05 3.85E+05 
ITIH3_HUMAN 3 178.07 0.03 1.93 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Homo sapiens 
GN=ITIH3 PE=1 SV=2 
4.42E+04 8.54E+04 
PROC_HUMAN 2 169.94 0.05 1.58 Vitamin K-dependent protein C OS=Homo sapiens GN=PROC PE=1 
SV=1 
1.36E+05 2.15E+05 
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Accession  Peptides  Score   Anova 
(p)*  
 Fold   Description   Average normalised 
abundances 
Control 
new 
Control 
old 
APOC3_HUMAN 2 168.49 8.73E-03 1.58 Apolipoprotein C-III OS=Homo sapiens GN=APOC3 PE=1 SV=1 4.03E+06 6.38E+06 
LCAT_HUMAN 3 161.32 0.04 1.41 Phosphatidylcholine-sterol acyltransferase OS=Homo sapiens 
GN=LCAT PE=1 SV=1 
1.72E+05 2.43E+05 
APOC4_HUMAN 2 120.95 7.18E-06 3.07 Apolipoprotein C-IV OS=Homo sapiens GN=APOC4 PE=1 SV=1 2.65E+04 8.13E+04 
ANGI_HUMAN 2 118.53 0.01 1.69 Angiogenin OS=Homo sapiens GN=ANG PE=1 SV=1 6.20E+04 1.05E+05 
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Patients with various autoimmune diseases vs. healthy controls to all patients with type 1 
diabetes  
List of differentially expressed proteins in ‘autoimmune’ versus ‘control-all’ samples. Control sample DS-175 was used as reference run. 
Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
Autoimmune All 
controls 
P02751 32 2998 0.02 1.52 Fibronectin 3.23E+07 4.91E+07 
P02768 24 2101 0.009 1.86 Serum albumin  2.72E+07 1.46E+07 
P20742 17 1420 0.01 5.03 Pregnancy zone protein 2.40E+06 4.78E+05 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
Autoimmune All 
controls 
P06727 10 990 0.02 1.53 Apolipoprotein A-IV  2.12E+07 1.39E+07 
P02748 10 968 0.02 1.6 Complement component C9  5.83E+06 3.64E+06 
P00450 6 736 0.05 1.42 Ceruloplasmin  1.20E+06 8.48E+05 
P01009 10 626 0.02 1.53 Alpha-1-antitrypsin  1.07E+06 7.00E+05 
P04264 5 546 0.05 2.95 Keratin, type II cytoskeletal 1  3.49E+05 1.18E+05 
P13645 7 509 0.04 3.27 Keratin, type I cytoskeletal 10  2.57E+05 7.84E+04 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
Autoimmune All 
controls 
P18428 6 457 0.05 1.77 Lipopolysaccharide-binding protein 1.60E+06 9.04E+05 
P00734 5 404 0.03 1.79 Prothrombin  2.71E+06 1.51E+06 
P10643 5 396 0.02 2 Complement component C7 1.07E+06 5.38E+05 
P01008 5 396 0.05 1.94 Antithrombin-III  3.50E+06 1.80E+06 
P51884 6 395 0.03 1.9 Lumican  4.56E+05 2.40E+05 
Q06033 6 364 0.01 1.77 Inter-alpha-trypsin inhibitor heavy chain H3  2.21E+05 1.25E+05 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
Autoimmune All 
controls 
P35527 2 177 0.04 2.37 Keratin, type I cytoskeletal 9  4.22E+04 1.78E+04 
Q15848 2 174 0.02 1.83 Adiponectin 1.98E+06 1.08E+06 
P07357 3 170 0.003 1.44 Complement component C8 alpha chain  9.45E+04 6.56E+04 
P00488 2 146 0.03 2.47 Coagulation factor XIII A chain  1.45E+04 3.58E+04 
P55056 2 121 0.04 2.12 Apolipoprotein C-IV  3.88E+04 8.23E+04 
P07360 2 108 0.05 1.47 Complement component C8 gamma chain 7.82E+04 5.31E+04 
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Accession Peptides Score Anova (p)* Fold Description Average normalised 
abundances 
Autoimmune All 
controls 
P02746 2 96 0.02 1.48 Complement C1q subcomponent subunit B 8.02E+04 5.43E+04 
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List of differentially expressed proteins in ‘autoimmune’ versus ‘control-all’ samples. Control sample DS-178 was used as reference run.  
Accession Peptides Score Anova (p)* Fold Description Average normalised abundances 
Autoimmune All controls 
P02751 36 2983.27 0.005 1.53 Fibronectin  2.59E+07 3.97E+07 
P04114 36 2388.22 0.03 1.52 Apolipoprotein B-100  1.72E+06 2.60E+06 
P02768 24 1979.44 0.01 1.93 Serum albumin 2.41E+07 1.25E+07 
P20742 18 1452.68 0.009 5.19 Pregnancy zone protein 2.43E+06 4.69E+05 
P06727 12 1049.54 0.02 1.53 Apolipoprotein A-IV  1.87E+07 1.22E+07 
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Accession Peptides Score Anova (p)* Fold Description Average normalised abundances 
Autoimmune All controls 
P02748 12 973.92 0.02 1.65 Complement component C9 4.92E+06 2.97E+06 
P00450 7 787.88 0.05 1.44 Ceruloplasmin 1.16E+06 8.06E+05 
P13645 9 661.8 0.04 3.78 Keratin, type I cytoskeletal 10  2.87E+05 7.58E+04 
P01009 10 625.66 0.03 1.55 Alpha-1-antitrypsin 9.69E+05 6.24E+05 
P10643 4 347.48 0.01 2.5 Complement component C7  6.79E+05 2.71E+05 
P18428 5 312.49 0.03 1.7 Lipopolysaccharide-binding protein 9.40E+05 5.53E+05 
P51884 5 307.51 0.04 1.88 Lumican 4.02E+05 2.14E+05 
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Accession Peptides Score Anova (p)* Fold Description Average normalised abundances 
Autoimmune All controls 
Q06033 5 305.6 0.02 1.65 Inter-alpha-trypsin inhibitor heavy chain H3 1.94E+05 1.17E+05 
P13671 4 286.31 0.03 1.53 Complement component C6 4.13E+05 2.69E+05 
Q15848 3 251.12 0.02 1.86 Adiponectin 2.00E+06 1.08E+06 
P00734 3 219.48 0.03 1.78 Prothrombin  2.39E+06 1.34E+06 
O14791 3 185.39 0.03 1.35 Apolipoprotein L1 1.13E+05 1.53E+05 
P07360 3 162.9 0.05 1.44 Complement component C8 gamma chain 9.52E+04 6.63E+04 
P07357 2 121.76 0.03 1.38 Complement component C8 alpha chain 5.57E+04 4.03E+04 
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Accession Peptides Score Anova (p)* Fold Description Average normalised abundances 
Autoimmune All controls 
P01700 2 113.45 0.02 1.6 Ig lambda chain V-I region HA  7.18E+04 4.47E+04 
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List of differentially expressed proteins in autoimmune versus control samples. Control sample DS-39 was used as reference run.  
Accession Peptides Score Anova (p)* Fold Description Average normalised abundances 
Autoimmune All Controls 
P02751 35 3096.62 0.03 1.53 Fibronectin 3.14E+07 4.80E+07 
P0C0L4 27 2157.02 0.05 1.39 Complement C4-A  5.43E+07 3.92E+07 
P02768 25 2054.78 0.02 1.86 Serum albumin  2.53E+07 1.36E+07 
P20742 22 1472.88 0.009 4.39 Pregnancy zone protein 3.21E+06 7.32E+05 
P06727 13 1084.59 0.02 1.52 Apolipoprotein A-IV  1.98E+07 1.31E+07 
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Accession Peptides Score Anova (p)* Fold Description Average normalised abundances 
Autoimmune All Controls 
P02748 13 997.78 0.03 1.59 Complement component C9  5.33E+06 3.35E+06 
P04264 10 906.06 0.05 2.67 Keratin, type II cytoskeletal 1  4.86E+05 1.82E+05 
P13645 10 685.93 0.04 3.24 Keratin, type I cytoskeletal 10  3.06E+05 9.45E+04 
P35908 5 606.39 0.03 4.21 Keratin, type II cytoskeletal 2 epidermal  7.93E+04 1.88E+04 
P01009 8 479.04 0.04 1.48 Alpha-1-antitrypsin  9.45E+05 6.40E+05 
Q06033 7 407.35 0.01 1.75 Inter-alpha-trypsin inhibitor heavy chain H3 2.23E+05 1.27E+05 
P51884 5 335.57 0.01 2.06 Lumican 2.87E+05 1.39E+05 
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Accession Peptides Score Anova (p)* Fold Description Average normalised abundances 
Autoimmune All Controls 
P10643 4 283.97 0.02 2.26 Complement component C7  8.63E+05 3.81E+05 
Q15848 3 265.93 0.02 1.81 Adiponectin  2.57E+06 1.42E+06 
P07357 3 170.49 0.006 1.39 Complement component C8 alpha chain  9.01E+04 6.50E+04 
P02671 2 165.21 0.03 1.63 Fibrinogen alpha chain 9.25E+04 1.51E+05 
P04220 2 134.48 0.02 16.64 Ig mu heavy chain disease protein  2.01E+03 3.35E+04 
 
